46. 悪性関節リウマチ Disease details / Clinical trials / Drug dev / DR info


臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
(+) erythromefloquine   
   Arakis Ltd
      2005   -   EUCTR2005-002421-31-GB   Germany;United Kingdom;
   Arakis Ltd.
      2005   -   EUCTR2005-002421-31-DE   Germany;United Kingdom;
(+) isomer of racemic mefloquine   
   Arakis Ltd.
      2005   -   EUCTR2005-002421-31-DE   Germany;United Kingdom;
(+) isomer or racemic mefloquine   
   Arakis Ltd.
      2005   -   EUCTR2005-002421-31-DE   Germany;United Kingdom;
(+)erythromefloquine   
   Arakis Ltd
      2005   -   EUCTR2005-002421-31-GB   Germany;United Kingdom;
   Arakis Ltd.
      2005   -   EUCTR2005-002421-31-DE   Germany;United Kingdom;
(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-   
   Pfizer Inc. 235 East 42nd Street, New York, NY10017
      2008   Phase 2;Phase 3   EUCTR2006-005035-19-GR   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2006-005036-24-BG   Bulgaria;Czech Republic;Hungary;Sweden;
      2007   -   EUCTR2006-005036-24-HU   Bulgaria;Czech Republic;Hungary;Sweden;
      2007   -   EUCTR2006-005036-24-CZ   Bulgaria;Czech Republic;Hungary;Sweden;
   Pfizer Ltd - Ramsgate Road, Sandwich CT139NJ, UK.
      2007   Phase 2   EUCTR2006-005036-24-SK   Bulgaria;Czech Republic;Hungary;Slovakia;Sweden;
      2007   -   EUCTR2006-005036-24-SE   Bulgaria;Czech Republic;Hungary;Sweden;
(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile,   
   Pfizer Corporation Austria Ges.m.b.H.
      2005   -   EUCTR2004-002846-36-AT   Austria;Germany;Italy;Spain;
   Pfizer Global & Developement, Pfizer Limited
      2005   Phase 2   EUCTR2004-002846-36-SK   Austria;Germany;Italy;Slovakia;Spain;
   Pfizer Pharma GmbH
      2005   -   EUCTR2004-002846-36-DE   Germany;Italy;Spain;
   Pfizer, S.A.
      2005   Phase 2   EUCTR2004-002846-36-ES   Austria;Germany;Italy;Slovakia;Spain;
(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-   
   Pfizer Inc. 235 East 42nd Street, New York, NY10017
      2008   Phase 2;Phase 3   EUCTR2006-005035-19-GR   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2006-005036-24-BG   Bulgaria;Czech Republic;Hungary;Sweden;
      2007   -   EUCTR2006-005036-24-HU   Bulgaria;Czech Republic;Hungary;Sweden;
      2007   -   EUCTR2006-005036-24-CZ   Bulgaria;Czech Republic;Hungary;Sweden;
   Pfizer Ltd - Ramsgate Road, Sandwich CT139NJ, UK.
      2007   Phase 2   EUCTR2006-005036-24-SK   Bulgaria;Czech Republic;Hungary;Slovakia;Sweden;
      2007   -   EUCTR2006-005036-24-SE   Bulgaria;Czech Republic;Hungary;Sweden;
(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile,   
   Pfizer Corporation Austria Ges.m.b.H.
      2005   -   EUCTR2004-002846-36-AT   Austria;Germany;Italy;Spain;
   Pfizer Global & Developement, Pfizer Limited
      2005   Phase 2   EUCTR2004-002846-36-SK   Austria;Germany;Italy;Slovakia;Spain;
   Pfizer Pharma GmbH
      2005   -   EUCTR2004-002846-36-DE   Germany;Italy;Spain;
   Pfizer, S.A.
      2005   Phase 2   EUCTR2004-002846-36-ES   Austria;Germany;Italy;Slovakia;Spain;
(3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-beta-oxo-1-   
   Pfizer S.A.
      2007   Phase 2   EUCTR2006-005035-19-ES   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
(3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-ß-oxo-1-   
   Pfizer S.A.
      2007   Phase 2   EUCTR2006-005035-19-ES   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
(CDP6038   
   R-Pharm
      2017   Phase 3   EUCTR2015-005309-35-LV   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-HU   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-GB   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005307-83-LV   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005308-27-HU   Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;United States;
      2016   Phase 3   EUCTR2015-005308-27-DE   Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Turkey;United States;
      2016   Phase 3   EUCTR2015-005307-83-PL   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-LT   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-HU   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-DE   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
   R-Pharm International LLC
      2017   Phase 3   EUCTR2015-005309-35-PL   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-LT   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-DE   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005309-35-CZ   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005308-27-CZ   Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;United States;
      2016   Phase 3   EUCTR2015-005307-83-CZ   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-BG   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
   R-Pharm International, LLC.
      2017   Phase 3   EUCTR2015-005309-35-BG   Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
0109-0012A 100 mg/ml   
   NOVO NORDISK
      2013   -   EUCTR2012-000610-11-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000609-58-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Novo Nordisk A/S
      2014   Phase 2   EUCTR2013-001492-20-PT   Ireland;Portugal;Spain;United Kingdom;
      2014   Phase 2   EUCTR2013-001492-20-ES   Ireland;Portugal;Spain;United Kingdom;
      2013   Phase 2   EUCTR2013-001492-20-GB   Belgium;Czech Republic;Germany;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2013   -   EUCTR2012-000610-11-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000610-11-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000609-58-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-000609-58-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-000609-58-GB   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2012-000610-11-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000610-11-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000610-11-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000609-58-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2012-000609-58-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      -   -   EUCTR2012-000609-58-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
0109-0012A 25 mg/ml   
   NOVO NORDISK
      2013   -   EUCTR2012-000610-11-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000609-58-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Novo Nordisk A/S
      2013   -   EUCTR2012-000610-11-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000610-11-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000609-58-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-000609-58-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-000609-58-GB   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2012-000610-11-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000610-11-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000610-11-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000609-58-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2012-000609-58-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      -   -   EUCTR2012-000609-58-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
0109-0012A 50 mg/ml   
   NOVO NORDISK
      2013   -   EUCTR2012-000610-11-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000609-58-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Novo Nordisk A/S
      2013   -   EUCTR2012-000610-11-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000610-11-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-000609-58-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-000609-58-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-000609-58-GB   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2012-000610-11-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000610-11-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000610-11-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
      2012   -   EUCTR2012-000609-58-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2012-000609-58-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      -   -   EUCTR2012-000609-58-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
0114-0006B   
   Novo Nordisk A/S
      2012   Phase 2   EUCTR2011-005376-42-ES   Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
      2012   -   EUCTR2011-005376-42-LV   Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
      2012   -   EUCTR2011-005376-42-HU   Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
      2012   -   EUCTR2011-005376-42-BG   Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
0881   
   Wyeth Pharmaceuticals
      2005   -   EUCTR2004-000563-96-FI   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2005   -   EUCTR2004-000563-96-AT   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-SE   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-IE   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-HU   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-ES   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-DK   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      -   Phase 4   EUCTR2004-000563-96-NO   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
   Wyeth Pharmaceuticals France
      2008   Phase 4   EUCTR2007-000896-41-FR   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-001625-10-PL   Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
      2008   -   EUCTR2007-001625-10-DE   Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
      2008   -   EUCTR2007-001625-10-AT   Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
      2008   -   EUCTR2007-000896-41-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000896-41-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-000896-41-NL   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Pharmaceuticals Inc. Philadelphia (A Pfizer Company)
      2009   Phase 4   EUCTR2008-002623-85-GB   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA
      2010   Phase 4   EUCTR2008-002623-85-SE   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000896-41-SE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
      2010   -   EUCTR2007-000896-41-AT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 4   EUCTR2007-000896-41-GB   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002623-85-IE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2009   -   EUCTR2008-002623-85-DE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2008   Phase 4   EUCTR2007-000896-41-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000896-41-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   Phase 4   EUCTR2008-002623-85-FR   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 4   EUCTR2008-002623-85-ES   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002623-85-NL   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmceuticals Inc. A Pfizer Company, Philadelphia, PA-19101, USA
      2008   -   EUCTR2007-000896-41-DE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
1 ml NaCl   
   Vrije Universiteit Brussel
      2010   -   NCT01154647   Belgium;
1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c   
   Merck Sharp & Dohme (Sweden) AB
      2004   -   EUCTR2004-000074-31-SE   Sweden;
   Merck Sharp & Dohme BV
      2005   Phase 2   EUCTR2004-000074-31-BE   Belgium;Sweden;
118-42-3   
   Karolinska Institutet
      2014   -   EUCTR2011-004720-35-FI   Denmark;Finland;Sweden;
13-valent pneumococcal conjugate vaccine   
   Region Skane
      2016   Phase 4   NCT03762824   -
15-O labeled water   
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2001   Phase 1   NCT00014794   United States;
18F-FDG   
   GlaxoSmithKline
      2015   Phase 1   NCT02350426   United Kingdom;
18F-GE-180   
   GlaxoSmithKline
      2015   Phase 1   NCT02350426   United Kingdom;
18F]PEG-Folate   
   VU Medical Center, department of Rheumatology
      2020   Phase 4   EUCTR2018-004429-94-NL   Netherlands;
      2018   Phase 4   EUCTR2018-001114-15-NL   Netherlands;
2 million hMSC   
   MetroHealth Medical Center
      2017   Phase 1   NCT03186417   United States;
2-HOBA   
   Vanderbilt University Medical Center
      2022   Phase 2   NCT05274243   United States;
2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1H-benz[e]-indolium hydroxide,inner salt   
   Knowledge Centre for Rheumatology and Back Diseases
      2013   Phase 4   EUCTR2013-004006-26-DK   Denmark;
23-Valent Pneumococcal Polysaccharide Vaccine   
   Genentech, Inc.
      2010   Phase 4   NCT01163747   United States;
23-valent pneumococcal polysaccharide vaccine   
   Genentech, Inc.
      2006   Phase 2   NCT00282308   United States;
   Region Skane
      2016   Phase 4   NCT03762824   -
2593   
   Aarhus University Hospital, Denmark
      2007   Phase 4   EUCTR2007-000082-38-DK   Denmark;
331731-18-1   
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 4   EUCTR2014-001114-26-SE   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2015   Phase 4   EUCTR2014-001114-26-NL   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2013-004019-37-DK   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2015   Phase 2   EUCTR2013-004019-37-BG   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2015   -   EUCTR2013-004019-37-DE   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   Phase 4   EUCTR2014-001114-26-IT   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2014   Phase 4   EUCTR2014-001114-26-IE   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2014-001114-26-HU   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2014-001114-26-GR   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2014   Phase 4   EUCTR2014-001114-26-GB   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2014-001114-26-FR   Australia;Austria;Canada;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2014   Phase 4   EUCTR2014-001114-26-ES   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2014   Phase 4   EUCTR2014-001114-26-DE   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2014-001114-26-AT   Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-004019-37-RO   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   Phase 2   EUCTR2013-004019-37-CZ   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   -   EUCTR2013-004019-37-HU   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
   Abbott Japan Co., Ltd.
      -   -   EUCTR2014-004558-33-Outside-EU/EEA   Japan;
35565011   
   DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II
      2016   Phase 3   EUCTR2015-000570-35-IT   Italy;
4 million hMSC   
   MetroHealth Medical Center
      2017   Phase 1   NCT03186417   United States;
4-[5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl] benzenesulfonamide   
   Pfizer Pharma GmbH
      2006   -   EUCTR2004-001234-17-DE   Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide   
   Laboratórios Pfizer, Lda
      2006   -   EUCTR2004-001234-17-PT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer AB
      2006   -   EUCTR2004-001234-17-SE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Healthcare Ireland
      2006   -   EUCTR2004-001234-17-IE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2005   -   EUCTR2004-001234-17-LT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Limited
      2006   Phase 4   EUCTR2004-001234-17-GB   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-001234-17-CZ   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer SA/NV
      2006   -   EUCTR2004-001234-17-BE   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer, S.A.
      2005   -   EUCTR2004-001234-17-ES   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide   
   Astellas Pharma Global Development
      2013   Phase 2   EUCTR2011-006021-23-CZ   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
      2013   Phase 2   EUCTR2011-006021-23-BG   Belgium;Bulgaria;Colombia;Czech Republic;Germany;Hungary;Mexico;Poland;
      2013   -   EUCTR2011-006021-23-HU   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
      2012   -   EUCTR2011-006021-23-BE   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
   Astellas Pharma Global Development Inc. (APGD)
      2013   Phase 2   EUCTR2011-006021-23-PL   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
42942019   
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2016   Phase 4   EUCTR2016-002061-54-IT   Italy;
5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin   
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
      2010   Phase 3   EUCTR2010-019871-31-GB   Austria;Belgium;Czech Republic;Finland;Germany;Lithuania;Slovakia;United Kingdom;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2010-019871-31-SK   Austria;Belgium;Czech Republic;Finland;Germany;Lithuania;Slovakia;United Kingdom;
      2011   Phase 3   EUCTR2010-019871-31-BE   Austria;Belgium;Czech Republic;Finland;Germany;Lithuania;Slovakia;United Kingdom;
      2011   -   EUCTR2010-019871-31-CZ   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019871-31-LT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019871-31-FI   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019871-31-DE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2010   -   EUCTR2010-019871-31-AT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
6 million hMSC   
   MetroHealth Medical Center
      2017   Phase 1   NCT03186417   United States;
6-(nitrooxy)hexyl(2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate   
   Merck Sharp & Dohme (Sweden) AB
      2004   Phase 2   EUCTR2004-000612-54-SE   Sweden;
68Ga-BNOTA-PRGD2   
   Peking Union Medical College Hospital
      2012   Early Phase 1   NCT01940926   China;
68Ga-FAPI   
   Peking Union Medical College Hospital
      2020   Early Phase 1   NCT04514614   China;
68Ga-NEB   
   Peking Union Medical College Hospital
      2019   Phase 1   NCT04273334   China;
7-valent Pneumococcal Conjugate vaccine   
   Dept of Rheumatology, Lund University Hospital, Lund, Sweden
      2008   -   EUCTR2007-006539-29-SE   Sweden;
70930.00.00   
   medac Gesellschaft für klinische Spezialpräparate mbH
      2012   -   EUCTR2012-000222-21-DE   Germany;
8594739041288   
   Merck & Co., Inc.
      2005   Phase 2   EUCTR2004-004302-24-CZ   Czech Republic;Finland;Germany;Italy;Spain;
89Zr-DFO-CZP   
   Robert Flavell, MD, PhD
      2018   Phase 1   NCT03546335   United States;
9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxaline   
   OxyPharma AB
      2008   -   EUCTR2006-004834-33-PL   Bulgaria;Latvia;Poland;United Kingdom;
      2007   Phase 2   EUCTR2006-004834-33-GB   Belgium;Bulgaria;Latvia;Lithuania;Poland;United Kingdom;
      2007   -   EUCTR2006-004834-33-BE   Belgium;Bulgaria;Latvia;Poland;United Kingdom;
9512   
   Center for Research and Development Uppsala University/County Council of Gävleborg
      2014   Phase 4   EUCTR2014-000993-20-SE   Sweden;
99mTc-3PRGD2   
   First Affiliated Hospital of Fujian Medical University
      2015   Phase 0   NCT02723760   China;
99mTc-S-HYNIC Certolizumab pegol   
   Ghent University Hospital
      2017   Phase 4   EUCTR2016-004300-65-BE   Belgium;
      2012   Phase 3   EUCTR2009-017998-37-BE   Belgium;
99mTc-rhAnnexin V-128   
   Advanced Accelerator Applications
      2014   Phase 1/Phase 2   NCT02328027   Switzerland;
A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs   
   University of Minnesota - Clinical and Translational Science Institute
      2004   -   NCT01600521   China;
AB1010   
   AB Science
      2014   -   EUCTR2010-020992-21-DE   Argentina;Bosnia and Herzegovina;Czech Republic;Germany;Greece;India;Mexico;Monaco;Morocco;Philippines;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Tunisia;Ukraine;United States;
      2012   Phase 3   EUCTR2010-020992-21-GR   Czech Republic;Germany;Greece;India;Monaco;Poland;Romania;Slovakia;Spain;Thailand;Turkey;United States;
      2011   Phase 3   EUCTR2010-020992-21-SK   Czech Republic;France;Germany;Greece;India;Poland;Romania;Slovakia;Spain;Thailand;Tunisia;Turkey;United States;
      2011   -   EUCTR2010-020992-21-ES   Czech Republic;Germany;Greece;India;Slovakia;Spain;Thailand;Turkey;United States;
      2011   -   EUCTR2010-020992-21-CZ   Czech Republic;Germany;Greece;India;Slovakia;Spain;Thailand;Turkey;United States;
ABA, open-label (OL)   
   Bristol-Myers Squibb
      2005   Phase 3   NCT00095147   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;Spain;Sweden;Switzerland;United States;
ABBV-105   
   AbbVie
      2019   Phase 2   NCT03823378   Belgium;Canada;Czechia;Hungary;Poland;Spain;United Kingdom;
      2018   Phase 2   NCT03682705   Belgium;Canada;Czechia;Germany;Hungary;Ireland;Poland;Puerto Rico;Spain;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co. KG
      2019   Phase 2   EUCTR2018-002306-31-HU   Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-002306-31-GB   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-002306-31-ES   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-002306-31-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-000666-10-BE   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
ABBV-105, A-1519938.0   
   AbbVie Deutschland GmbH & Co. KG
      2019   Phase 2   EUCTR2018-000666-10-HU   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-000666-10-ES   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2018   Phase 2   EUCTR2018-000666-10-GB   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
ABBV-154   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2021   Phase 2   EUCTR2020-005303-39-IT   Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   AbbVie
      2021   Phase 2   NCT04888585   Australia;Canada;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co. KG
      2021   Phase 2   EUCTR2020-005303-39-PL   Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005303-39-NL   Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005303-39-GR   Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005303-39-ES   Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005303-39-DE   Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
ABBV-257   
   AbbVie
      2015   Phase 1   NCT02531178   Germany;
ABBV-3373   
   AbbVie
      2019   Phase 2   NCT03823391   Germany;Hungary;Israel;Netherlands;Poland;Puerto Rico;United States;
   AbbVie Deutschland GmbH & Co. KG
      2019   Phase 2   EUCTR2018-003053-21-PL   Israel;Poland;Puerto Rico;United States;
ABP 501   
   Amgen
      2014   Phase 3   NCT02114931   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 3   NCT01970475   Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
   Amgen Inc
      2014   Phase 3   EUCTR2013-000525-31-DE   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   -   EUCTR2013-000525-31-RO   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-PL   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-HU   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-GB   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-ES   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-CZ   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-BG   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
   Amgen Inc.
      2014   Phase 3   EUCTR2013-004654-13-RO   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004654-13-PL   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004654-13-GB   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004654-13-ES   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004654-13-DE   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004654-13-CZ   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004654-13-BG   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   -   EUCTR2013-004654-13-HU   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
ABP 710   
   Amgen
      2016   Phase 3   NCT02937701   Australia;Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Poland;Spain;United States;
ABP 710 - Biosimilar to infliximab   
   Amgen Inc.
      2016   Phase 3   EUCTR2014-004704-29-PL   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
      2016   Phase 3   EUCTR2014-004704-29-HU   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
      2016   Phase 3   EUCTR2014-004704-29-ES   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
      2016   Phase 3   EUCTR2014-004704-29-DE   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
      2016   Phase 3   EUCTR2014-004704-29-CZ   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
      2016   Phase 3   EUCTR2014-004704-29-BG   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
ABP 798   
   Amgen
      2016   Phase 3   NCT02792699   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
ABP 798 - Biosimilar to rituximab   
   Amgen Inc
      2015   Phase 1;Phase 3   EUCTR2013-005543-90-BG   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
      2014   Phase 1;Phase 3   EUCTR2013-005543-90-PL   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
      2014   Phase 1;Phase 3   EUCTR2013-005543-90-HU   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
      2014   Phase 1;Phase 3   EUCTR2013-005543-90-DE   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
ABP 798 Biosimilar to Rituximab   
   Amgen Inc
      2017   Phase 1;Phase 3   EUCTR2013-005543-90-EE   Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
ABT 494   
   AbbVie Deutschland GmbH & Co. KG
      2014   Phase 2   EUCTR2013-003984-72-LV   Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2014   Phase 2   EUCTR2013-003984-72-CZ   Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2014   Phase 2   EUCTR2013-003530-33-NL   Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Netherlands;Puerto Rico;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003530-33-LV   Belgium;Bulgaria;Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Netherlands;New Zealand;Puerto Rico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003530-33-ES   Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Netherlands;Puerto Rico;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-002358-57-NL   Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-002358-57-CZ   Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-002358-57-BE   Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
      2014   -   EUCTR2013-003984-72-SK   Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2014   -   EUCTR2013-002358-57-HU   Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co.KG
      2014   -   EUCTR2013-003984-72-HU   Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
   AbbVie Inc.
      2014   -   EUCTR2013-003984-72-ES   Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2014   -   EUCTR2013-002358-57-ES   Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
ABT-122   
   AbbVie
      2015   Phase 2   NCT02433340   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   Phase 2   NCT02141997   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;United States;
      2013   Phase 1   NCT01853033   United States;
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 2   EUCTR2014-001471-31-RO   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2015   Phase 2   EUCTR2014-001471-31-HU   Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;
      2015   Phase 2   EUCTR2014-001471-31-DE   Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;
      2015   Phase 2   EUCTR2014-001471-31-CZ   Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;
      2015   Phase 2   EUCTR2014-001471-31-BG   Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;
      2015   Phase 2   EUCTR2013-004019-37-DK   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2015   Phase 2   EUCTR2013-004019-37-BG   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2015   -   EUCTR2013-004019-37-DE   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   Phase 2   EUCTR2013-004019-37-RO   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   Phase 2   EUCTR2013-004019-37-CZ   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   -   EUCTR2013-004019-37-HU   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
ABT-494   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2017   Phase 3   EUCTR2016-000933-37-IT   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;European Union;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-IT   Argentina;Australia;Austria;Barbados;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Kazakhstan;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   AbbVie
      2014   Phase 2   NCT02049138   Australia;Belgium;Bulgaria;Chile;Czech Republic;Czechia;Hungary;Israel;Latvia;Mexico;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 2   NCT01960855   Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;New Zealand;Poland;Puerto Rico;Spain;United Kingdom;United States;
   AbbVie (prior sponsor, Abbott)
      2012   Phase 1   NCT01741493   United States;
   AbbVie Deutschland GmbH & Co. KG
      2019   Phase 2   EUCTR2018-002306-31-HU   Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-002306-31-GB   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-002306-31-ES   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-002306-31-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-000666-10-HU   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-000666-10-ES   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2019   Phase 2   EUCTR2018-000666-10-BE   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
      2018   Phase 3   EUCTR2016-000933-37-BG   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2018-000666-10-GB   Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-SK   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-SE   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-PT   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-NL   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-DE   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-CZ   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000933-37-BE   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000933-37-LV   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000933-37-HU   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000933-37-ES   Argentina;Australia;Belarus;Brazil;Canada;Chile;Colombia;European Union;Hungary;Israel;Korea, Democratic People's Republic of;Latvia;Mexico;New Zealand;Norway;Puerto Rico;Russian Federation;Spain;Switzerland;Turkey;United States;
      2016   Phase 3   EUCTR2015-003376-75-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-GR   Argentina;Australia;Austria;Belgium;Chile;Colombia;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-ES   Argentina;Australia;Austria;Chile;Colombia;European Union;Israel;Japan;Mexico;New Zealand;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003376-75-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003335-35-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-SI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-SE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-NO   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-LV   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-IE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-GR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-FR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003335-35-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-SI   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-RO   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-PT   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-PL   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-LV   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-LT   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-IE   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-HU   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Greece;Hong Kong;Hungary;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003334-27-HR   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-GR   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Egypt;European Union;Greece;Hong Kong;Hungary;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003334-27-GB   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-FI   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-ES   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Egypt;European Union;Greece;Hong Kong;Hungary;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-CZ   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-BG   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003334-27-BE   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-PT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-LV   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-LT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-IE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-HU   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003333-95-HR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-GR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-GB   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-FI   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-ES   Argentina;Australia;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Denmark;Egypt;European Union;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003333-95-DK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-DE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-BG   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-BE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003333-95-AT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-SK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-PT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-PL   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-LV   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-LT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-IE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-HU   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-HR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-GR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-GB   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-FI   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-ES   Argentina;Australia;Austria;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Norway;Poland;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-003332-13-DK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-BG   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-BE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003332-13-AT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   -   EUCTR2015-003332-13-NO   Argentina;Australia;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Denmark;Egypt;European Union;Finland;Hong Kong;Israel;Kazakhstan;Korea, Republic of;Malaysia;Mexico;New Zealand;Norway;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2015   Phase 3   EUCTR2015-003334-27-SK   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-003333-95-SK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003530-33-LV   Belgium;Bulgaria;Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Netherlands;New Zealand;Puerto Rico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
ABT-Humira   
   Abbott GmbH & Co. KG
      2008   -   EUCTR2007-005905-23-GB   Germany;United Kingdom;
      2008   -   EUCTR2007-005905-23-DE   Germany;United Kingdom;
ABX464   
   Abivax
      2019   Phase 2   EUCTR2019-001578-27-HU   Hungary;
      2019   Phase 2   EUCTR2018-004677-27-HU   Belgium;Hungary;
      2019   Phase 2   EUCTR2018-004677-27-BE   Belgium;Hungary;
   Abivax S.A.
      2019   Phase 2   NCT04049448   Belgium;Czechia;France;Hungary;Poland;
      2019   Phase 2   NCT03813199   Belgium;Czechia;France;Hungary;Poland;
AC430   
   Daiichi Sankyo Inc.
      2010   Phase 1   NCT01287858   United States;
ACZ885   
   NOVARTIS FARMA
      2007   -   EUCTR2007-001665-15-IT   Germany;Italy;Netherlands;Spain;
      2007   -   EUCTR2006-001553-10-IT   Germany;Italy;Netherlands;
   Novartis
      2007   Phase 2   NCT00554606   Belgium;Germany;Italy;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United States;
      2007   Phase 1/Phase 2   NCT00505089   Belgium;Germany;Netherlands;Poland;
      2003   Phase 1/Phase 2   NCT00619905   Germany;Netherlands;Switzerland;
   Novartis Farmacéutica S.A.
      2009   Phase 2   EUCTR2008-005320-81-ES   Austria;Belgium;Germany;Spain;
   Novartis Pharma AG
      2007   -   EUCTR2006-001550-27-FI   Austria;Finland;Germany;Spain;
      2007   -   EUCTR2006-001550-27-DE   Austria;Finland;Germany;Spain;
      2006   -   EUCTR2006-001550-27-BE   Austria;Belgium;Finland;Germany;Spain;
      2006   -   EUCTR2006-001550-27-AT   Austria;Finland;Germany;Spain;
   Novartis Pharma Services AG
      2009   -   EUCTR2008-005320-81-DE   Austria;Germany;Spain;
      2009   -   EUCTR2008-005320-81-BE   Austria;Belgium;Germany;Spain;
      2008   -   EUCTR2008-005320-81-AT   Austria;Germany;Spain;
      2007   -   EUCTR2007-001665-15-DE   Germany;Italy;Netherlands;Spain;
      2007   -   EUCTR2007-000491-16-DE   Austria;Germany;Spain;
      2007   -   EUCTR2006-001553-10-DE   Germany;Italy;Netherlands;
ACZ885 (investigational)   
   Novartis
      2007   Phase 2   NCT00504595   Russian Federation;Spain;Switzerland;Turkey;
ACZ885 Drug Substance   
   Novartis Farmaceutica S.A.
      2007   -   EUCTR2007-001665-15-ES   Belgium;Germany;Italy;Netherlands;Spain;
   Novartis Farmacéutica S.A
      2007   -   EUCTR2006-004669-32-ES   Spain;
   Novartis Farmacéutica, S.A.
      2007   -   EUCTR2007-000491-16-ES   Austria;Belgium;Germany;Spain;
   Novartis Pharma Services AG
      2007   Phase 2   EUCTR2006-001553-10-BE   Belgium;Germany;Italy;Netherlands;
      2007   -   EUCTR2007-001665-15-NL   Germany;Italy;Netherlands;Spain;
      2007   -   EUCTR2007-001665-15-BE   Belgium;Germany;Italy;Netherlands;Spain;
      2007   -   EUCTR2007-000491-16-BE   Austria;Belgium;Germany;Spain;
      2007   -   EUCTR2007-000491-16-AT   Austria;Germany;Spain;
      2007   -   EUCTR2006-004666-14-DE   Germany;
      2007   -   EUCTR2006-004666-14-BE   Belgium;Germany;
      2007   -   EUCTR2006-001553-10-NL   Germany;Italy;Netherlands;
AD 452   
   Arakis Ltd.
      2005   -   EUCTR2005-002421-31-DE   Germany;United Kingdom;
   Sosei
      2005   Phase 2   NCT00141934   United States;
AD 452 18 mg tablet   
   Arakis Ltd
      2005   -   EUCTR2005-002421-31-GB   Germany;United Kingdom;
AD 452 4.5 mg Tablet   
   Arakis Ltd
      2005   -   EUCTR2005-002421-31-GB   Germany;United Kingdom;
AD 452 9 mg tablet   
   Arakis Ltd
      2005   -   EUCTR2005-002421-31-GB   Germany;United Kingdom;
ADALIMUMAB HUMIRA   
   Pfizer Inc
      2020   Phase 4   EUCTR2019-000284-24-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2019   Phase 3   EUCTR2019-000284-24-LT   Argentina;Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Mexico;Peru;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
ADALIMUMAB-EU   
   Pfizer Inc.
      2015   Phase 3   EUCTR2014-000352-29-HR   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-FR   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-EE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-BG   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000352-29-LT   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000352-29-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-GB   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-ES   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-CZ   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
ADL5859   
   Cubist Pharmaceuticals LLC
      2007   Phase 2   NCT00626275   United States;
AGM 719   
   Amgen
      2002   Phase 2   NCT00038298   United States;
AI-1000 G2   
   Hoffmann-La Roche
      2016   Phase 4   NCT02682823   United States;
AIN457   
   NOVARTIS FARMA
      2012   -   EUCTR2012-002760-27-IT   Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2011-000275-13-IT   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
   Novartis Farma S.p.A.
      2013   -   EUCTR2013-000944-25-IT   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Thailand;United States;
   Novartis Farmaceutica, S.A.
      2012   -   EUCTR2012-002760-27-ES   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
   Novartis Farmacéutica S.A.
      2011   -   EUCTR2011-000102-21-ES   Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
   Novartis Pharma AG
      2012   -   EUCTR2012-002760-27-SK   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2012   -   EUCTR2012-002760-27-HU   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2012   -   EUCTR2012-002760-27-CZ   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2012   -   EUCTR2011-006058-94-PT   Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Japan;Korea, Republic of;Panama;Portugal;South Africa;United States;
      2012   -   EUCTR2011-006058-94-GR   Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Korea, Republic of;Panama;Portugal;South Africa;United States;
      2011   -   EUCTR2011-000275-13-HU   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
      2011   -   EUCTR2011-000275-13-GB   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
      2011   -   EUCTR2011-000275-13-BE   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
      2011   -   EUCTR2011-000102-21-SK   Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2010-024516-34-SK   Bulgaria;Canada;Hungary;Italy;Slovakia;United States;
      2011   -   EUCTR2010-024516-34-HU   Bulgaria;Canada;Hungary;Italy;United States;
      2011   -   EUCTR2010-024516-34-BG   Bulgaria;Canada;Hungary;Italy;Slovakia;United States;
   Novartis Pharma K.K.
      2013   Phase 3   JPRN-JapicCTI-132209   -
      2012   Phase 3   JPRN-JapicCTI-132091   -
   Novartis Pharma Services AG
      2013   -   EUCTR2012-002760-27-BG   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
   Novartis Pharma Services AG
      2013   -   EUCTR2013-000944-25-HU   Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Thailand;United States;
      2013   -   EUCTR2011-006058-94-DE   Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Japan;Korea, Republic of;Panama;Portugal;South Africa;United States;
      2012   -   EUCTR2012-002760-27-DE   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2012   -   EUCTR2011-006058-94-CZ   Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Japan;Korea, Republic of;Panama;Portugal;South Africa;United States;
      2011   Phase 2   EUCTR2011-001220-38-GB   Belgium;Germany;Russian Federation;United Kingdom;United States;
      2011   Phase 2   EUCTR2011-001220-38-BE   Belgium;Germany;Russian Federation;United Kingdom;United States;
      2011   -   EUCTR2011-001220-38-DE   Belgium;Germany;Russian Federation;United Kingdom;United States;
      2011   -   EUCTR2011-000102-21-HU   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2011-000102-21-DE   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2011-000102-21-CZ   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2011-000102-21-BG   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2009   -   EUCTR2009-011000-34-SK   Czech Republic;Germany;Hungary;Slovakia;
      2009   -   EUCTR2009-011000-34-HU   Czech Republic;Germany;Hungary;Slovakia;
      2009   -   EUCTR2009-011000-34-DE   Czech Republic;Germany;Hungary;Slovakia;
      2009   -   EUCTR2009-011000-34-CZ   Czech Republic;Germany;Hungary;Slovakia;
      2009   -   EUCTR2009-011000-34-BE   Belgium;Czech Republic;Germany;Hungary;Slovakia;
   Novartis Pharmaceuticals
      2011   Phase 3   NCT01350804   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
      2005   Phase 1/Phase 2   NCT00669942   Belgium;Germany;Netherlands;Singapore;Spain;United States;
AIN457F   
   NOVARTIS FARMA
      2012   -   EUCTR2011-006058-94-IT   Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Korea, Republic of;Panama;Portugal;South Africa;United States;
      2011   -   EUCTR2011-000102-21-IT   Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
      2011   -   EUCTR2010-024516-34-IT   Bulgaria;Canada;Hungary;Italy;United States;
AK106-001616   
   Asahi Kasei Pharma Corporation
      2011   Phase 2   NCT01285752   Czech Republic;Germany;Hungary;Poland;Slovakia;Ukraine;United Kingdom;
      2011   -   EUCTR2010-021558-21-SK   Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
      2011   -   EUCTR2010-021558-21-HU   Czech Republic;Germany;Hungary;Slovakia;United Kingdom;
      2011   -   EUCTR2010-021558-21-GB   Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
      2011   -   EUCTR2010-021558-21-DE   Czech Republic;Germany;Hungary;Slovakia;United Kingdom;
      2010   -   EUCTR2010-021558-21-CZ   Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
      2009   Phase 2   NCT00902369   Czech Republic;Germany;Hungary;Lithuania;Romania;United Kingdom;
      2009   -   EUCTR2008-006075-75-HU   Czech Republic;Germany;Hungary;United Kingdom;
      2009   -   EUCTR2008-006075-75-GB   Czech Republic;Germany;Hungary;United Kingdom;
      2009   -   EUCTR2008-006075-75-DE   Czech Republic;Germany;Hungary;United Kingdom;
      2009   -   EUCTR2008-006075-75-CZ   Czech Republic;Germany;Hungary;United Kingdom;
ALD518 monoclonal antibody (anti IL-6 mAb)   
   Alder Biopharmaceuticals, Inc
      2008   -   EUCTR2008-004931-39-PL   Poland;
ALX-0061   
   Ablynx
      2015   Phase 2   NCT02518620   Belgium;Bulgaria;Georgia;Germany;Hungary;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;
      2015   Phase 2   NCT02309359   Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   NCT02287922   Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;United States;
      2014   Phase 1   NCT02101073   Netherlands;
      2011   Phase 1/Phase 2   NCT01284569   Czech Republic;Czechia;Hungary;Netherlands;Poland;
   Ablynx NV
      2015   Phase 2   EUCTR2014-003034-42-HU   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
      2015   Phase 2   EUCTR2014-003034-42-ES   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
      2015   Phase 2   EUCTR2014-003034-42-DE   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
      2015   Phase 2   EUCTR2014-003034-42-BG   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
      2015   Phase 2   EUCTR2014-003034-42-BE   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
      2015   Phase 2   EUCTR2014-003033-26-HU   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003033-26-ES   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003033-26-DE   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003033-26-CZ   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003033-26-BG   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003033-26-BE   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-HU   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-ES   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-DE   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-CZ   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-BG   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
      2015   Phase 2   EUCTR2014-003012-36-BE   Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
ALX-0061 Nanobody   
   Ablynx NV
      2011   -   EUCTR2010-022865-81-HU   Czech Republic;Hungary;
      2011   -   EUCTR2010-022865-81-CZ   Czech Republic;Hungary;
AMG 108   
   AMGEN S.P.A.
      2007   -   EUCTR2006-003698-29-IT   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2006   -   EUCTR2005-003558-83-IT   Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
   Amgen
      2006   Phase 2   NCT00369473   Australia;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Mexico;Netherlands;Poland;Puerto Rico;Slovakia;Spain;United Kingdom;United States;
      2006   Phase 2   NCT00293826   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Mexico;Netherlands;Poland;Puerto Rico;Slovakia;Spain;Sweden;United Kingdom;United States;
   Amgen Inc.
      2007   -   EUCTR2006-003698-29-LV   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2006-003698-29-IE   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2006-003698-29-HU   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2006-003698-29-EE   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2006-003698-29-AT   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2005-003558-83-LV   Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2005-003558-83-IE   Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2005-003558-83-EE   Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2006   Phase 2   EUCTR2006-003698-29-SK   Austria;Belgium;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Slovakia;Sweden;United Kingdom;
      2006   Phase 2   EUCTR2006-003698-29-FR   Austria;Belgium;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Slovakia;Sweden;United Kingdom;
      2006   Phase 2   EUCTR2005-003558-83-SK   Austria;Belgium;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2006   Phase 2   EUCTR2005-003558-83-GB   Austria;Belgium;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2006   Phase 2   EUCTR2005-003558-83-ES   Austria;Belgium;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-003698-29-SE   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2006   -   EUCTR2006-003698-29-NL   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2006   -   EUCTR2006-003698-29-GB   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2006   -   EUCTR2006-003698-29-CZ   Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2006   -   EUCTR2006-003698-29-BE   Austria;Belgium;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
      2006   -   EUCTR2005-003558-83-SE   Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003558-83-NL   Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003558-83-CZ   Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003558-83-BE   Austria;Belgium;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-003558-83-AT   Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
AMG 162   
   DAIICHISANKYO Co.,Ltd.
      2013   Phase 3   JPRN-JapicCTI-132277   -
      2010   Phase 2   JPRN-JapicCTI-101263   -
AMG 357   
   Amgen
      2015   Phase 1   NCT02499315   United States;
AMG 570   
   Amgen
      2017   Phase 1   NCT03156023   Germany;United States;
AMG 592   
   Amgen
      2018   Phase 1/Phase 2   NCT03410056   Bulgaria;Germany;Poland;Spain;United States;
   Amgen Inc
      2018   Phase 1;Phase 2   EUCTR2017-001944-36-ES   Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2017   Phase 1;Phase 2   EUCTR2017-001944-36-PL   Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
AMG 714   
   Amgen
      2002   Phase 2   NCT00433875   -
AMG 719   
   Amgen
      2002   Phase 2   NCT00038298   United States;
AMG 827   
   Amgen
      2010   Phase 2   NCT01059448   Bulgaria;Canada;Czech Republic;Latvia;Mexico;Poland;United Kingdom;United States;
      2009   Phase 2   NCT00950989   Bulgaria;Canada;Czech Republic;Hungary;Latvia;Mexico;Poland;United Kingdom;United States;
      2008   Phase 1/Phase 2   NCT00771030   Canada;Mexico;United States;
   Amgen Inc
      2010   Phase 2   EUCTR2009-012566-32-HU   Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
      2010   -   EUCTR2009-016119-38-PL   Bulgaria;Latvia;Poland;United Kingdom;
      2010   -   EUCTR2009-016119-38-LV   Bulgaria;Latvia;Poland;United Kingdom;
      2010   -   EUCTR2009-016119-38-GB   Australia;Bulgaria;Czech Republic;Latvia;Poland;United Kingdom;
      2010   -   EUCTR2009-016119-38-CZ   Bulgaria;Czech Republic;Latvia;Poland;United Kingdom;
      2010   -   EUCTR2009-016119-38-BG   Bulgaria;Latvia;Poland;United Kingdom;
      2010   -   EUCTR2009-012566-32-CZ   Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
      2010   -   EUCTR2009-012566-32-BG   Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
      2009   -   EUCTR2009-012566-32-PL   Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
      2009   -   EUCTR2009-012566-32-LV   Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
      2009   -   EUCTR2009-012566-32-GB   Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
AMG592   
   Amgen Inc
      2018   Phase 1;Phase 2   EUCTR2017-001944-36-ES   Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-001944-36-BG   Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2017   Phase 1;Phase 2   EUCTR2017-001944-36-PL   Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
AMP-110   
   MedImmune LLC
      2014   Phase 1   NCT02277574   United States;
      2013   Phase 1   NCT01878123   United States;
AMT-101   
   Applied Molecular Transport Inc.
      2020   Phase 2   EUCTR2020-003955-14-DE   Germany;
AP1189   
   SynAct Pharma ApS
      2020   Phase 2   EUCTR2019-001185-15-NO   Bulgaria;Denmark;Moldova, Republic of;Norway;Sweden;
      2020   Phase 2   EUCTR2019-001185-15-BG   Bulgaria;Denmark;Moldova, Republic of;Norway;Sweden;
      2019   Phase 2   EUCTR2019-001185-15-SE   Bulgaria;Denmark;Moldova, Republic of;Norway;Sweden;
      2019   Phase 2   EUCTR2019-001185-15-DK   Bulgaria;Denmark;Moldova, Republic of;Norway;Sweden;
   SynAct Pharma Aps
      2019   Phase 2   NCT04004429   Denmark;Norway;
APLA12   
   VA Office of Research and Development
      2009   Phase 1   NCT01123655   United States;
ARA290   
   LUMC
      2011   -   EUCTR2010-023469-22-NL   Netherlands;
ARAVA   
   sanofi-aventis Groupe
      2008   -   EUCTR2007-000886-40-IT   Italy;Portugal;
ARAVA®   
   sanofi-aventis groupe
      2007   Phase 3   EUCTR2007-000886-40-CZ   Czech Republic;Italy;Portugal;
      2007   -   EUCTR2007-000886-40-PT   Italy;Portugal;
ARRY-371797, p38 inhibitor   
   Array Biopharma, now a wholly owned subsidiary of Pfizer
      2008   Phase 1   NCT00729209   United States;
ARRY-438162   
   Array BioPharma Inc.
      2008   -   EUCTR2007-007859-14-PL   Hungary;Poland;
      2008   -   EUCTR2007-007859-14-HU   Hungary;Poland;
ARRY-438162, MEK inhibitor   
   Array Biopharma, now a wholly owned subsidiary of Pfizer
      2008   Phase 2   NCT00650767   Argentina;Brazil;Hungary;Peru;Poland;Romania;United States;
ART621   
   Arana Therapeutics Ltd
      2009   Phase 2   NCT00928317   Argentina;Australia;Czech Republic;India;Malaysia;New Zealand;Poland;United States;
      2009   Phase 2   NCT00854685   Sri Lanka;
      2009   -   EUCTR2009-014824-40-CZ   Czech Republic;
      2009   -   EUCTR2008-006930-92-CZ   Czech Republic;
AS Domelock System   
   Zimmer Biomet
      2017   -   NCT03312465   Belgium;Germany;Switzerland;United Kingdom;
ASK8007   
   Astellas Pharma Inc
      2007   Phase 1/Phase 2   NCT00411424   Belgium;France;Hungary;Ireland;Netherlands;Spain;United Kingdom;
ASP015K   
   Astellas Pharma Global Development
      2013   Phase 2   EUCTR2011-006021-23-CZ   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
      2013   Phase 2   EUCTR2011-006021-23-BG   Belgium;Bulgaria;Colombia;Czech Republic;Germany;Hungary;Mexico;Poland;
      2013   -   EUCTR2011-006021-23-HU   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
      2012   -   EUCTR2011-006021-23-BE   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
   Astellas Pharma Global Development Inc. (APGD)
      2013   Phase 2   EUCTR2011-006021-23-PL   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
ASP015K hydrobromide, AS1940150-BR, JKT-201A, 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide   
   Astellas Pharma Global Development, Inc. (APGD)
      2013   -   EUCTR2011-006020-20-PL   Bulgaria;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
      2013   -   EUCTR2011-006020-20-BG   Bulgaria;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
      2013   -   EUCTR2011-006018-15-PL   Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
      2013   -   EUCTR2011-006018-15-HU   Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
      2013   -   EUCTR2011-006018-15-BG   Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
      2012   Phase 2   EUCTR2011-006018-15-BE   Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
      2012   -   EUCTR2011-006020-20-HU   Bulgaria;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
      2012   -   EUCTR2011-006020-20-CZ   Bulgaria;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
      2012   -   EUCTR2011-006018-15-CZ   Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
ASP1707   
   Astellas Pharma Global Development, Inc.
      2016   Phase 1   NCT02867306   Moldova, Republic of;
   Astellas Pharma Inc
      2016   Phase 2   NCT02884635   Japan;
ASP2408   
   Astellas Pharma Global Development, Inc.
      2012   Phase 1   NCT02052375   United States;
ASP2409   
   Astellas Pharma Global Development, Inc.
      2012   Phase 1   NCT02171143   United States;
ASP5094   
   Astellas Pharma Global Development, Inc.
      2016   Phase 1   NCT02698657   Poland;United States;
   Astellas Pharma Inc
      2017   Phase 2   NCT03257852   Japan;
ATI-450   
   Aclaris Therapeutics, Inc.
      2020   Phase 2   NCT04247815   United States;
ATN-103   
   Ablynx
      2010   Phase 2   NCT01063803   Canada;Hungary;Japan;Russian Federation;Serbia;South Africa;Switzerland;United States;
      2009   Phase 1/Phase 2   NCT00959036   Belgium;Canada;Germany;Hungary;Russian Federation;Serbia;South Africa;Switzerland;United States;
   Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company
      2010   -   EUCTR2009-015636-15-HU   Belgium;Canada;Germany;Hungary;Japan;Russian Federation;South Africa;Switzerland;United States;
      2010   -   EUCTR2008-007185-33-DE   Belgium;Germany;Hungary;Netherlands;United Kingdom;
      2010   -   EUCTR2008-007185-33-BE   Belgium;Germany;Hungary;Netherlands;United Kingdom;
   Wyeth Pharmaceuticals Inc., Acting through its division Wyeth Research, a Pfizer Company
      2009   -   EUCTR2008-007185-33-GB   Belgium;Germany;Hungary;Netherlands;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc.
      2010   -   EUCTR2008-007185-33-NL   Belgium;Germany;Hungary;Netherlands;United Kingdom;
      2009   -   EUCTR2008-007185-33-HU   Belgium;Germany;Hungary;Netherlands;United Kingdom;
ATN-103 10 mg q4wks   
   Ablynx
      2009   Phase 1/Phase 2   NCT01007175   Japan;
ATN-103 10 mg q8wks   
   Ablynx
      2009   Phase 1/Phase 2   NCT01007175   Japan;
ATN-103 30 mg q4wks   
   Ablynx
      2009   Phase 1/Phase 2   NCT01007175   Japan;
ATN-103 80 mg q4wks   
   Ablynx
      2009   Phase 1/Phase 2   NCT01007175   Japan;
ATN-103 80 mg q8wks   
   Ablynx
      2009   Phase 1/Phase 2   NCT01007175   Japan;
AVE9897   
   Millennium Pharmaceuticals Inc
      2006   Phase 2   EUCTR2005-006165-14-GB   Czech Republic;Netherlands;United Kingdom;
      2006   -   EUCTR2005-006165-14-NL   Czech Republic;Netherlands;United Kingdom;
      2006   -   EUCTR2005-006165-14-CZ   Czech Republic;Netherlands;United Kingdom;
AZD5672   
   ASTRAZENECA
      2008   -   EUCTR2007-007539-14-IT   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
   AstraZeneca
      2009   Phase 1   NCT00887770   United Kingdom;
      2009   Phase 1   NCT00871767   United Kingdom;
      2008   Phase 2   NCT00713544   Argentina;Bulgaria;Colombia;Czech Republic;Hungary;Italy;Latvia;Malta;Netherlands;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Ukraine;
      2008   Phase 1   NCT00711074   United Kingdom;
   AstraZeneca AB
      2009   -   EUCTR2009-011044-20-GB   United Kingdom;
      2008   Phase 2   EUCTR2007-007539-14-SK   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;Slovakia;
      2008   -   EUCTR2007-007539-14-PL   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-MT   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-LV   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-HU   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-CZ   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-BG   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
AZD9056   
   AstraZeneca
      2009   Phase 1   NCT00920608   -
      2008   Phase 1   NCT00700986   United Kingdom;
      2007   Phase 2   NCT00520572   Argentina;Australia;Belgium;Canada;Czech Republic;France;Hungary;Mexico;Poland;Romania;Russian Federation;Slovakia;Sweden;United States;
AZD9056 hydrochloride   
   AstraZeneca AB
      2008   -   EUCTR2007-001420-12-CZ   Czech Republic;France;Poland;Sweden;
      2007   Phase 2   EUCTR2007-001420-12-SK   Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
      2007   Phase 2   EUCTR2007-001420-12-FR   Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
      2007   -   EUCTR2007-001420-12-SE   Czech Republic;France;Poland;Sweden;
      2007   -   EUCTR2007-001420-12-PL   Czech Republic;France;Poland;Sweden;
      2007   -   EUCTR2007-001420-12-BE   Belgium;Czech Republic;France;Poland;Sweden;
AZD9567   
   AstraZeneca
      2018   Phase 2   NCT03368235   Denmark;Netherlands;Sweden;
      2016   Phase 1   NCT02760316   Germany;United Kingdom;
AZD9567 Monohydrat   
   AstraZeneca
      2015   Phase 1   NCT02512575   Germany;
AZD9567 monohydrate   
   AstraZeneca AB
      2017   Phase 2   EUCTR2017-000838-64-SE   Denmark;Netherlands;Sweden;
      2017   Phase 2   EUCTR2017-000838-64-NL   Denmark;Netherlands;Sweden;
      2017   Phase 2   EUCTR2017-000838-64-DK   Denmark;Netherlands;Sweden;
Abatacept   
   AbbVie
      2017   Phase 3   NCT03086343   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czechia;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Academisch Medisch Centrum Amsterdam
      2010   -   EUCTR2010-021435-14-NL   Netherlands;
   Arthritis & Rheumatic Disease Specialties Research
      2011   Phase 3   NCT01351480   United States;
   Astellas Pharma Inc
      2011   -   NCT01339481   United States;
   Astellas Pharma Korea, Inc.
      2019   Phase 4   NCT03737708   Korea, Republic of;
   BRISTOL-M.SQUIBB
      2005   -   EUCTR2004-005102-68-IT   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2021   Phase 3   EUCTR2020-000350-96-IT   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
   Brigham and Women's Hospital
      2020   -   NCT04529902   United States;
      2020   -   NCT04529876   United States;
      2020   -   NCT04529863   United States;
   Bristol Myers Squibb International Corporation
      2010   Phase 3   EUCTR2010-018674-20-FR   Belgium;Denmark;Finland;France;Germany;Italy;Sweden;
      2010   Phase 3   EUCTR2010-018674-20-BE   Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-SE   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;Sweden;United States;
      2010   -   EUCTR2010-018674-20-IT   Denmark;Finland;France;Germany;Italy;Sweden;
      2010   -   EUCTR2010-018674-20-FI   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-DK   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-DE   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2006   -   EUCTR2005-000784-26-IT   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-000784-26-AT   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-GB   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-ES   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-DE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-IE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-BE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-000922-59-DK   Czech Republic;Denmark;Spain;Sweden;
      2005   -   EUCTR2004-000922-59-CZ   Czech Republic;Denmark;Spain;Sweden;
      2004   Phase 3   EUCTR2004-000922-59-ES   Czech Republic;Denmark;Spain;Sweden;
      2004   -   EUCTR2004-000922-59-SE   Czech Republic;Denmark;Spain;Sweden;
      -   -   EUCTR2005-000443-28-Outside-EU/EEA   Austria;Brazil;France;Germany;Italy;Mexico;Peru;Portugal;Spain;Switzerland;United States;
   Bristol-Myers Squibb
      2021   Phase 3   NCT04909801   Argentina;Australia;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2020   Phase 2   NCT04186871   Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2018   Phase 1   NCT03714022   United States;
      2017   -   NCT03457792   Germany;
      2017   -   NCT03188081   Italy;
      2016   -   NCT02037737   -
      2015   Phase 4   NCT02557100   Algeria;Canada;Mexico;United States;
      2015   Phase 3   NCT02504268   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Poland;Puerto Rico;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;United States;
      2015   -   NCT02598466   -
      2014   -   NCT02169544   -
      2013   Phase 4   NCT01758198   Japan;
      2013   Phase 3   NCT01844895   -
      2013   Phase 1   NCT01890473   Argentina;Mexico;Peru;South Africa;United States;
      2012   -   NCT02090556   Australia;Austria;France;Germany;Greece;Italy;Monaco;Netherlands;Spain;Switzerland;United Kingdom;
      2010   Phase 3   NCT01142726   Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Norway;Poland;Russian Federation;South Africa;Sweden;United States;
      2010   Phase 1   NCT01221636   United States;
      2009   Phase 3   NCT00929864   Argentina;Canada;Chile;Peru;United States;
      2008   Phase 3   NCT00767325   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2008   -   NCT02109666   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Ireland;Italy;Netherlands;Spain;Switzerland;
      2007   Phase 3   NCT00989235   -
      2007   Phase 3   NCT00547521   Australia;Brazil;Canada;Mexico;Peru;South Africa;United States;
      2007   Phase 3   NCT00533897   Argentina;Brazil;Canada;Mexico;South Africa;United States;
      2007   Phase 3   NCT00420199   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   Phase 3   NCT00409838   Korea, Republic of;
      2006   Phase 3   NCT00484289   Japan;
      2006   Phase 2   NCT00345748   Japan;
      2006   Phase 1/Phase 2   NCT00254293   United States;
      2005   Phase 3   NCT00124982   Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Mexico;Spain;United Kingdom;United States;
      2005   Phase 3   NCT00122382   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2005   Phase 2   NCT00124449   Australia;Belgium;France;Germany;Italy;Mexico;Puerto Rico;Spain;United Kingdom;United States;
      2003   Phase 3   NCT00095173   Austria;Brazil;France;Germany;Italy;Mexico;Peru;Portugal;Spain;Switzerland;United States;
      2003   Phase 1   NCT00162201   United Kingdom;
      2002   Phase 3   NCT00048581   United States;
      2002   Phase 3   NCT00048568   United States;
      2000   Phase 2   NCT00162279   United States;
      2000   Phase 1/Phase 2   NCT00279760   Belgium;Canada;France;Germany;Ireland;Netherlands;Switzerland;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2008   -   EUCTR2007-004241-15-IT   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-003768-67-GB   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-003768-67-ES   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-SE   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-NL   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-DE   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-BE   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-AT   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2004-005102-68-CZ   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-005102-68-GB   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-005102-68-ES   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-002620-18-GB   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-002620-18-ES   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-CZ   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-IE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-DE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-BE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002620-18-DE   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002620-18-BE   Belgium;Germany;Italy;Spain;United Kingdom;
   Bristol-Myers Squibb K.K.
      2013   Phase 4   JPRN-JapicCTI-132121   -
   Cambridge University Hospitals NHS Foundation Trust
      2018   Phase 2   NCT03084419   United Kingdom;
   Columbia University
      2019   Phase 4   NCT03619876   United States;
   Dr. Larry W. Moreland
      2015   Phase 4   NCT02353780   United States;
   Hokkaido University Hospital
      2013   -   JPRN-UMIN000010286   Japan;
   Jeffrey Curtis
      2021   Phase 4   NCT05080218   United States;
   Jiangsu Simcere Pharmaceutical Co., Ltd.
      2016   Phase 1   NCT02805010   -
   Julia Brown
      2011   Phase 4   NCT01295151   United Kingdom;
   Leiden University Medical Center
      2018   Phase 4   NCT03492658   Netherlands;
   Maldonado A Michael
      2021   Phase 3   JPRN-jRCT2071210068   Australia;France;Germany;Japan;Taiwan;USA;
   NHS Greater Glasgow and Clyde
      2016   Phase 4   NCT02652273   United Kingdom;
      2015   Phase 4   EUCTR2014-004419-35-GB   United Kingdom;
   NYU Langone Health
      2019   Phase 4   NCT03652961   United States;
   National Health Organization Nagoya Medical Center
      2010   -   JPRN-UMIN000011789   Japan;
   Novartis Pharmaceuticals
      2011   Phase 3   NCT01350804   Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
   Osaka Medical College
      2014   -   JPRN-UMIN000013440   Japan;
   Shinshu University
      2018   Phase 2   NCT03784261   Japan;
   St George's, University of London
      2020   Phase 4   EUCTR2019-004468-23-GB   United Kingdom;
   St.Marianna University School of Medicine
      2014   -   JPRN-UMIN000015175   Japan;
   The Cleveland Clinic
      2013   Phase 2   NCT02027298   United States;
   The First Hospital, Jilin University
      2016   Phase 1 study   ChiCTR-IIR-16008693   China;
   University Hospital, Montpellier
      2016   -   NCT02547493   France;Monaco;
   University of California, Los Angeles
      2014   -   NCT02053727   United States;
      2011   Phase 3   NCT01299961   United States;
   University of Leeds
      2011   Phase 4   EUCTR2010-023880-17-GB   United Kingdom;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
   University of Occupational and Environmental Health, Japan
      2010   -   JPRN-UMIN000008756   Japan;
   University of Washington
      2019   Phase 4   NCT03882008   United States;
   Vastra Gotaland Region
      2017   -   NCT03440892   Sweden;
   Yokohama City University Graduate School of Medicine
      2014   -   JPRN-UMIN000015217   Japan;
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)   
   Bristol-Myers Squibb
      2005   Phase 3   NCT00095147   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;Spain;Sweden;Switzerland;United States;
Abatacept (BMS-188667)   
   Bristol-Myers Squibb
      2011   Phase 1   NCT01439204   United States;
      2000   Phase 2   NCT00162266   Argentina;Australia;Belgium;Canada;France;Germany;Ireland;Netherlands;South Africa;United Kingdom;United States;
Abatacept (IV)   
   Bristol Myers Squibb International Corporation
      2011   Phase 3   EUCTR2008-001523-57-NO   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2010   -   EUCTR2008-001523-57-HU   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2010   -   EUCTR2008-001523-57-DE   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-001523-57-GB   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-001523-57-ES   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   -   EUCTR2008-001523-57-DK   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2008   Phase 3   EUCTR2008-001523-57-FR   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-005434-37-FR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-NL   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-IE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-HU   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-GR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-DE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-BE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-AT   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
   Bristol-Myers Squibb International Corporation
      2008   Phase 3   EUCTR2007-005434-37-GB   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
Abatacept (SC)   
   Bristol Myers Squibb International Corporation
      2008   Phase 3   EUCTR2007-005434-37-FR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-NL   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-IE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-HU   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-GR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-DE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-BE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-AT   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
   Bristol-Myers Squibb International Corporation
      2008   Phase 3   EUCTR2007-005434-37-GB   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
Abatacept + Methotrexate   
   Bristol-Myers Squibb K.K.
      2015   Phase 3   JPRN-JapicCTI-153081   Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
Abatacept + csDMARD   
   New York University School of Medicine
      2019   Phase 4   NCT03700021   United States;
Abatacept Injection   
   Fundacion Clinic per a la Recerca Biomédica
      2019   Phase 4   NCT03669367   -
   St George's, University of London
      2020   Phase 4   NCT04255134   United Kingdom;
   University of Erlangen-Nürnberg Medical School
      2019   Phase 2   NCT04120831   Germany;
Abatacept Placebo   
   Bristol-Myers Squibb K.K.
      2015   Phase 3   JPRN-JapicCTI-153081   Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
Abatacept Prefilled Syringe   
   Lille Catholic University
      2018   Phase 4   NCT03227419   France;
Abatacept combination product (ACP)   
   Bristol-Myers Squibb
      2009   Phase 3   NCT01173120   -
Abatacept, rituximab or tocilizumab   
   University Hospital, Strasbourg, France
      2009   Phase 4   NCT01000441   France;Monaco;
Acalabrutinib   
   Acerta Pharma BV
      2015   Phase 2   NCT02387762   United States;
Aceclofenac   
   Chung Shan Medical University
      2007   Phase 4   NCT04144101   -
Acellbia   
   Biocad
      2015   Phase 3   NCT02744196   -
Acetaminophen   
   Hoffmann-La Roche
      2011   Phase 4   NCT01382940   United States;
   Kojima Toshihisa
      2016   -   JPRN-jRCTs041180071   Japan;
   Merck Sharp & Dohme Corp.
      2011   Phase 1   NCT01390441   Belarus;Bulgaria;Colombia;Georgia;Hungary;Italy;Philippines;Poland;Russian Federation;Singapore;Spain;Ukraine;United Kingdom;United States;
   Nekoyama Miyao Hospital
      2016   -   JPRN-UMIN000018931   Japan;
   Osaka City University Medical School, Department of Orthopedic Surgery
      2014   -   JPRN-UMIN000012364   Japan;
   Yamaguchi University
      2018   -   JPRN-UMIN000031692   Japan;
Acetaminophen tablets   
   Maoxiang Group Jilin Pharmaceutical Co., Ltd.
      2014   Phase 2   NCT02029599   China;
Acide folique   
   CHU de Bordeaux
      2019   Phase 2   EUCTR2018-004287-56-FR   France;
Actemra   
   F. Hoffmann- La Roche Ltd
      2009   -   EUCTR2008-000587-17-GR   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   F. Hoffmann-La Roche Limited
      2007   -   EUCTR2007-001114-17-GB   United Kingdom;
   F. Hoffmann-La Roche Ltd
      2010   Phase 3   EUCTR2008-006924-68-AT   Austria;Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2008-000587-17-HU   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-000587-17-DE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-SE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-PT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-GB   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-FI   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-DK   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-CZ   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-BE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000587-17-AT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   ROCHE
      2009   -   EUCTR2008-000587-17-IT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Actemra(EU-licensed)   
   Bio-Thera Solutions
      2018   Phase 3   NCT03830203   China;
Acthar   
   Veena Ranganath, MD, MS
      2017   Phase 4   NCT02541955   United States;
Acthar Gel   
   Mallinckrodt
      2016   Phase 4   NCT02919761   Argentina;Colombia;Mexico;Peru;Puerto Rico;United States;
Acthar Injectable Product   
   Attune Health Research, Inc.
      2018   Phase 3   NCT03511625   United States;
Active Stimulation   
   Galvani Bioelectronics
      2021   -   NCT05003310   United States;
Active comparator   
   Asahi Kasei Pharma Corporation
      2011   Phase 2   NCT01285752   Czech Republic;Germany;Hungary;Poland;Slovakia;Ukraine;United Kingdom;
      2009   Phase 2   NCT00902369   Czech Republic;Germany;Hungary;Lithuania;Romania;United Kingdom;
Acupuncture   
   Chinese Academy of Sciences
      2012   -   NCT01619176   China;
Acycloguanosine   
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy;
Ad26.COV2.S   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
Adalimuab, Etanercept, Tocilizumab, or Abatacept   
   Hanyang University
      2020   -   NCT04449224   Korea, Republic of;
Adalimumab   
    Department of Rheumatology and Clinical Immunology
   AbbVie
      2019   Phase 2   NCT03823391   Germany;Hungary;Israel;Netherlands;Poland;Puerto Rico;United States;
      2016   -   NCT02750800   Hungary;
      2016   -   NCT02668640   China;
      2015   Phase 4   NCT02198651   Australia;Austria;Canada;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2015   Phase 3   NCT02629159   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 2   NCT02141997   Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;United States;
      2013   -   NCT01768858   Austria;
      2007   Phase 1   NCT00650156   China;
   AbbVie (prior sponsor, Abbott)
      2012   Phase 2   NCT01561313   Belgium;Czech Republic;
      2012   Phase 2   NCT01502423   Australia;Canada;Germany;
      2012   -   NCT01736189   Japan;
      2010   Phase 4   NCT01185288   Puerto Rico;United States;
      2010   Phase 4   NCT01162421   Canada;
      2010   Phase 3   NCT01185301   Argentina;Austria;Belgium;Canada;Czech Republic;Germany;Poland;Puerto Rico;Spain;United States;
      2009   Phase 4   NCT00808509   Sweden;
      2000   Phase 3   NCT00195663   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
   Abbott
      2008   Phase 3   NCT00690573   Japan;
      2007   Phase 3   NCT01231321   Russian Federation;
      2007   Phase 3   NCT00647270   Australia;Canada;Germany;Puerto Rico;United Kingdom;United States;
      2007   Phase 2/Phase 3   NCT00538902   China;
      2006   Phase 4   NCT00420927   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Hungary;Mexico;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2006   Phase 3   NCT00603993   Japan;
      2004   Phase 4   NCT00234897   United States;
      2004   Phase 3   NCT00235872   Japan;
      2004   Phase 2/Phase 3   NCT00647491   Japan;
      2004   -   NCT00650390   -
      2003   Phase 4   NCT00649922   -
      2003   Phase 3   NCT00647920   Taiwan;
      2003   Phase 3   NCT00235859   -
      2003   Phase 3   NCT00234936   -
      2003   Phase 3   NCT00234845   United States;
      2003   Phase 2   NCT00235833   Japan;
      2003   -   NCT00649545   -
      2003   -   NCT00234884   Australia;Austria;Belgium;France;Germany;Greece;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2002   Phase 3   NCT00448383   -
      2002   Phase 3   NCT00049751   United States;
      2002   -   NCT00650026   -
      2000   Phase 3   NCT00195702   Canada;United States;
      2000   Phase 3   NCT00195650   Canada;United States;
   Abbott GmbH & Co. KG
      2008   -   EUCTR2007-005905-23-GB   Germany;United Kingdom;
      2008   -   EUCTR2007-005905-23-DE   Germany;United Kingdom;
      2008   -   EUCTR2006-004139-31-NO   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2006-004139-31-GR   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   Phase 4   EUCTR2006-004139-31-SK   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
      2007   Phase 4   EUCTR2006-004139-31-HU   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
      2007   Phase 4   EUCTR2006-004139-31-FR   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-SE   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-NL   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-GB   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-ES   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-DE   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-CZ   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-BE   Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004139-31-AT   Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
   Abbott Japan Co., Ltd.
      2009   Phase 3   JPRN-JapicCTI-090751   -
      2008   Phase 3   JPRN-JapicCTI-080587   -
   Abbott Scandinavia AB
      2008   -   EUCTR2008-004398-16-SE   Sweden;
   Amgen
      2013   Phase 3   NCT01970475   Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
   Astellas Pharma Korea, Inc.
      2019   Phase 4   NCT03737708   Korea, Republic of;
   AstraZeneca
      2011   Phase 2   NCT02092961   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;South Africa;United Kingdom;United States;
      2011   Phase 2   NCT01264770   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
   Biogen
      2006   Phase 2   NCT00298272   United States;
   Biologic Mate Study Group
      2014   -   JPRN-UMIN000015616   Japan;
   Bristol-Myers Squibb
      2021   Phase 3   NCT04909801   Argentina;Australia;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2015   Phase 4   NCT02557100   Algeria;Canada;Mexico;United States;
      2009   Phase 3   NCT00929864   Argentina;Canada;Chile;Peru;United States;
   CHU Saint-Etienne
      2008   -   EUCTR2008-006256-22-FR   France;
   CSL Behring
      2011   Phase 2   NCT01373151   Argentina;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
   Charité-Universitätsmedizin Berlin
   Cinnagen
      2015   Phase 3   NCT03172325   Iran, Islamic Republic of;
   Columbia University
      2019   Phase 4   NCT03619876   United States;
   Department of Rheumatosurgery, Osaka City University Medical School
      2009   Phase 4   JPRN-UMIN000002340   Japan;
   Dept. of Rhematology UMAS
      2005   -   EUCTR2005-000129-47-SE   Sweden;
   Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences
      2011   -   JPRN-UMIN000013750   Japan;
   EMD Serono
      2007   Phase 2   NCT00595413   Germany;United States;
   Eli Lilly Japan K.K.
      -   Phase 3   JPRN-JapicCTI-132125   -
   Eli Lilly and Company
      2012   Phase 3   NCT01710358   Argentina;Belgium;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2008   Phase 4   EUCTR2007-000593-24-GB   Sweden;United Kingdom;
   F. Hoffmann-La Roche Ltd.
      2011   -   EUCTR2010-023587-40-IT   Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
   F.Hoffmann-La Roche Ltd
      2008   -   EUCTR2007-000593-24-SE   Sweden;United Kingdom;
   Fen Li
      2016   Phase 4   NCT02878161   -
   Genentech, Inc.
      2016   Phase 2   NCT02833350   Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
      2010   Phase 2   NCT01225393   Bulgaria;Chile;Germany;Hungary;Mexico;Peru;Poland;Romania;Spain;United States;
   Georgetown University
      2013   Phase 4   NCT01793519   United States;
   Gilead Sciences
      2016   Phase 3   NCT02889796   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
   Glostrup University Hospital, Copenhagen
      2009   -   NCT01029613   Denmark;
   Goupe d'Etudes et de Recherche Clinique En Rhumatologie
      2004   Phase 4   NCT00291915   France;
   Hamed Rezaei
      2012   Phase 4   NCT01609205   Sweden;
   Heinrich-Heine University, Duesseldorf
      2014   Phase 3   NCT02150473   Germany;
   Hoffmann-La Roche
      2011   Phase 4   NCT01283971   Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Puerto Rico;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   NCT01592292   Korea, Republic of;
      2010   Phase 4   NCT01119859   Australia;Belgium;Brazil;Czech Republic;Finland;Germany;Greece;Mexico;Norway;Portugal;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Hvidovre University Hospital
      2005   Phase 4   NCT00216177   Denmark;
   Imperial College London South Kensington London
      2009   Phase 4   EUCTR2009-012424-87-GB   United Kingdom;
   Jagiellonian University
      2013   Phase 4   NCT02132234   Poland;
   Janssen Research & Development, LLC
      2014   Phase 3   NCT02019472   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
   Jonathan Graf
      2013   Phase 4   NCT01893996   United States;
   Julia Brown
      2011   Phase 4   NCT01295151   United Kingdom;
   Karolinska Institutet
      2010   -   NCT01197144   Sweden;
   Keio University
      2018   Phase 4   NCT03505008   Japan;Korea, Republic of;Taiwan;
      2011   Phase 4   NCT01270035   Japan;
   King's College London
      2010   Phase 4   EUCTR2010-020738-24-GB   United Kingdom;
   Leeds University
      2014   -   JPRN-UMIN000016928   Japan,Europe;
   Leiden University Medical Center, department of rheumatology
      2007   -   EUCTR2006-006186-16-NL   Netherlands;
   MERCK SERONO INTERNATIONAL SA
      2008   -   EUCTR2007-002536-29-IT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
   Maldonado A Michael
      2021   Phase 3   JPRN-jRCT2071210068   Australia;France;Germany;Japan;Taiwan;USA;
   Mario Negri Institute for Pharmacological Research
      2018   Phase 4   NCT03100253   Italy;
   Merck Serono International
      2008   Phase 2   EUCTR2007-002536-29-FR   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   Phase 2   EUCTR2007-002536-29-ES   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-PT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-GR   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-DE   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-CZ   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-BG   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-BE   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   Phase 2   EUCTR2007-002536-29-FI   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   -   EUCTR2007-002536-29-SE   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   -   EUCTR2007-002536-29-AT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      -   -   EUCTR2007-002536-29-PL   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
   Merck Sharp & Dohme Corp.
      2008   -   NCT00724672   -
   Mianyang Hospital of Traditional Chinese Medicine
      2021   Phase 4   ChiCTR2100044045   China;
   NHS Greater Glasgow and Clyde
      2022   -   NCT05090124   -
      2009   -   EUCTR2009-011268-13-GB   United Kingdom;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2009   Phase 4   NCT00837434   United States;
      2008   Phase 4   NCT00796705   United States;
   Novo Nordisk A/S
      2014   Phase 2   NCT02097264   Ireland;Portugal;Spain;United Kingdom;
   OSPEDALE POLICLINICO S. MATTEO
      2006   -   EUCTR2006-003843-22-IT   Italy;
   Osaka City University Medical School
      2012   -   JPRN-UMIN000010315   Japan;
      2010   -   JPRN-UMIN000003880   Japan;
   Osaka Medical College
      2015   -   JPRN-UMIN000016950   Japan;
   Ottawa Hospital Research Institute
      2022   Phase 4   NCT05153200   -
   PFIZER
      2008   -   EUCTR2007-002066-35-IT   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
   Pfizer
      2020   Phase 3   NCT04230213   Bosnia and Herzegovina;Bulgaria;Czechia;Lithuania;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2015   Phase 3   NCT02480153   Australia;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Czechia;Estonia;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 4   NCT02092467   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czech Republic;Czechia;Finland;Hong Kong;Israel;Jordan;Lebanon;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2007   Phase 2   NCT00550446   Brazil;Bulgaria;Chile;Croatia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Romania;Slovakia;Ukraine;United States;
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2012   Phase 2   EUCTR2007-002066-35-SK   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
      2008   Phase 2   EUCTR2007-002066-35-GR   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
      2008   Phase 2   EUCTR2007-002066-35-BG   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2008   -   EUCTR2007-002066-35-HU   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2008   -   EUCTR2007-002066-35-DE   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2008   -   EUCTR2007-002066-35-CZ   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2009   -   EUCTR2008-008338-35-DE   Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   Reade Rheumatology Research Institute
      2020   Phase 4   NCT04251741   Netherlands;
      2020   Phase 4   NCT04222920   Netherlands;
      2020   Phase 4   NCT04194827   Netherlands;
   Rennes University Hospital
      2017   -   NCT03110094   France;
   Sanofi
      2015   Phase 3   NCT02332590   Chile;Czech Republic;Czechia;France;Germany;Hungary;Israel;Korea, Republic of;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   NCT01764997   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Czechia;Ecuador;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
   Skåne University Hospital
      2005   Phase 4   NCT01270087   Sweden;
   Takeda
      2015   Phase 2   NCT02393378   Czech Republic;Czechia;Estonia;Russian Federation;Spain;United Kingdom;
   TcLand Expression S.A.
      2016   -   NCT03016260   Czech Republic;Czechia;France;Israel;Netherlands;Turkey;
   The Rheumatological Center of Helsinki
      2011   Phase 4   NCT01405326   Finland;
   University Hospital, Bordeaux
      2021   Phase 3   NCT04870203   France;Monaco;
   University Hospital, Rouen
      2006   Phase 4   NCT00234234   France;
   University Hospital, Tours
      2011   Phase 4   NCT01382160   France;
      2006   -   NCT00497614   France;
   University of Aarhus
      2007   Phase 3   NCT00660647   Denmark;
   University of Leeds
      2013   Phase 4   NCT02056184   United Kingdom;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
   Université de Sherbrooke
      2013   Phase 4   NCT02035800   Canada;
      2008   -   NCT00814866   Canada;
   Yazawa Rie
      2017   Phase 1   JPRN-jRCT2071200057   Japan;
   Yonemura Takuma
      2015   Phase 1   JPRN-jRCT2071200058   Japan;
   Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100042440   China;
Adalimumab (ADA)   
   UCB Pharma SA
      2011   Phase 4   NCT01500278   Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Monaco;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
Adalimumab (HUMIRA®)   
   Abbott
      2006   -   NCT01078571   Spain;
Adalimumab (Humira)   
   Hvidovre University Hospital
      2004   Phase 4   NCT00696059   Denmark;
   R-Pharm
      2016   Phase 3   EUCTR2015-005307-83-PL   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Adalimumab (Humira®)   
   R-Pharm
      2017   Phase 3   EUCTR2015-005307-83-LV   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-PL   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-LT   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-HU   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-DE   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
   R-Pharm International LLC
      2016   Phase 3   EUCTR2015-005307-83-CZ   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005307-83-BG   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Adalimumab (up to 9 months exposure)   
   Abbott
      2005   Phase 4   NCT00233558   United States;
Adalimumab - GP2017   
   Sandoz
      2016   Phase 3   NCT02744755   Czech Republic;Czechia;Germany;Hungary;Italy;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
Adalimumab - US licensed Humira   
   Sandoz
      2016   Phase 3   NCT02744755   Czech Republic;Czechia;Germany;Hungary;Italy;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
Adalimumab 40 mg subcutaneous (SC) every other week (EOW)   
   Abbott
      2000   Phase 3   NCT00233571   -
Adalimumab 40mg q2w   
   R-Pharm
      2016   Phase 3   NCT02760407   Argentina;Brazil;Bulgaria;China;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Adalimumab Injection   
   St George's, University of London
      2020   Phase 4   NCT04255134   United Kingdom;
Adalimumab PFS and Pen   
   Samsung Bioepis Co., Ltd.
      2015   Phase 2   NCT02565810   Poland;
Adalimumab delivered in Physiolis autoinjector   
   AbbVie (prior sponsor, Abbott)
      2010   Phase 2   NCT01163617   United States;
Adalimumab delivered in Physiolis syringe   
   AbbVie (prior sponsor, Abbott)
      2010   Phase 2   NCT01163617   United States;
Adalimumab delivered in current autoinjector   
   AbbVie (prior sponsor, Abbott)
      2010   Phase 2   NCT01163617   United States;
Adalimumab delivered in current syringe   
   AbbVie (prior sponsor, Abbott)
      2010   Phase 2   NCT01163617   United States;
Adalimumab with methotrexate   
   Pfizer
      2014   Phase 4   NCT02187055   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Adalimumab, Solution for Injection 40 mg/ (0.8 ml) Pre-filled Syringe   
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 2   EUCTR2013-004019-37-DK   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2015   Phase 2   EUCTR2013-004019-37-BG   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2015   -   EUCTR2013-004019-37-DE   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   Phase 2   EUCTR2013-004019-37-RO   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   Phase 2   EUCTR2013-004019-37-CZ   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
      2014   -   EUCTR2013-004019-37-HU   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
Adalimumab, current formulation   
   AbbVie (prior sponsor, Abbott)
      2012   Phase 2   NCT01712178   Belgium;Czech Republic;Germany;Puerto Rico;Romania;Slovakia;United States;
Adalimumab, new formulation   
   AbbVie (prior sponsor, Abbott)
      2012   Phase 2   NCT01712178   Belgium;Czech Republic;Germany;Puerto Rico;Romania;Slovakia;United States;
Adalimumab, plus prednisone   
   IRCCS Policlinico S. Matteo
      2007   Phase 4   NCT00480272   Italy;
Adalimumab-Pfizer   
   Pfizer Inc
      2020   Phase 4   EUCTR2019-000284-24-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2019   Phase 3   EUCTR2019-000284-24-LT   Argentina;Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Mexico;Peru;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
   Pfizer Inc.
      2015   Phase 3   EUCTR2014-000352-29-HR   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-FR   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-EE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-BG   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000352-29-LT   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000352-29-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-GB   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-ES   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-CZ   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
Adalimummab   
   Hvidovre Hospital
      2009   Phase 4   EUCTR2009-014394-41-DK   Denmark;
Adefovir   
   Department of general internal medicine, Kyushu-University hospital
      2012   -   JPRN-UMIN000018017   Japan;
Administration of Cimzia®   
   University Hospital, Ghent
      2012   Phase 3   NCT01590966   Belgium;
Agrippal S1 (Influenza vaccination)   
   Tel-Aviv Sourasky Medical Center
      2009   Phase 4   NCT01002716   Israel;
Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994)   
   The Newcastle upon Tyne Hospitals NHS Foundation Trust
      2012   Phase 4   EUCTR2010-021146-22-GB   United Kingdom;
Alendronat Teva   
   Aarhus University Hospital
      2015   Phase 2   EUCTR2015-003638-28-DK   Denmark;
Alendronate   
   Chinese University of Hong Kong
      2012   Phase 4   NCT01770106   Hong Kong;
   People's Hospital, Peking University
      2009   -   ChiCTR-TRC-09000473   China;
   University of Aarhus
      2015   Phase 2   NCT02944799   Denmark;
Alendronate versus alfacalcidol (1-alpha OH vitamin D)   
   UMC Utrecht
      2000   Phase 3   NCT00138983   Netherlands;
AlloRx   
   The Foundation for Orthopaedics and Regenerative Medicine
      2022   Phase 1   NCT05003934   Antigua and Barbuda;
Allogeneic Mesenchymal Precursor Cells   
   Mesoblast, Ltd.
      2013   Phase 2   NCT01851070   Australia;United States;
Allopurinol   
   University of Dundee
      2005   Phase 4   EUCTR2005-000551-15-GB   United Kingdom;
Amoxapine & dipyridamole   
   CombinatoRx, Inc
      2004   -   EUCTR2004-001490-26-GB   Estonia;United Kingdom;
Amoxicilina   
   Dra Beatriz Lozano-Hospital Universitario de Canarias
      2018   Phase 4   EUCTR2017-003259-40-ES   Spain;
Anakinra   
   Amgen
      2001   Phase 2   NCT00037700   United States;
      2000   Phase 2   NCT00037648   United States;
   Prof. Roberto Giacomelli
      2013   Phase 4   NCT02236481   Italy;
   Swedish Orphan Biovitrum
      2012   -   NCT02915094   Germany;
   University of Athens
      2011   -   NCT01566201   Greece;
   Xi-jing Hospital, the 4th Military Medical University, Shanghai Changzheng Hospital
      2008   Phase 3 study   ChiCTR-TRC-09000383   China;
Anakinra (Kineret®)   
   Amgen
      2004   Phase 3   NCT00117091   -
Anakinra (r-metHuIL-1ra)   
   Amgen
      2005   Phase 4   NCT00111410   -
Anakinra and PEG sTNF-R1   
   Amgen
      2001   Phase 2   NCT00537667   -
Andecaliximab   
   Gilead Sciences
      2016   Phase 2   NCT02862574   Australia;Hungary;Taiwan;United States;
Angiotensin receptor blockers   
   Sherief Abd-Elsalam
      2018   Phase 3   NCT03770702   Egypt;
Anifrolumab   
   Josef Smolen, Univ. Prof. Dr.
      2018   Phase 2   NCT03435601   Austria;
Anifrolumab (MEDI-546)   
   Medical University of Vienna
      2017   Phase 2   EUCTR2017-001717-92-AT   Austria;Italy;Switzerland;
Anit human granulocyt-macrophage colony-stimulating factor (GM-CSF)monoclonal   
   GlaxoSmithKline Research & Development Limited
      2019   Phase 3   EUCTR2019-000797-39-PL   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
Anti IL 6 mAb   
   BRISTOL-M.SQUIBB
      2011   -   EUCTR2010-023956-99-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;South Africa;Spain;Taiwan;United States;
Anti IL-1beta antibody, subclass IgG4   
   Eli Lilly and Company Limited
      2007   -   EUCTR2005-002660-29-HU   Hungary;Spain;
Anti IL-1ß antibody, subclass IgG4   
   Eli Lilly and Company Limited
      2007   -   EUCTR2005-002660-29-HU   Hungary;Spain;
Anti LP40 antibody, subclass IgG4 LA294   
   Eli Lilly and Company
      2009   Phase 2   EUCTR2008-004875-23-FR   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004875-23-PL   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004875-23-HU   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004875-23-DE   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004875-23-BE   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004875-23-AT   Austria;Belgium;France;Germany;Hungary;Poland;
      2009   -   EUCTR2008-001105-42-PL   Austria;Belgium;France;Germany;Poland;
      2008   Phase 2   EUCTR2008-001105-42-FR   Austria;Belgium;France;Germany;Poland;
      2008   -   EUCTR2008-001105-42-DE   Austria;Belgium;France;Germany;Poland;
      2008   -   EUCTR2008-001105-42-BE   Austria;Belgium;France;Germany;Poland;
      2008   -   EUCTR2008-001105-42-AT   Austria;Belgium;France;Germany;Poland;
   Eli Lilly and Company limited
      2009   Phase 2   EUCTR2008-004894-16-HU   Czech Republic;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004894-16-PL   Czech Republic;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004894-16-DE   Czech Republic;Germany;Hungary;Poland;
      2009   -   EUCTR2008-004894-16-CZ   Czech Republic;Germany;Hungary;Poland;
Anti TNF + Meth   
   Hamad Medical Corporation
      2012   Phase 3   NCT01724268   Qatar;
Anti human granulocyte-macrophage colo   
   GlaxoSmithKline Research & Development Limited
      2019   Phase 3   EUCTR2019-000868-18-GB   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal   
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2019   Phase 3   EUCTR2019-000868-18-IT   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
   GlaxoSmithKline Research & Development Limited
      2021   Phase 3   EUCTR2019-000878-30-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-LV   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-LT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000868-18-DE   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000867-26-DE   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-PL   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-LT   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-HU   Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-GB   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-ES   Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-CZ   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-PL   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-HU   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-GB   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-ES   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-EE   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-BG   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-PL   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-LV   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-HU   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-GB   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-ES   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-CZ   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2019-000878-30-EE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody   
   GlaxoSmithKline Research & Development Limited
      2018   Phase 2   EUCTR2015-004386-91-PL   Germany;Poland;United States;
      2016   Phase 2   EUCTR2015-004386-91-DE   Germany;Poland;United States;
      2015   Phase 2   EUCTR2014-003453-34-PL   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-HU   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-GB   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-ES   Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-EE   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-DE   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-CZ   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF)monoclonal   
   GlaxoSmithKline Research & Development Limited
      2019   Phase 3   EUCTR2019-000797-39-PL   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
Anti-C5aR   
   Novo Nordisk A/S
      2012   -   EUCTR2009-011791-30-HU   Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
      2010   Phase 2   EUCTR2009-011791-30-GB   Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
      2010   -   EUCTR2009-011791-30-DK   Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
      2010   -   EUCTR2009-011791-30-CZ   Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
Anti-CD20 small modular immunopharmaceutical, WYE-400087   
   Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company
      2010   -   EUCTR2009-010516-15-PL   Greece;Hungary;Poland;Spain;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc.
      2010   Phase 2   EUCTR2009-010516-15-GR   Greece;Hungary;Poland;Spain;
      2010   Phase 2   EUCTR2009-010516-15-ES   Greece;Hungary;Poland;Spain;
      2009   -   EUCTR2009-010516-15-HU   Greece;Hungary;Poland;Spain;
Anti-GM-CSF receptor alpha   
   MedImmune Ltd
      2010   -   EUCTR2009-014735-20-PL   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2010   -   EUCTR2009-014735-20-LT   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2010   -   EUCTR2009-014735-20-HU   Bulgaria;Czech Republic;Estonia;Hungary;Lithuania;Poland;
      2010   -   EUCTR2009-014735-20-CZ   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2010   -   EUCTR2009-014735-20-BG   Bulgaria;Czech Republic;Estonia;Hungary;Latvia;Lithuania;Poland;
      2009   -   EUCTR2009-014735-20-LV   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2009   -   EUCTR2009-014735-20-EE   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
Anti-IL-20   
   Novo Nordisk A/S
      2010   Phase 1   NCT01038674   Belgium;Poland;
      2008   Phase 1   NCT00818064   Netherlands;
Anti-IL-20 (109-0012)   
   NOVO NORDISK
      2011   -   EUCTR2010-021283-14-IT   Hungary;Italy;Portugal;Spain;United Kingdom;
   Novo Nordisk A/S
      2011   Phase 2   EUCTR2010-021283-14-PT   Czech Republic;Hungary;Italy;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-021283-14-HU   Hungary;Italy;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-021283-14-GB   Hungary;Italy;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-021283-14-ES   Hungary;Italy;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-021283-14-CZ   Czech Republic;Hungary;Italy;Portugal;Spain;United Kingdom;
Anti-IL-6 mAb   
   Bristol-Myers Squibb International Corporation
      2011   -   EUCTR2010-023956-99-NL   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
Anti-Interleukin-6 Monoclonal   
   BRISTOL-M.SQUIBB
      2011   -   EUCTR2010-023956-99-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;South Africa;Spain;Taiwan;United States;
Anti-Interleukin-6 Monoclonal Antibody   
   Bristol-Myers Squibb International Corporation
      2011   -   EUCTR2010-023956-99-NL   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
Anti-TNF   
   Hospital Universitari Vall d'Hebron Research Institute
      2016   -   NCT02804204   Spain;
Anti-TNF Biologics Therapy   
   Queen Mary University of London
      2015   -   NCT02620189   United Kingdom;
Anti-TNF humanized antibody Fab fragment - PEG conjugate   
   UCB Pharma S.A.
      2008   -   EUCTR2007-000830-38-FR   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000830-38-DE   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000830-38-AT   Austria;France;Germany;Italy;Poland;
Anti-TNF humanized antibody Fab' fragment - PEG conjugate   
   UCB Pharma S.A.
      2009   -   EUCTR2007-005288-86-FR   France;
Anti-TNF suspended perioperatively   
   CHU de Quebec-Universite Laval
      2015   Phase 4   NCT02242474   Canada;
Anti-TNF therapy   
   Barts & The London NHS Trust
      2010   -   NCT02528292   United Kingdom;
Anti-TNF therapy (etanercept or adalimumab)   
   Imperial College London
      2010   -   NCT01060098   United Kingdom;
Anti-TNF-alpha   
   Hoffmann-La Roche
      2016   Phase 2   NCT03001219   Argentina;Austria;Colombia;Czech Republic;Czechia;Germany;Guatemala;Italy;Mexico;Peru;Poland;Spain;United Kingdom;United States;
Anti-TNFa continued perioperatively   
   CHU de Quebec-Universite Laval
      2015   Phase 4   NCT02242474   Canada;
Anti-Tumor Necrosing Factor (TNF) Therapy   
   Bristol-Myers Squibb
      2005   Phase 3   NCT00124982   Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Mexico;Spain;United Kingdom;United States;
Anti-Tumor Necrosis Factor Alpha Drug (Product)   
   R.Bos
      2021   Phase 4   NCT04985435   Netherlands;
Anti-inflammatory drugs   
   Genentech, Inc.
      2007   Phase 3   NCT00443651   United States;
Anti-pandemic H1N1 influenza vaccine   
   University of Sao Paulo
      2010   Phase 4   NCT01151644   Brazil;
Anti-thymocyte globulin   
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Anticorpo monoclonale anti GM-CSF umano   
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2015   Phase 2   EUCTR2014-003453-34-IT   Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
Anticuerpo monoclonal anti-humano recombinante humanizado, receptor de IL-6R.   
   F. Hoffmann-La Roche Ltd.
      2011   Phase 4   EUCTR2010-020065-24-ES   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
Antihistamine   
   Hoffmann-La Roche
      2011   Phase 4   NCT01382940   United States;
Antihuman granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal   
   GlaxoSmithKline Research & Development Limited
      2019   Phase 3   EUCTR2019-000868-18-PL   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
Apratastat   
   WYETH LEDERLE
      2005   -   EUCTR2004-000012-13-IT   Czech Republic;Estonia;Italy;
Apremilast   
   Amgen
      2010   Phase 2   NCT01285310   Czech Republic;Czechia;Poland;Spain;United States;
   Baylor Research Institute
      2010   Phase 2   NCT01250548   United States;
   Celgene Corporation
      2011   -   EUCTR2010-019926-15-CZ   Czech Republic;United States;
Arava   
   Karolinska Institutet
      2015   -   EUCTR2011-004720-35-NO   Denmark;Finland;Norway;Sweden;
      2014   -   EUCTR2011-004720-35-FI   Denmark;Finland;Sweden;
   University Hospitals Leuven
      2009   Phase 4   EUCTR2008-007225-39-BE   Belgium;
   University of Leeds
      2006   Phase 4   EUCTR2005-004582-41-GB   United Kingdom;
   Universitätsklinkum Erlangen
      2010   Phase 3   EUCTR2009-015740-42-DE   Germany;
Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)   
   Sandoz
      2002   Phase 1   NCT00946686   -
Arava 20 mg filmdrasjerte tabletter   
   Diakonhjemmet Hospital AS
      2013   Phase 4   EUCTR2012-005275-14-NO   Norway;
Arm B: Rituxan®/Mabthera®   
   Dr. Reddy's Laboratories Limited
      2020   Phase 3   NCT04268771   United States;
Arthroscopic synovectomy of the wrist   
   Maasstad Hospital
      2021   -   NCT04755127   Netherlands;
Arthroscopic synovial tissue biopsy   
   Nathan Wei, MD, FACP, FACR:
      2011   Phase 3   NCT01374971   United States;
Arthroscopy & saline irrigation alone   
   Newcastle University
      2012   Phase 1   NCT01352858   United Kingdom;
Artilog   
   GlaxoSmithKline s.a.
      2005   Phase 3   EUCTR2005-000158-61-ES   Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
Ascal(r) / carbasalate calcium   
   Leiden University Medical Center
      2006   -   EUCTR2006-001359-36-NL   Netherlands;
Asendis   
   CombinatoRx, Inc
      2004   -   EUCTR2004-001490-26-GB   Estonia;United Kingdom;
Aspirin 81mg tablet   
   Inova Health Care Services
      2018   Phase 4   NCT03699293   United States;
Aspirin Tablets   
   Merck Sharp & Dohme (Sweden) AB
      2004   Phase 2   EUCTR2004-000612-54-SE   Sweden;
Atacicept   
   EMD Serono
      2006   Phase 2   NCT00430495   Canada;United States;
   MERCK SERONO INTERNATIONAL SA
      2008   -   EUCTR2007-002536-29-IT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
   Merck KGaA
      2008   Phase 2   NCT00664521   Finland;France;Netherlands;Sweden;United Kingdom;
   Merck Serono Int, a branch of Laboratoires Seron SA an affiliate of Merck KGaA, Darmstadt, Germany
      2007   -   EUCTR2006-004140-23-DE   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono Int, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt, Germany
      2008   -   EUCTR2006-004140-23-GB   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   Phase 2   EUCTR2006-004140-23-SK   Belgium;Bulgaria;Czech Republic;Finland;Germany;Greece;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004140-23-PT   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004140-23-CZ   Belgium;Bulgaria;Czech Republic;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004140-23-BE   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono Int, a branch of Laboratoires Serono SA, an affiliate of Merck KGaA, Darmstadt, Germany
      2007   -   EUCTR2006-004140-23-FI   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono Int, a branch ofLaboratories Serono S.A. an affiliate of Merck KGaA, Darmstadt, Germany
      2007   -   EUCTR2006-004140-23-SE   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono Int.a branch of Laboratoires Serono SA an affiliate of Merck KgaA, Darmstadt, Germany
      2006   -   EUCTR2006-004140-23-NL   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono International
      2008   Phase 2   EUCTR2007-003647-75-FR   Finland;France;Netherlands;Sweden;United Kingdom;
      2008   Phase 2   EUCTR2007-002536-29-FR   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   Phase 2   EUCTR2007-002536-29-ES   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-003647-75-SE   Finland;France;Netherlands;Sweden;United Kingdom;
      2008   -   EUCTR2007-003647-75-NL   Finland;France;Netherlands;Sweden;United Kingdom;
      2008   -   EUCTR2007-003647-75-FI   Finland;France;Netherlands;Sweden;United Kingdom;
      2008   -   EUCTR2007-002536-29-PT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-GR   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-DE   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-CZ   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-BG   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2008   -   EUCTR2007-002536-29-BE   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   Phase 2   EUCTR2007-002536-29-FI   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   -   EUCTR2007-002536-29-SE   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      2007   -   EUCTR2007-002536-29-AT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
      -   -   EUCTR2007-002536-29-PL   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
   Merck Serono International S.A.
      2007   -   EUCTR2006-004140-23-GR   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono SA - Geneva
      2008   Phase 2   EUCTR2007-003647-75-GB   Finland;France;Netherlands;Sweden;United Kingdom;
   Serono International S.A.
      2007   Phase 2   EUCTR2006-004140-23-ES   Belgium;Bulgaria;Czech Republic;Finland;Germany;Greece;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-004140-23-BG   Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Atacicept: with loading dose   
   EMD Serono
      2007   Phase 2   NCT00595413   Germany;United States;
Atorvastatin   
   Gilead Sciences
      2020   Phase 1   NCT04608344   United States;
   Hospital Central Dr. Ignacio Morones Prieto
      2018   Phase 2   NCT04056039   Mexico;
   Inner Mongolia University of Science and Technology Baotou Medical College First Affiliated Hospital
      2017   -   ChiCTR-INR-17011772   China;
   Pfizer
      2010   Phase 2   NCT01059864   Korea, Republic of;United States;
   University of California, Los Angeles
      2003   Phase 4   NCT00356473   -
Atorvastatin tablet   
   Chengdu PLA General Hospital
      2014   -   NCT02219191   China;
Auto-Injector Device (AID)   
   Sanofi
      2014   Phase 3   NCT02057250   Chile;France;Mexico;Poland;Russian Federation;South Africa;United States;
Autoinjector   
   Momenta Pharmaceuticals, Inc.
      2016   Phase 3   NCT02722044   United States;
   Samsung Bioepis Co., Ltd.
      2017   Phase 2   NCT03193957   Poland;
Autologous Peripheral Blood Stem Cell Transplantation   
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Autologous adipose derived stem cells   
   Celltex Therapeutics Corporation
      2021   Phase 1/Phase 2   NCT04170426   -
Autologous apoptotic cells injection   
   Centre Hospitalier Universitaire de Besancon
      2021   Phase 1/Phase 2   NCT02903212   -
Autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70   
   UMC Utrecht
      2021   Phase 1/Phase 2   NCT05251870   Netherlands;
Autologous mesenchymal stem cells   
   Mashhad University of Medical Sciences
      2016   Phase 1   NCT03333681   -
Autologous stromal vascular fraction cells   
   Translational Biosciences
      2013   Phase 1/Phase 2   NCT01885819   Panama;
Avelox- Moxifloxacin   
   AstraZeneca AB
      2009   -   EUCTR2009-011044-20-GB   United Kingdom;
Avelox®   
   AstraZeneca AB
      2009   -   EUCTR2009-011044-20-GB   United Kingdom;
Azathioprin   
   Universitätsklinkum Erlangen
      2010   Phase 3   EUCTR2009-015740-42-DE   Germany;
Azathioprine   
   Hoffmann-La Roche
      2013   Phase 3   NCT01941095   Greece;
   Sanofi
      2018   Phase 4   NCT03449758   France;
   The Karolinska Institutet, ClinTRID
      2014   Phase 4   EUCTR2014-002374-36-SE   Sweden;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
B03BB01   
   CHU de Bordeaux
      2019   Phase 2   EUCTR2018-004287-56-FR   France;
BAT1806   
   Bio-Thera Solutions
      2018   Phase 3   NCT03830203   China;
   Bio-Thera Solutions, Ltd.
      2019   Phase 3   EUCTR2018-002202-31-BG   Bulgaria;China;Georgia;Poland;Ukraine;
BAT1806 injection   
   Bio-Thera Solutions
      2018   Phase 1   NCT03606876   China;
BCD-055   
   Biocad
      2016   Phase 3   NCT02762838   Belarus;India;Russian Federation;
BCD-089   
   Biocad
      2019   Phase 3   NCT04227366   Russian Federation;
BCD-089, 162 mg, s/c, q2w   
   Biocad
      2018   Phase 2   NCT03455842   Belarus;Russian Federation;
BCD-089, 162 mg, s/c, qw   
   Biocad
      2018   Phase 2   NCT03455842   Belarus;Russian Federation;
BDMARD   
   CHU Saint-Etienne
      2020   Phase 4   EUCTR2019-003700-12-FR   France;
BDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)   
   Medical University of Graz
      2012   Phase 4   NCT01602302   Austria;
BETAMETHASONE ACIBUTATE   
   Knowledge Centre for Rheumatology and Back Diseases
      2013   -   EUCTR2013-003486-34-DK   Denmark;
   Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet
      2017   Phase 4   EUCTR2017-003425-15-DK   Denmark;
BG00012   
   Biogen Idec
      2008   Phase 2   NCT00810836   Australia;Canada;Czech Republic;India;Poland;Slovakia;
   Biogen Idec Limited
      2009   Phase 2   EUCTR2008-004754-33-SK   Czech Republic;Poland;Slovakia;
      2009   -   EUCTR2008-004754-33-PL   Czech Republic;Poland;
      2009   -   EUCTR2008-004754-33-CZ   Czech Republic;Poland;
BG9924   
   Biogen Idec
      2007   Phase 2   NCT00523328   Belgium;Canada;United Kingdom;United States;
      2007   Phase 2   NCT00458861   United States;
      2005   Phase 2   NCT00292422   Poland;United States;
   Biogen Idec Ltd
      2007   Phase 2   EUCTR2006-005467-26-GB   Belgium;United Kingdom;
      2007   Phase 2   EUCTR2006-005466-39-GB   Hungary;United Kingdom;
      2007   -   EUCTR2007-000734-38-GB   United Kingdom;
      2007   -   EUCTR2007-000734-38-BE   Belgium;United Kingdom;
      2007   -   EUCTR2007-000733-19-HU   Hungary;United Kingdom;
      2007   -   EUCTR2007-000733-19-GB   Hungary;United Kingdom;
      2007   -   EUCTR2006-005467-26-BE   Belgium;United Kingdom;
      2007   -   EUCTR2006-005466-39-HU   Hungary;United Kingdom;
BGX-0214   
   Coherus BioSciences, Inc.
      2015   Phase 3   EUCTR2015-000665-30-GB   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
      2015   Phase 3   EUCTR2015-000665-30-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
      2015   Phase 3   EUCTR2015-000665-30-DE   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
BI 655064   
   Boehringer Ingelheim B.V
      2013   -   EUCTR2012-004090-16-NL   Czech Republic;Germany;Netherlands;New Zealand;Poland;Spain;
   Boehringer Ingelheim España, S.A.
      2013   -   EUCTR2012-004090-16-ES   Australia;Czech Republic;Germany;Netherlands;New Zealand;Spain;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2013   -   EUCTR2012-004090-16-DE   Czech Republic;Germany;Netherlands;New Zealand;Poland;Spain;
   Boehringer Ingelheim RCV GmbH & Co KG
      2013   Phase 1;Phase 2   EUCTR2012-004090-16-CZ   Czech Republic;Germany;Netherlands;New Zealand;Poland;Spain;
BI 655064 high dose   
   Boehringer Ingelheim
      2012   Phase 1   NCT01751776   Czech Republic;Germany;Netherlands;New Zealand;Poland;Romania;Spain;
BI 655064 low dose   
   Boehringer Ingelheim
      2012   Phase 1   NCT01751776   Czech Republic;Germany;Netherlands;New Zealand;Poland;Romania;Spain;
BI 655064 medium dose   
   Boehringer Ingelheim
      2012   Phase 1   NCT01751776   Czech Republic;Germany;Netherlands;New Zealand;Poland;Romania;Spain;
BI 695500   
   Boehringer Ingelheim
      2013   Phase 3   NCT01955733   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Germany;Greece;Hungary;Ireland;Mexico;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2012   Phase 3   NCT01682512   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   Boehringer Ingelheim International GmbH
      2013   Phase 1;Phase 3   EUCTR2011-002894-48-NO   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2013   Phase 1;Phase 3   EUCTR2011-002894-48-BG   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002894-48-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002894-48-DE   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-002894-48-PT   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 1;Phase 3   EUCTR2011-002894-48-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 1;Phase 3   EUCTR2011-002894-48-GB   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 1;Phase 3   EUCTR2011-002894-48-EE   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 1;Phase 3   EUCTR2011-002894-48-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-002894-48-NL   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-002894-48-HU   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
BI 695501   
   Boehringer Ingelheim
      2016   Phase 3   NCT02640612   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
      2015   Phase 3   NCT02137226   Argentina;Bulgaria;Chile;Colombia;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
   Boehringer Ingelheim International GmbH
      2016   Phase 3   EUCTR2015-002634-41-PL   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
      2016   Phase 3   EUCTR2015-002634-41-HU   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
      2016   Phase 3   EUCTR2015-002634-41-DE   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
      2016   Phase 3   EUCTR2015-002634-41-BG   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
      2015   Phase 3   EUCTR2015-002634-41-ES   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
      2014   Phase 3   EUCTR2012-002945-40-HU   Argentina;Bulgaria;Chile;Colombia;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
      2014   Phase 3   EUCTR2012-002945-40-ES   Argentina;Belgium;Bulgaria;Chile;Colombia;Estonia;France;Germany;Hungary;Indonesia;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
      2014   Phase 3   EUCTR2012-002945-40-EE   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
      2014   Phase 3   EUCTR2012-002945-40-DE   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
      2014   Phase 3   EUCTR2012-002945-40-BG   Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
BI 695501 Autoinjector   
   Boehringer Ingelheim
      2016   Phase 2   NCT02636907   Poland;Ukraine;United States;
BI 695501 Prefilled syringe   
   Boehringer Ingelheim
      2016   Phase 2   NCT02636907   Poland;Ukraine;United States;
BIBR 796 BS   
   Boehringer Ingelheim
      2001   Phase 2   NCT02209779   -
BIIB023   
   Biogen Idec
      2008   Phase 1   NCT00771329   Russian Federation;Ukraine;United States;
BIIB057   
   Biogen Idec
      2012   Phase 2   NCT01652937   Canada;
BIIL 284 BS high dose   
   Boehringer Ingelheim
      2001   Phase 2   NCT02251210   -
BIIL 284 BS low dose   
   Boehringer Ingelheim
      2001   Phase 2   NCT02251210   -
BIIL 284 BS medium dose   
   Boehringer Ingelheim
      2001   Phase 2   NCT02251210   -
BIRB 796 BS, high dose   
   Boehringer Ingelheim
      2003   Phase 2   NCT02214888   -
BIRB 796 BS, low dose   
   Boehringer Ingelheim
      2003   Phase 2   NCT02214888   -
BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)   
   Bristol-Myers Squibb
      2016   Phase 1   NCT02762123   United States;
BMS-188667   
   Academisch Medisch Centrum Amsterdam
      2010   -   EUCTR2010-021435-14-NL   Netherlands;
   BRISTOL-M.SQUIBB
      2005   -   EUCTR2004-005102-68-IT   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002620-18-IT   Belgium;Germany;Italy;Spain;United Kingdom;
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2021   Phase 3   EUCTR2020-000350-96-IT   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-001275-50-IT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
   Bristol Myers Squibb International Corporation
      2011   Phase 3   EUCTR2008-001523-57-NO   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2010   Phase 3   EUCTR2010-018674-20-FR   Belgium;Denmark;Finland;France;Germany;Italy;Sweden;
      2010   Phase 3   EUCTR2010-018674-20-BE   Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-SE   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;Sweden;United States;
      2010   -   EUCTR2010-018674-20-FI   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-DK   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-DE   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2008-001523-57-HU   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2010   -   EUCTR2008-001523-57-DE   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-001523-57-GB   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-001523-57-ES   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   -   EUCTR2008-001523-57-DK   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2008   Phase 3   EUCTR2008-001523-57-FR   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-005434-37-FR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-NL   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-IT   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-IE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-HU   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-GR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-DE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-BE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-AT   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2006   -   EUCTR2005-000784-26-IT   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-000784-26-AT   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-GB   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-ES   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-DE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-IE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-BE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-000922-59-DK   Czech Republic;Denmark;Spain;Sweden;
      2005   -   EUCTR2004-000922-59-CZ   Czech Republic;Denmark;Spain;Sweden;
      2004   Phase 3   EUCTR2004-000922-59-ES   Czech Republic;Denmark;Spain;Sweden;
      2004   -   EUCTR2004-000922-59-SE   Czech Republic;Denmark;Spain;Sweden;
      -   -   EUCTR2005-000443-28-Outside-EU/EEA   Austria;Brazil;France;Germany;Italy;Mexico;Peru;Portugal;Spain;Switzerland;United States;
   Bristol-Myers Squibb Company
      -   Phase 2   EUCTR2015-005450-36-Outside-EU/EEA   United States;
   Bristol-Myers Squibb International Corporation
      2022   Phase 3   EUCTR2020-000350-96-DE   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000350-96-PL   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000350-96-FR   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000350-96-ES   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000350-96-CZ   Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001275-50-RO   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2016   Phase 3   EUCTR2015-001275-50-NL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2016   Phase 3   EUCTR2015-001275-50-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-SE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-GB   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-FR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-FI   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-ES   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-CZ   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2015   Phase 3   EUCTR2015-001275-50-AT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
      2008   Phase 3   EUCTR2007-005434-37-GB   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2007   Phase 3   EUCTR2006-003768-67-GB   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-003768-67-ES   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-SE   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-NL   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-DE   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-BE   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-AT   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2004-005102-68-CZ   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-005102-68-GB   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-005102-68-ES   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-002620-18-GB   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-002620-18-ES   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-CZ   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-IE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-DE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-BE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002620-18-DE   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002620-18-BE   Belgium;Germany;Italy;Spain;United Kingdom;
BMS-582949   
   Bristol Myers Squibb International Corporation
      2008   Phase 2   EUCTR2008-000170-20-FR   Czech Republic;France;Spain;
      2008   Phase 2   EUCTR2008-000170-20-ES   Czech Republic;France;Spain;
      2008   -   EUCTR2008-000170-20-CZ   Czech Republic;France;Spain;
   Bristol-Myers Squibb
      2008   Phase 2   NCT00605735   Argentina;Brazil;Czech Republic;France;Korea, Republic of;Mexico;Spain;Taiwan;United States;
BMS-582949 and Methotrexate   
   Bristol-Myers Squibb
      2005   Phase 1   NCT00162292   Mexico;United States;
BMS-817399   
   Bristol-Myers Squibb
      2011   Phase 2   NCT01404585   Argentina;Korea, Republic of;Mexico;Russian Federation;South Africa;Spain;United States;
   Bristol-Myers Squibb International Corporation
      2012   -   EUCTR2011-002024-40-ES   Argentina;Korea, Republic of;Mexico;Russian Federation;South Africa;Spain;United States;
BMS-945429   
   BRISTOL-M.SQUIBB
      2011   -   EUCTR2010-023956-99-IT   Argentina;Belgium;Brazil;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;South Africa;Spain;Taiwan;United States;
   Bristol-Myers Squibb International Corporation
      2014   -   EUCTR2013-003780-65-IT   Argentina;Australia;Canada;Czech Republic;France;Hungary;Italy;Japan;Mexico;South Africa;United States;
      2014   -   EUCTR2013-003780-65-HU   Argentina;Australia;Canada;France;Hungary;Italy;Japan;Mexico;South Africa;United States;
      2011   -   EUCTR2010-023956-99-NL   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-ES   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-CZ   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
      2011   -   EUCTR2010-023956-99-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
   CSL Behring
      2011   Phase 2   NCT01373151   Argentina;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
BMS-986104   
   Bristol-Myers Squibb
      2014   Phase 1   NCT02211469   United States;
BMS-986142   
   Bristol-Myers Squibb
      2016   Phase 2   NCT02638948   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2016   Phase 1   NCT02762123   United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2015-002887-17-FR   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2016   Phase 2   EUCTR2015-002887-17-NL   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2016   Phase 2   EUCTR2015-002887-17-ES   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2016   Phase 2   EUCTR2015-002887-17-BE   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2016   Phase 2   EUCTR2015-002887-17-AT   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
   Bristol-Myers Squibb K.K.
      2016   Phase 2   JPRN-JapicCTI-163317   Japan, Asia except Japan, North America, South America, Europe, Oceania;
BMS-986195   
   Bristol-Myers Squibb
      2017   Phase 1   NCT03262740   United States;
      2017   Phase 1   NCT03245515   Netherlands;
      2017   Phase 1   NCT03131973   United States;
      2016   Phase 1   NCT02705989   Australia;
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
BMS-986251   
   Bristol-Myers Squibb
      2017   Phase 1/Phase 2   NCT03329885   Netherlands;
BMS188667   
   Bristol Myers Squibb International Corporation
      2010   -   EUCTR2010-018674-20-IT   Denmark;Finland;France;Germany;Italy;Sweden;
BMS986142   
   Bristol-Myers Squibb International Corporation
      2016   Phase 2   EUCTR2015-002887-17-AT   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
BMS986195   
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
BNP   
   Itabashi Chuo Medical Center
      2012   -   JPRN-UMIN000013885   Japan;
BNT162b2   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
BOW015   
   Epirus Biopharmaceuticals (Switzerland) GmbH
      2016   Phase 3   NCT02683564   -
BR9001   
   Boryung Pharmaceutical Co., Ltd
      2018   Phase 1   NCT03718611   Korea, Republic of;
BR900A   
   Boryung Pharmaceutical Co., Ltd
      2018   Phase 1   NCT03718611   Korea, Republic of;
BRL-049653   
   GlaxoSmithKline Research & Development Ltd.
      2005   -   EUCTR2004-000482-35-LT   Lithuania;United Kingdom;
      2004   Phase 2   EUCTR2004-000482-35-GB   Lithuania;United Kingdom;
BT061   
   Biotest
      2010   Phase 2   NCT01481493   Czech Republic;Germany;Hungary;Italy;Latvia;Poland;Spain;
   Biotest AG
      2013   Phase 2   EUCTR2013-000114-38-CZ   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-SK   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-LT   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-HU   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-EE   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-DE   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2013   -   EUCTR2013-000114-38-BG   Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
      2012   -   EUCTR2010-018485-24-LV   Czech Republic;Germany;Hungary;Latvia;Spain;
      2012   -   EUCTR2010-018485-24-HU   Czech Republic;Germany;Hungary;Latvia;Spain;
      2011   -   EUCTR2010-018485-24-ES   Czech Republic;Germany;Hungary;Latvia;Spain;
      2011   -   EUCTR2010-018485-24-DE   Czech Republic;Germany;Hungary;Latvia;Spain;
      2010   -   EUCTR2010-018485-24-CZ   Czech Republic;Germany;Hungary;Latvia;Spain;
BT061 (CD4 monoclonal antibody)   
   Biotest AG
      2008   -   EUCTR2008-001241-26-HU   Bulgaria;Hungary;
      2008   -   EUCTR2008-001241-26-BG   Bulgaria;Hungary;
BT971   
   Biotest AG
      2008   -   EUCTR2008-001241-26-HU   Bulgaria;Hungary;
      2008   -   EUCTR2008-001241-26-BG   Bulgaria;Hungary;
BTK Inhibitor   
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2015-002887-17-FR   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2016   Phase 2   EUCTR2015-002887-17-NL   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2016   Phase 2   EUCTR2015-002887-17-ES   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
      2016   Phase 2   EUCTR2015-002887-17-BE   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
BTT-1023   
   Biotie Therapies Corp.
      2009   Phase 1   NCT00851240   Bulgaria;
BUMEKIZUMAB   
   UCB Celltech, UK Registered Branch of UCB Pharma SA
      2015   -   EUCTR2014-003307-30-SK   Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
Background Treatment   
   Galvani Bioelectronics
      2021   -   NCT05003310   United States;
Baminercept alfa   
   Biogen Idec
      2007   Phase 2   NCT00664716   Argentina;Brazil;Hungary;Mexico;Poland;Romania;Russian Federation;United Kingdom;
Baminercept alfa (BG9924)   
   Biogen Idec
      2007   Phase 2   NCT00664573   Argentina;Brazil;Hungary;Mexico;Poland;Romania;Russian Federation;United Kingdom;
Baricitinib   
   Division of Diabetes, Endocrinology and Clinical Immunology, Department of Internal Medicine, Hyogo college of Medicine
      2020   -   JPRN-UMIN000040094   Japan;
   Eli Lilly Japan K.K.
      -   Phase 3   JPRN-JapicCTI-142405   -
      -   Phase 3   JPRN-JapicCTI-132156   -
      -   Phase 3   JPRN-JapicCTI-132138   -
      -   Phase 3   JPRN-JapicCTI-132134   -
      -   Phase 3   JPRN-JapicCTI-132125   -
   Eli Lilly and Company
      2020   Phase 4   NCT04086745   United States;
      2019   Phase 4   NCT03915964   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   NCT02265705   Argentina;Brazil;China;
      2014   Phase 3   EUCTR2012-003686-17-SI   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-003686-17-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   NCT01885078   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   NCT01721044   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-SK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-LV   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-HR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003686-17-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002339-27-GB   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   Phase 3   EUCTR2012-002324-32-GB   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002324-32-BE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002323-15-GB   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002323-15-DK   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002323-15-BE   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002322-73-SI   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002322-73-GB   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002322-73-DE   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002339-27-SK   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002339-27-PT   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002339-27-HU   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002339-27-DE   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002339-27-CZ   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002339-27-BE   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002324-32-SE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-PT   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-GR   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-DE   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002324-32-AT   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-002323-15-PL   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002323-15-NL   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002323-15-HR   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002323-15-GR   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002323-15-AT   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-SK   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-PT   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-NL   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-LV   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-LT   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-HU   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-GR   Argentina;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-CZ   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-BE   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2012   Phase 3   NCT01721057   Argentina;Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 3   NCT01711359   Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Puerto Rico;Russian Federation;South Africa;Sweden;United Kingdom;United States;
      2012   Phase 3   NCT01710358   Argentina;Belgium;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2011   Phase 2   NCT01469013   Japan;
   Galvani Bioelectronics
      2021   -   NCT05003310   United States;
   Lilly S.A.
      2013   -   EUCTR2012-003686-17-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002339-27-ES   Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
      2013   -   EUCTR2012-002323-15-ES   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002322-73-ES   Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
   Transparency in Healthcare
      2019   Phase 4   EUCTR2019-000505-72-NL   Netherlands;
   University of Erlangen-Nürnberg Medical School
      2018   Phase 3   NCT03701789   Germany;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
Baricitinib Oral Tablet [Olumiant]   
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 4   NCT05238896   France;
Baricitinib treatment   
   University Hospital, Bordeaux
      2021   Phase 3   NCT04870203   France;Monaco;
Baricitinib, olumiant®   
   Shinshu University
      2018   Phase 2   NCT03755466   Japan;
Belatacept   
   Bristol-Myers Squibb
      2000   Phase 1/Phase 2   NCT00279760   Belgium;Canada;France;Germany;Ireland;Netherlands;Switzerland;United Kingdom;United States;
Belimumab   
   Human Genome Sciences Inc.
      2005   Phase 2   NCT00583557   Poland;United States;
      2003   Phase 2   NCT00071812   United States;
   Human Genome Sciences Inc., a GSK Company
      2009   Phase 4   NCT00931086   United States;
Benepali   
   Biogen
      2017   -   NCT03327454   Germany;
      2017   -   NCT03100734   Germany;
   Department of Clinical Biochemestry, Aarhus University Hospital
      2015   Phase 4   EUCTR2015-004173-32-DK   Denmark;
   University of Leeds
      2019   Phase 4   NCT03813771   United Kingdom;
      2018   Phase 4   EUCTR2016-002344-16-GB   United Kingdom;
Benzimidazole,5-methoxy-2-[[(4-methoxy- 3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole   
   Pfizer Pharma GmbH
      2006   -   EUCTR2004-001234-17-DE   Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole   
   Laboratórios Pfizer, Lda
      2006   -   EUCTR2004-001234-17-PT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer AB
      2006   -   EUCTR2004-001234-17-SE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Healthcare Ireland
      2006   -   EUCTR2004-001234-17-IE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2005   -   EUCTR2004-001234-17-LT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Limited
      2006   Phase 4   EUCTR2004-001234-17-GB   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-001234-17-CZ   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer SA/NV
      2006   -   EUCTR2004-001234-17-BE   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer, S.A.
      2005   -   EUCTR2004-001234-17-ES   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Bi 695500   
   Boehringer Ingelheim International GmbH
      2014   Phase 3   EUCTR2013-002622-23-PT   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-002622-23-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2013-002622-23-NL   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2013-002622-23-HU   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2013-002622-23-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2013-002622-23-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2013-002622-23-DE   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2013-002622-23-BG   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
Bicain spinal   
   Helsinki University Central Hospital
      2016   Phase 4   EUCTR2016-002035-15-FI   Finland;
Bimekizumab   
   UCB Biopharma Sprl
      2016   Phase 2   EUCTR2016-000393-37-BG   Bulgaria;Georgia;Hungary;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;United Kingdom;
   UCB Celltech
      2015   Phase 2   NCT02430909   Czech Republic;Czechia;Hungary;Moldova, Republic of;Poland;Russian Federation;Slovakia;United Kingdom;
   UCB Celltech, UK Registered Branch of UCB Pharma SA
      2015   Phase 2   EUCTR2014-003307-30-GB   Czech Republic;Hungary;Russian Federation;Slovakia;United Kingdom;
      2015   -   EUCTR2014-003307-30-SK   Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
Binyrebarkhormon   
   Knowledge Centre for Rheumatology and Back Diseases
      2013   -   EUCTR2013-003486-34-DK   Denmark;
Binyrebsrkhormon   
   Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet
      2017   Phase 4   EUCTR2017-003425-15-DK   Denmark;
Biodmards   
   Pfizer
      2012   -   NCT01438892   United States;
Biologic Agents   
   Simon Krabbe
      2006   -   NCT03496831   -
Biologic DMARD   
   Seoul National University Hospital
      2013   -   NCT01965132   Korea, Republic of;
Biologic TNFi   
   Pfizer
      2009   Phase 3   NCT00853385   Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;Germany;Korea, Republic of;Mexico;Philippines;Poland;Slovakia;Spain;Thailand;United Kingdom;United States;
Biologic/targeted therapy   
   Tuen Mun Hospital
      2022   -   NCT05182203   China;
Biological Drug   
   Sohag University
      2022   -   NCT05267431   Egypt;
Biological agents   
   Astellas Pharma Inc
      2012   -   NCT01870908   Japan;
Biological disease-modifying antirheumatic drugs (bDMARDs)   
   Universidade Nova de Lisboa
      2020   -   NCT04973787   Portugal;
Biologics   
   Shinshu University
      2018   Phase 2   NCT03755466   Japan;
Biosimilar   
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2018   -   NCT03729674   Canada;
   Opal Rheumatology Ltd.
      2018   -   NCT03470688   Australia;
Biosimilar Infliximab   
   Hikma Pharmaceuticals LLC
      2017   -   NCT03348046   Jordan;
   Janssen Scientific Affairs, LLC
      2016   -   NCT02728934   United States;
Biosimilar infliximab   
   Diakonhjemmet Hospital
      2014   Phase 4   NCT02148640   Norway;
Biosimilar product to adalimumab   
   Amgen Inc
      2014   Phase 3   EUCTR2013-000525-31-DE   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2014   -   EUCTR2013-000525-31-RO   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-PL   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-HU   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-GB   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-ES   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-CZ   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2013   -   EUCTR2013-000525-31-BG   Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
Blood   
   Centre Hospitalier Universitaire, Amiens
      2013   -   NCT02894047   France;
Blood Collection for PK Testing (15 Mins Before Injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Blood Collection for PK Testing (15 minutes post injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Blood Collection for PK Testing (18-20 hours post injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Blood Collection for PK Testing (180 minutes post injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Blood Collection for PK Testing (60 minutes post injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Blood Collection for PK Testing (after injection)   
   Navidea Biopharmaceuticals
      2017   Phase 1/Phase 2   NCT02865434   United States;
Blood sample   
   Centre Hospitalier Universitaire de Saint Etienne
      2020   Phase 4   NCT04470453   France;
      2018   Phase 4   NCT03445871   France;
   University Hospital, Bordeaux
      2018   -   NCT03550833   France;
Blood samples   
   Assistance Publique Hopitaux De Marseille
      2011   Phase 3   NCT01954381   France;
Blood sampling   
   University Hospital, Toulouse
      2021   -   NCT05039216   France;
Blood sampling from infant   
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02019602   France;Netherlands;Switzerland;United States;
Blood sampling from mother   
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02019602   France;Netherlands;Switzerland;United States;
Blood sampling from umbilical cord   
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02019602   France;Netherlands;Switzerland;United States;
Blood tests   
   Assistance Publique - Hôpitaux de Paris
      2020   -   NCT04584541   France;
Boostrix®   
   Eli Lilly and Company
      2011   -   EUCTR2010-022205-17-PL   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
      2011   -   EUCTR2010-022205-17-BG   Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
Bortezomib   
   Charite University, Berlin, Germany
      2014   Phase 2   NCT02102594   Germany;
Bovine intesastinal alkaline phosphatase (bIAP)   
   Alloksys Life Sciences B.V.
      2011   -   EUCTR2008-007346-63-GB   United Kingdom;
Branebrutinib   
   Bristol-Myers Squibb
      2020   Phase 2   NCT04186871   Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
Breast milk sampling   
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02154425   France;Netherlands;Switzerland;United States;
Bredinin tablet   
   Chong Kun Dang Pharmaceutical
      2013   Phase 2   NCT02005757   Korea, Republic of;
Bucillamine   
   BASIC study group
      2007   -   JPRN-UMIN000000837   Japan;
   Higashi-Hiroshima Memorial Hospital
      2009   Phase 4   JPRN-UMIN000002169   Japan;
   Japan Association of Rheumatologists in Private Practice
      2010   -   JPRN-UMIN000003807   Japan;
   KONAMON Study Group
      2013   -   JPRN-UMIN000007404   Japan;
   National hospital organization Chiba east national hospital Clinical Research Center
      2013   -   JPRN-UMIN000012690   Japan;
   Saitama Medical University
      2007   Phase 4   NCT00716248   Japan;
   Sanofi
      2015   Phase 3   NCT02373202   Japan;
   St Luke'
   Tokyo Medical and Dental University
      2012   -   JPRN-UMIN000006702   Japan;
   s International Hospital
Bupivacaine hydrochloride (Marcaine, Pfizer)   
   Sohag University
      2020   Phase 4   NCT04361513   Egypt;
Buprenorphine Transdermal Patch   
   Mundipharma Pharmaceuticals Sdn. Bhd.
      2013   Phase 4   NCT02519387   Malaysia;
Buprenorphine transdermal patch   
   Mundipharma Pte Ltd.
      2013   Phase 4   NCT01961271   Hong Kong;Korea, Republic of;Philippines;
C-Stem™ AMT Femoral Component (standard and high off-set variants)   
   DePuy International
      2006   Phase 4   NCT00872573   United Kingdom;
C. albicans   
   Genentech, Inc.
      2006   Phase 2   NCT00282308   United States;
C10AA05   
   Reade
      2015   Phase 4   EUCTR2013-005524-42-NL   Netherlands;
CAM-3001   
   MedImmune Limited
      2013   Phase 2   EUCTR2011-005649-10-GB   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
   MedImmune Ltd
      2013   Phase 2   EUCTR2011-005648-93-SK   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
      2013   Phase 2   EUCTR2011-005648-93-GB   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
      2013   -   EUCTR2011-005649-10-SK   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005649-10-PT   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005649-10-HU   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005649-10-DE   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005649-10-CZ   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2013   -   EUCTR2011-005648-93-PT   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
      2012   Phase 2   EUCTR2011-005648-93-GR   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
      2012   Phase 2   EUCTR2011-005648-93-ES   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
      2012   Phase 2   EUCTR2011-005648-93-DE   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
      2012   Phase 2   EUCTR2011-005648-93-BG   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-005649-10-GR   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-005649-10-ES   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-005648-93-HU   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-005648-93-EE   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-005648-93-CZ   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-005634-19-PL   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-HU   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-ES   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-EE   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-DE   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-CZ   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2012   -   EUCTR2011-005634-19-BG   Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
      2010   -   EUCTR2009-014735-20-PL   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2010   -   EUCTR2009-014735-20-LT   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2010   -   EUCTR2009-014735-20-HU   Bulgaria;Czech Republic;Estonia;Hungary;Lithuania;Poland;
      2010   -   EUCTR2009-014735-20-CZ   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2010   -   EUCTR2009-014735-20-BG   Bulgaria;Czech Republic;Estonia;Hungary;Latvia;Lithuania;Poland;
      2009   -   EUCTR2009-014735-20-LV   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2009   -   EUCTR2009-014735-20-EE   Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
      2008   Phase 1   NCT00771420   Germany;
CAPTURE   
   Dept. of orthopedic surgery, Osaka Medical College
      2014   -   JPRN-UMIN000012650   Japan;
   GlaxoSmithKline
      2017   -   NCT03285191   United Kingdom;
CC-10004   
   Celgene Corporation
      2011   -   EUCTR2010-019926-15-CZ   Czech Republic;United States;
CC-292   
   Celgene
      2013   Phase 2   NCT01975610   United States;
CCI-779   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2003   Phase 2   NCT00076206   United States;
CCR1 Antagonist   
   Bristol-Myers Squibb International Corporation
      2012   -   EUCTR2011-002024-40-ES   Argentina;Korea, Republic of;Mexico;Russian Federation;South Africa;Spain;United States;
CCX 354-C   
   ChemoCentryx
      2009   Phase 1/Phase 2   NCT01027728   Belgium;Romania;
CCX-354-C   
   ChemoCentryx
      2010   Phase 2   NCT01242917   Belgium;Czech Republic;Germany;Hungary;Netherlands;Poland;Romania;Ukraine;
CCX354-C   
   ChemoCentryx
      2010   Phase 2   NCT01242917   Belgium;Czech Republic;Germany;Hungary;Netherlands;Poland;Romania;Ukraine;
   ChemoCentryx, Inc.
      2010   Phase 2   EUCTR2010-019964-36-BE   Belgium;Czech Republic;Germany;Hungary;
      2010   -   EUCTR2010-019964-36-HU   Belgium;Czech Republic;Hungary;
      2010   -   EUCTR2010-019964-36-DE   Belgium;Czech Republic;Germany;Hungary;
      2010   -   EUCTR2010-019964-36-CZ   Belgium;Czech Republic;Germany;Hungary;
CDMARD   
   Eli Lilly and Company
      2013   Phase 3   NCT01721044   Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Spain;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   NCT01721057   Argentina;Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
CDP 6038 SC   
   UCB Pharma
      2009   Phase 1/Phase 2   NCT01009242   Germany;United States;
CDP6038   
   R-Pharm
      2016   Phase 3   EUCTR2014-004719-36-BG   Belarus;Bulgaria;Russian Federation;Turkey;
   UCB BIOSCIENCES, Inc.
      2011   Phase 2   NCT01296711   Belgium;United Kingdom;United States;
   UCB Biosciences Inc
      2011   -   EUCTR2010-022224-77-GB   Belgium;United Kingdom;United States;
   UCB Biosciences, Inc
      2011   -   EUCTR2010-020839-39-GB   United Kingdom;United States;
   UCB Biosciences, Inc.
      2011   Phase 2   EUCTR2010-022224-77-BE   Belgium;United Kingdom;United States;
   UCB Biosciences, Inc. A Member of the UCB Group of Companies
      2011   Phase 2   EUCTR2010-020839-39-BE   Belgium;United Kingdom;United States;
   UCB Celltech
      2009   -   EUCTR2009-010813-57-DE   Germany;
   UCB Pharma
      2010   Phase 2   NCT01242488   Belgium;United Kingdom;United States;
      2009   Phase 1/Phase 2   NCT01009242   Germany;United States;
CDP870   
   Astellas Pharma Inc
      2011   Phase 3   NCT02586246   Japan;
   Celltech R&D Ltd
      2005   Phase 3   EUCTR2004-002993-49-FI   Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;Sweden;
      2005   -   EUCTR2004-002993-49-LV   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2005   -   EUCTR2004-002993-49-HU   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2005   -   EUCTR2004-002993-49-GB   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;United Kingdom;
      2005   -   EUCTR2004-002993-49-DE   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2005   -   EUCTR2004-002993-49-BE   Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Sweden;
   Korea Otsuka Pharmaceutical Co., Ltd.
      2009   Phase 3   NCT00993317   Korea, Republic of;
   Otsuka Pharmaceutical Co., Ltd.
      2008   Phase 3   NCT00791921   Japan;
      2008   Phase 2/Phase 3   NCT00791999   Japan;
   UCB Celltech
      2007   -   EUCTR2004-002993-49-EE   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2006   Phase 3   EUCTR2005-002629-30-SK   Czech Republic;Estonia;Latvia;Lithuania;Slovakia;
      2006   -   EUCTR2005-002629-30-LV   Czech Republic;Estonia;Latvia;Lithuania;
      2006   -   EUCTR2005-002326-63-EE   Czech Republic;Estonia;Latvia;Lithuania;
      2005   Phase 3   EUCTR2005-002326-63-SK   Czech Republic;Estonia;Latvia;Lithuania;Slovakia;
      2005   Phase 3   EUCTR2004-002993-49-SK   Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;Sweden;
      2005   -   EUCTR2005-002326-63-LV   Czech Republic;Estonia;Latvia;Lithuania;
      2005   -   EUCTR2005-002326-63-LT   Czech Republic;Estonia;Latvia;Lithuania;
      2005   -   EUCTR2004-002993-49-LT   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2005   -   EUCTR2004-002993-49-CZ   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
   UCB Inc
      2006   -   EUCTR2005-002629-30-LT   Czech Republic;Estonia;Latvia;Lithuania;
      2006   -   EUCTR2005-002629-30-EE   Czech Republic;Estonia;Latvia;Lithuania;
      2006   -   EUCTR2005-002629-30-CZ   Czech Republic;Estonia;Latvia;Lithuania;
   UCB Pharma
      2003   Phase 3   NCT00548834   -
      2002   Phase 3   NCT00544154   -
   UCB Pharma S.A.
      2011   -   EUCTR2009-013758-33-NL   Denmark;Netherlands;Sweden;
      2010   -   EUCTR2009-013758-33-SE   Denmark;Netherlands;Sweden;
      2010   -   EUCTR2009-013758-33-DK   Denmark;Netherlands;Sweden;
      2010   -   EUCTR2007-000830-38-PL   Austria;France;Germany;Italy;Poland;
      2009   -   EUCTR2007-005288-86-FR   France;
      2009   -   EUCTR2007-000828-40-PL   Austria;France;Germany;Italy;Poland;
      2008   Phase 3   EUCTR2007-000828-40-FR   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000830-38-FR   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000830-38-DE   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000830-38-AT   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000828-40-DE   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000828-40-AT   Austria;France;Germany;Italy;Poland;
      2005   -   EUCTR2005-002326-63-CZ   Czech Republic;Estonia;Latvia;Lithuania;
      2005   -   EUCTR2004-002993-49-SE   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
   UCB Pharma SA
      2015   -   EUCTR2011-002067-20-FR   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2011-002067-20-GR   Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-PT   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-IE   Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-GB   Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-DE   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-CZ   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-BG   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001729-25-SE   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001729-25-IE   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001729-25-GB   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002067-20-HU   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002067-20-ES   Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002067-20-AT   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-NL   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-HU   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-ES   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-DE   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-CZ   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-AT   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-005427-28-FR   France;Germany;Italy;Netherlands;Spain;
      2009   -   EUCTR2008-005427-28-NL   France;Germany;Italy;Netherlands;Spain;
      2009   -   EUCTR2008-005427-28-IT   France;Germany;Italy;Netherlands;Spain;
      2009   -   EUCTR2008-005427-28-ES   France;Germany;Italy;Netherlands;Spain;
      2009   -   EUCTR2008-005427-28-DE   France;Germany;Italy;Netherlands;Spain;
   UCB S.A. (Casa Madre)
      2008   -   EUCTR2007-000830-38-IT   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000828-40-IT   Austria;France;Germany;Italy;Poland;
CDP870 Fab'-PEG   
   UCB Celltech
      2005   Phase 3   EUCTR2005-001350-24-SK   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;
   UCB Inc.
      2005   -   EUCTR2005-001350-24-LV   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-LT   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-HU   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-FI   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-EE   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-CZ   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
CE 224,535   
   Pfizer
      2009   Phase 1   NCT00838058   United States;
CE-224,535   
   PFIZER S.A.
      2008   Phase 2   EUCTR2008-000327-25-ES   Czech Republic;Poland;Spain;
   Pfizer
      2009   Phase 1   NCT00838058   United States;
      2008   Phase 2/Phase 3   NCT00628095   Chile;Czech Republic;Korea, Republic of;Mexico;Poland;Spain;United States;
      2007   Phase 1   NCT00446784   United States;
   Pfizer Inc. 235 East 42nd Street NY10017
      2008   Phase 2   EUCTR2008-000327-25-PL   Czech Republic;Poland;Spain;
      2008   -   EUCTR2008-000327-25-CZ   Czech Republic;Poland;Spain;
CELBESTA®   
   Dong-A ST Co., Ltd.
      2015   Phase 4   NCT02780323   Korea, Republic of;
CELEBREX   
   GlaxoSmithKline Research & Development Limited
      2006   -   EUCTR2005-000158-61-EE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-CZ   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-AT   Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
CELEBREX 200MG 20CPS   
   GLAXO SMITHKLINE
      2005   -   EUCTR2005-000158-61-IT   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
CELEBREX®   
   Dong-A ST Co., Ltd.
      2015   Phase 4   NCT02780323   Korea, Republic of;
CERTOLUZIMAB PEGOL   
   UCB PHARMA
      2011   -   EUCTR2011-000385-35-IT   Italy;
CF101   
   Can-Fite BioPharma
      2017   Phase 3   NCT02647762   Bosnia and Herzegovina;Canada;Israel;Moldova, Republic of;Poland;Romania;Serbia;
      2010   Phase 2   NCT01034306   Bulgaria;Israel;
      2008   Phase 2   NCT00556894   Bulgaria;Czech Republic;Czechia;Former Serbia and Montenegro;Israel;Poland;Serbia;Ukraine;
      2006   Phase 2   NCT00280917   Bulgaria;Former Serbia and Montenegro;Israel;Poland;Romania;Serbia;Ukraine;United States;
   Can-Fite BioPharma Ltd.
      2008   -   EUCTR2007-006527-13-BG   Bulgaria;
   Can-Fite BioPharma, Ltd.
      2019   Phase 3   EUCTR2016-003682-26-PL   Bosnia and Herzegovina;Bulgaria;Canada;Israel;Moldova, Republic of;Poland;Romania;Serbia;
CFZ533   
   Novartis Pharmaceuticals
      2013   Phase 1   NCT02089087   Taiwan;United States;
CH-1504   
   Chelsea Therapeutics
      2008   Phase 2   NCT00658047   Canada;
CH-4051   
   Chelsea Therapeutics
      2010   Phase 2   NCT01116141   -
   Chelsea Therapeutics, Inc
      2010   -   EUCTR2010-019134-27-CZ   Bulgaria;Czech Republic;
      2010   -   EUCTR2010-019134-27-BG   Argentina;Bulgaria;Czech Republic;Mexico;Poland;United States;
CHS-0214   
   COHERUS BIOSCIENCES, INC.
      2015   Phase 3   EUCTR2015-000665-30-IT   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
   Coherus BioSciences, Inc
      2014   Phase 3   EUCTR2014-000443-33-PL   Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000443-33-GB   Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   Coherus BioSciences, Inc.
      2015   Phase 3   EUCTR2015-000665-30-GB   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
      2015   Phase 3   EUCTR2015-000665-30-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
      2015   Phase 3   EUCTR2015-000665-30-DE   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
   Coherus Biosciences, Inc
      2014   Phase 3   EUCTR2014-000443-33-IT   Argentina;Belarus;Brazil;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000443-33-HU   Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000443-33-ES   Argentina;Belarus;Brazil;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000443-33-DE   Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   Coherus Biosciences, Inc.
      2015   Phase 3   NCT02486939   Japan;
      2014   Phase 3   NCT02115750   Belarus;France;Germany;Hungary;Israel;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
   DAIICHISANKYO Co.,Ltd.
      2014   Phase 3   JPRN-JapicCTI-142621   -
CIMZIA (Certolizumab Pegol)   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 4   EUCTR2016-003129-40-IT   Italy;
CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI   
   SOCIETA' ITALIANA DI REUMATOLOGIA - SIR
      2017   Phase 4   EUCTR2016-001987-12-IT   Italy;
CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 4   EUCTR2016-003129-40-IT   Italy;
CKD-374 5mg Tab.   
   Chong Kun Dang Pharmaceutical
      2019   Phase 1   NCT03858725   Korea, Republic of;
CKD-506   
   Chong Kun Dang Pharmaceutical
      2018   Phase 2   NCT04204603   Czechia;Georgia;Poland;Russian Federation;Ukraine;
   Chong Kun Dang Pharmaceutical Corporation (CKD)
      2018   Phase 2   EUCTR2018-001377-24-CZ   Czech Republic;Georgia;Poland;Russian Federation;Ukraine;
CLS Brevius stem with Kinectiv technology   
   Zimmer Biomet
      2011   -   NCT03410940   Italy;Poland;Spain;
CMAB008   
   Shanghai Biomabs Pharmaceutical Co., Ltd.
      2018   Phase 3   NCT03478111   China;
CNTO 136   
   Centocor, Inc.
      2008   Phase 2   NCT00718718   Argentina;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Taiwan;Ukraine;United States;
   Janssen-Cilag International N.V.
      2014   Phase 3   EUCTR2013-001417-32-LT   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2013-001417-32-HU   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2013-001417-32-ES   Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001417-32-DE   Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001417-32-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
CNTO 136 IgG   
   Centocor B.V.
      2009   -   EUCTR2007-006603-20-HU   Hungary;
CNTO 148   
   CENTOCOR
      2010   -   EUCTR2009-010582-23-IT   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
   Centocor B.V.
      2006   Phase 3   EUCTR2005-001742-16-GB   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-003232-21-MT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LV   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-HU   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-DE   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-001742-16-NL   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-ES   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2004-003296-36-HU   Germany;Hungary;
      2006   -   EUCTR2004-003296-36-DE   Germany;Hungary;
   Centocor BV
      2010   -   EUCTR2009-010582-23-GR   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2004-003295-10-GB   Austria;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-HU   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-ES   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-AT   Austria;Hungary;Italy;Spain;United Kingdom;
   Janssen Biologics B.V.
      2010   Phase 3   EUCTR2009-010582-23-BE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2010   -   EUCTR2009-010582-23-DE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-010582-23-GB   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   -   EUCTR2009-010582-23-SE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   -   EUCTR2009-010582-23-AT   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2006   -   EUCTR2005-001742-16-FI   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-DE   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-AT   Austria;Germany;Netherlands;Spain;United Kingdom;
   Janssen Pharmaceutical K.K.
      2008   Phase 3   NCT00771251   Japan;
      2008   Phase 3   NCT00727987   Japan;
CNTO 1959 + MTX (Group 4)   
   Janssen Research & Development, LLC
      2012   Phase 2   NCT01645280   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;Singapore;Turkey;Ukraine;United States;
CNTO 1959 + MTX (Group 5)   
   Janssen Research & Development, LLC
      2012   Phase 2   NCT01645280   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;Singapore;Turkey;Ukraine;United States;
CNTO 1959 IgG   
   Janssen-Cilag International NV
      2013   -   EUCTR2011-001122-18-BG   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
      2012   Phase 2   EUCTR2011-001122-18-CZ   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
      2012   -   EUCTR2011-001122-18-HU   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
CNTO 6785   
   Janssen Research & Development, LLC
      2013   Phase 2   NCT01909427   Argentina;Colombia;Czech Republic;Philippines;Poland;Russian Federation;Thailand;
CNTO1275   
   Janssen-Cilag International NV
      2013   -   EUCTR2011-001122-18-BG   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
      2012   Phase 2   EUCTR2011-001122-18-CZ   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
      2012   -   EUCTR2011-001122-18-HU   Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
CNTO136   
   Centocor B.V.
      2009   -   EUCTR2007-006603-20-HU   Hungary;
   JANSSEN-CILAG INTERNATIONAL N.V.
      2012   -   EUCTR2010-022243-38-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Germany;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Portugal;Spain;Taiwan;United Kingdom;United States;
   Janssen-Cilag International N.V.
      2015   Phase 3   EUCTR2012-001176-10-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001417-32-LT   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2013-001417-32-HU   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2013-001417-32-ES   Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001417-32-DE   Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001417-32-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2012-001176-10-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-PL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-HR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001176-10-LT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001176-10-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2010-022242-24-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;United States;
      2013   -   EUCTR2010-022243-38-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-022243-38-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-022242-24-LT   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;United States;
      2012   -   EUCTR2010-022243-38-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022243-38-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
CNTO148   
   CENTOCOR
      2006   Phase 3   EUCTR2004-003295-10-IT   Austria;Hungary;Italy;Spain;United Kingdom;
   Centocor B.V.
      2010   -   EUCTR2008-006064-11-HU   Hungary;Lithuania;
   Janssen Biologics B.V.
      2011   Phase 3   EUCTR2009-015019-42-BE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2011   -   EUCTR2009-015019-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
      2010   -   EUCTR2009-015019-42-LT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2010   -   EUCTR2009-015019-42-FI   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2010   -   EUCTR2009-015019-42-AT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2009   -   EUCTR2008-006064-11-LT   Argentina;Australia;Colombia;Hungary;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Ukraine;United States;
      -   -   EUCTR2009-015019-42-Outside-EU/EEA   Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
CNTO6785   
   Janssen-Cilag International NV
      2013   -   EUCTR2012-003629-40-CZ   Argentina;China;Colombia;Czech Republic;India;Philippines;Poland;Russian Federation;Thailand;
COVID-19 Vaccine (ChAdOx1-S [recombinant])   
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
COVID-19 mRNA Vaccine (nucleoside modified)   
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
COVID-19 mRNA vaccine (nucleoside-modified)   
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
COVID-19 mRNA vaccine Moderna (CX-024414)   
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
COVID-19 vaccine   
   Paul R Fortin
      2022   Phase 2/Phase 3   NCT05236491   -
COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19)   
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
CP 690,550   
   PFIZER
      2005   -   EUCTR2004-002846-36-IT   Germany;Italy;Spain;
   PFIZER INC
      2017   Phase 3   EUCTR2016-001825-15-IT   Bulgaria;Czech Republic;Germany;Hungary;Italy;Poland;Slovakia;Spain;
   Pfizer
      2009   Phase 3   NCT00853385   Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;Germany;Korea, Republic of;Mexico;Philippines;Poland;Slovakia;Spain;Thailand;United Kingdom;United States;
   Pfizer Inc.
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-SK   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-CZ   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, New York
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-PL   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-HU   Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-GB   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-DE   Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-BG   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2017   Phase 3;Phase 4   EUCTR2016-001825-15-BE   Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
CP 690550 MR   
   Pfizer Inc.
      2020   Phase 2   EUCTR2019-002676-14-SE   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-HU   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-CZ   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
      2020   Phase 2   EUCTR2019-002676-14-BG   Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
CP-195,543   
   Pfizer
      2006   Phase 2   NCT00424294   United States;
CP-690, 550 - 10   
   Pfizer Inc. 235 East 42nd Street, New York, NY 10017
      2016   Phase 3;Phase 4   EUCTR2014-000358-13-DE   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2015   Phase 3;Phase 4   EUCTR2014-000358-13-HR   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2015   Phase 3;Phase 4   EUCTR2014-000358-13-ES   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-RO   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-LV   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-LT   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Hungary;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-GB   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-EE   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-CZ   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-BG   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
CP-690,55-10   
   Arthritis Alapítvány
      2016   -   EUCTR2015-002523-26-HU   Hungary;
CP-690,550   
   PFIZER
      2010   Phase 3   EUCTR2009-016987-34-ES   Belgium;Bulgaria;Czech Republic;Germany;Hungary;Poland;Slovakia;Spain;Sweden;
      2008   -   EUCTR2007-002066-35-IT   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2007   Phase 2   EUCTR2006-005035-19-IT   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-001984-31-IT   Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;
   Pfizer
      2016   Phase 4   NCT02831855   Australia;Belgium;Bulgaria;Czechia;Germany;Hungary;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
      2012   Phase 1   NCT01484561   Czech Republic;Germany;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
      2011   Phase 2   NCT01359150   Poland;United States;
      2010   Phase 3   NCT01039688   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Czechia;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
      2010   Phase 2   NCT01059864   Korea, Republic of;United States;
      2009   Phase 3   NCT00960440   Australia;Austria;Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Korea, Republic of;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
      2009   Phase 3   NCT00856544   Australia;Chile;China;Colombia;Croatia;Denmark;Finland;Germany;Greece;Malaysia;Mexico;Poland;Russian Federation;Slovakia;Spain;Sweden;Thailand;United Kingdom;United States;Venezuela;
      2009   Phase 3   NCT00853385   Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;Germany;Korea, Republic of;Mexico;Philippines;Poland;Slovakia;Spain;Thailand;United Kingdom;United States;
      2009   Phase 3   NCT00847613   Australia;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Greece;India;Japan;Korea, Republic of;Mexico;Poland;Taiwan;Ukraine;United States;Venezuela;
      2009   Phase 3   NCT00814307   Brazil;Bulgaria;Chile;Colombia;Czech Republic;Dominican Republic;Germany;India;Malaysia;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;Ukraine;United States;
      2009   Phase 2   NCT00687193   Japan;
      2008   Phase 3   NCT00661661   Japan;
      2008   Phase 2   NCT00603512   Japan;
      2007   Phase 3   NCT00413699   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Czechia;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;United States Minor Outlying Islands;
      2007   Phase 2   NCT00550446   Brazil;Bulgaria;Chile;Croatia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Romania;Slovakia;Ukraine;United States;
      2007   Phase 2   NCT00413660   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Hungary;Mexico;Poland;Slovakia;Spain;Sweden;Turkey;United States;
      2007   -   NCT00414661   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Costa Rica;Czech Republic;Dominican Republic;Finland;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;Ukraine;United States;
      2005   Phase 2   NCT00147498   Austria;Belgium;Brazil;Canada;Germany;Italy;Mexico;Slovakia;Spain;United States;
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2010   Phase 2;Phase 3   EUCTR2006-005035-19-HU   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-007023-26-GR   Bulgaria;Czech Republic;Greece;Poland;
      2009   -   EUCTR2008-008337-11-GB   Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-007023-26-PL   Bulgaria;Czech Republic;Poland;
      2009   -   EUCTR2008-007023-26-BG   Bulgaria;Czech Republic;Poland;
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA
      2009   -   EUCTR2008-008337-11-DE   Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2011   -   EUCTR2010-020890-18-CZ   Czech Republic;Hungary;
      2009   Phase 3   EUCTR2008-008337-11-SK   Denmark;Finland;Germany;Greece;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008338-35-CZ   Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2008-008337-11-SE   Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008337-11-GR   Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008337-11-FI   Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008337-11-DK   Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-007788-17-CZ   Bulgaria;Czech Republic;Germany;
      2009   -   EUCTR2008-007023-26-CZ   Bulgaria;Czech Republic;Poland;
   Pfizer Inc. 235 East 42nd Street, New York, NY 10017
      2011   -   EUCTR2010-020890-18-HU   Czech Republic;Hungary;
      2010   -   EUCTR2009-014296-40-IT   Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-008337-11-PL   Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
   Pfizer Inc. 235 East 42nd Street, New York, NY10017
      2009   Phase 2;Phase 3   EUCTR2006-006373-25-GB   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2006-006373-25-FI   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
      2008   Phase 2;Phase 3   EUCTR2006-005035-19-GR   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2006-006373-25-GR   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2006-006373-25-BG   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2006-005036-24-BG   Bulgaria;Czech Republic;Hungary;Sweden;
      2007   -   EUCTR2006-006373-25-CZ   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-005036-24-HU   Bulgaria;Czech Republic;Hungary;Sweden;
      2007   -   EUCTR2006-005036-24-CZ   Bulgaria;Czech Republic;Hungary;Sweden;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2010   Phase 3   EUCTR2009-014296-40-FR   Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2010   -   EUCTR2009-016987-34-SE   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
      2010   -   EUCTR2009-016987-34-PL   Bulgaria;Czech Republic;Germany;Hungary;Poland;Spain;Sweden;
      2010   -   EUCTR2009-016987-34-HU   Bulgaria;Czech Republic;Germany;Hungary;Poland;Spain;Sweden;
      2010   -   EUCTR2009-014296-40-IE   Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2010   -   EUCTR2009-014296-40-GB   Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2010   -   EUCTR2009-014296-40-BE   Australia;Austria;Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Korea, Republic of;Spain;Sweden;Taiwan;Tanzania, United Republic of;United Kingdom;United States;
      2010   -   EUCTR2009-014296-40-AT   Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-008338-35-SK   Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-008338-35-DK   Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2009-014296-40-DE   Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-008338-35-GB   Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-008338-35-FI   Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-008338-35-DE   Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-008338-35-BG   Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-007788-17-DE   Bulgaria;Czech Republic;Germany;
      2009   -   EUCTR2008-007788-17-BG   Bulgaria;Czech Republic;Germany;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
      2010   Phase 3   EUCTR2009-016987-34-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
      2010   Phase 3   EUCTR2009-016987-34-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
      2010   -   EUCTR2009-016987-34-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
      2010   -   EUCTR2009-016987-34-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
      2010   -   EUCTR2009-016987-34-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
   Pfizer Ltd - Ramsgate Road, Sandwich CT139NJ, UK.
      2007   Phase 2   EUCTR2006-005036-24-SK   Bulgaria;Czech Republic;Hungary;Slovakia;Sweden;
      2007   -   EUCTR2006-005036-24-SE   Bulgaria;Czech Republic;Hungary;Sweden;
   Pfizer Ltd, Ramsgate Road, Sandwich CT139NJ, UK
      2007   Phase 2   EUCTR2006-006373-25-SK   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-006373-25-SE   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-006373-25-AT   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
   Pfizer S.A.
      2009   Phase 3   EUCTR2009-014296-40-ES   Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2007   Phase 2   EUCTR2006-005035-19-ES   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
   Pfizer, S.A
      2009   Phase 3   EUCTR2008-008338-35-ES   Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
   Pfizer, S.A.
      2009   -   EUCTR2008-008337-11-ES   Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-006373-25-ES   Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
CP-690,550 (tasocitinib)   
   Pfizer
      2011   Phase 1   NCT01262118   Hungary;United States;
CP-690,550 (tofacitinib)   
   Pfizer
      2005   Phase 1   NCT01745055   United States;
CP-690,550 + methotrexate   
   Pfizer
      2009   Phase 2   NCT00976599   United States;
CP-690,550 – 10   
   Pfizer Inc. 235 East 42nd Street, New York, NY 10017
      2014   -   EUCTR2014-000706-34-GB   Germany;Hungary;United Kingdom;United States;
CP-690,550-10   
   Pfizer Inc, 235 East 42nd Street, New York 10017
      2013   -   EUCTR2011-005689-39-HU   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2012   Phase 2   EUCTR2007-002066-35-SK   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
      2010   Phase 2;Phase 3   EUCTR2006-005035-19-IE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2009   Phase 2;Phase 3   EUCTR2006-005035-19-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2009   Phase 2;Phase 3   EUCTR2006-005035-19-FI   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2009   Phase 2;Phase 3   EUCTR2006-005035-19-DK   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2008   Phase 2;Phase 3   EUCTR2006-005035-19-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2008   Phase 2;Phase 3   EUCTR2006-005035-19-BG   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2008   Phase 2   EUCTR2007-002066-35-GR   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
      2008   Phase 2   EUCTR2007-002066-35-BG   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2008   -   EUCTR2007-002066-35-HU   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2008   -   EUCTR2007-002066-35-DE   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2008   -   EUCTR2007-002066-35-CZ   Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-SK   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-SE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
   Pfizer Inc.
      2017   Phase 2   EUCTR2016-002337-30-SK   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-CZ   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc. 235 East 42nd Street, New York, 10017
      2015   Phase 3;Phase 4   EUCTR2013-003177-99-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-SE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2011-005689-39-SK   Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
      2014   -   EUCTR2011-005689-39-NL   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
      2014   -   EUCTR2011-005689-39-DE   Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
      2013   Phase 2   EUCTR2011-005689-39-ES   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
      2013   -   EUCTR2011-005689-39-CZ   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
   Pfizer Inc., 235 East 42nd Street, New York, 10017
      2015   Phase 3;Phase 4   EUCTR2013-003177-99-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2017   Phase 2   EUCTR2016-002337-30-HU   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-HR   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-ES   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-DE   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2017   Phase 2   EUCTR2016-002337-30-BG   Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
      2014   Phase 3;Phase 4   EUCTR2014-000358-13-PL   Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2007   Phase 2;Phase 3   EUCTR2006-005035-19-CZ   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
CP-690-550   
   Pfizer
      2007   Phase 2   NCT00550446   Brazil;Bulgaria;Chile;Croatia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Romania;Slovakia;Ukraine;United States;
CP690,550   
   Pfizer Corporation Austria Ges.m.b.H.
      2005   -   EUCTR2004-002846-36-AT   Austria;Germany;Italy;Spain;
   Pfizer Global & Developement, Pfizer Limited
      2005   Phase 2   EUCTR2004-002846-36-SK   Austria;Germany;Italy;Slovakia;Spain;
   Pfizer Pharma GmbH
      2005   -   EUCTR2004-002846-36-DE   Germany;Italy;Spain;
   Pfizer, S.A.
      2005   Phase 2   EUCTR2004-002846-36-ES   Austria;Germany;Italy;Slovakia;Spain;
CR 1   
   Pfizer
      2008   Phase 1   NCT00782600   United States;
CR 2   
   Pfizer
      2008   Phase 1   NCT00782600   United States;
CR 3   
   Pfizer
      2008   Phase 1   NCT00782600   United States;
CR0686   
   Rottapharm Biotech S.r.l.
      2017   Phase 2   EUCTR2016-004834-11-GB   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
CR6086   
   Rottapharm Biotech
      2017   Phase 2   NCT03163966   Czechia;
   Rottapharm Biotech S.r.l.
      2017   Phase 2   EUCTR2016-004834-11-PL   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-GB   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-DK   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-CZ   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-BG   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
CR6086Z   
   Rottapharm Biotech S.r.l.
      2017   Phase 2   EUCTR2016-004834-11-PL   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-GB   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-DK   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-CZ   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
      2017   Phase 2   EUCTR2016-004834-11-BG   Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
CRx-102   
   CombinatoRx, Inc
      2006   -   EUCTR2004-001930-18-EE   Estonia;
   CombinatoRx, Incorporated
      2008   -   EUCTR2007-004399-38-LT   Estonia;Lithuania;United Kingdom;
      2008   -   EUCTR2007-004399-38-GB   Estonia;Lithuania;United Kingdom;
      2008   -   EUCTR2007-004399-38-EE   Estonia;Lithuania;United Kingdom;
      2008   -   EUCTR2007-003069-42-LT   Estonia;Hungary;Lithuania;United Kingdom;
      2008   -   EUCTR2007-003069-42-HU   Estonia;Hungary;Lithuania;United Kingdom;
      2008   -   EUCTR2007-003069-42-GB   Estonia;Hungary;Lithuania;United Kingdom;
      2007   -   EUCTR2007-003069-42-EE   Estonia;Hungary;Lithuania;United Kingdom;
   Zalicus
      2004   Phase 2   NCT00747214   -
CRx-102 (2.7/180)   
   Zalicus
      2007   Phase 2   NCT00551707   Argentina;Canada;Estonia;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa;United States;
CRx-102 (2.7/360)   
   Zalicus
      2007   Phase 2   NCT00551707   Argentina;Canada;Estonia;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa;United States;
CRx-139   
   CombinatoRx, Inc.
      2006   Phase 2   EUCTR2004-004995-35-GB   Austria;Czech Republic;Denmark;Germany;Italy;United Kingdom;
      2006   -   EUCTR2004-004995-35-DK   Czech Republic;Denmark;Germany;Italy;United Kingdom;
      2005   -   EUCTR2004-004995-35-CZ   Czech Republic;Denmark;Germany;Italy;United Kingdom;
      2005   -   EUCTR2004-004995-35-AT   Austria;Czech Republic;Denmark;Germany;Italy;United Kingdom;
CRx-150   
   CombinatoRx, Inc
      2006   -   EUCTR2004-001490-26-EE   Estonia;United Kingdom;
      2004   -   EUCTR2004-001490-26-GB   Estonia;United Kingdom;
CT- P10   
   CELLTRION, Inc.
      2014   Phase 3   EUCTR2013-004555-21-SK   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-PT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-LV   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-HU   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-GR   Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-DE   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
      2014   Phase 3   EUCTR2013-004555-21-AT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
CT-P10   
   Celltrion
      2014   Phase 3   NCT02149121   Austria;Korea, Republic of;
CT-P13   
   CELLTRION, INC.
      2012   -   EUCTR2011-004468-31-IT   Austria;Bosnia and Herzegovina;Chile;Colombia;Italy;Jordan;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Spain;Ukraine;United Kingdom;
   CELLTRION, Inc
      2012   Phase 3   EUCTR2011-004468-31-GB   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2012   Phase 3   EUCTR2011-004468-31-ES   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-004468-31-PL   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-004468-31-LV   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-004468-31-LT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2011-004468-31-AT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2011   -   EUCTR2011-004468-31-SK   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
      2010   Phase 3   EUCTR2010-018646-31-SK   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Slovakia;Spain;United Kingdom;
      2010   Phase 3   EUCTR2010-018646-31-ES   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-PT   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-LV   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-LT   Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Indonesia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;
      2010   -   EUCTR2010-018646-31-IT   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-GB   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-BG   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-018646-31-AT   Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
   Celltrion
      2018   Phase 3   NCT03707535   China;
      2016   Phase 3   NCT03147248   Korea, Republic of;
   Celltrion, Inc
      2017   Phase 1;Phase 3   EUCTR2016-002125-11-ES   Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
      2016   Phase 1;Phase 3   EUCTR2016-002125-11-LV   Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
      2016   Phase 1;Phase 3   EUCTR2016-002125-11-HU   Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
      2016   Phase 1;Phase 3   EUCTR2016-002125-11-EE   Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
      2016   Phase 1;Phase 3   EUCTR2016-002125-11-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Hungary;Korea, Republic of;Latvia;Lithuania;Poland;Russian Federation;South Africa;Spain;Ukraine;
      2016   Phase 1;Phase 3   EUCTR2016-002125-11-BG   Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
   Pfizer
      2015   -   NCT02605642   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Spain;United Kingdom;
CT-P17   
   CELLTRION, Inc.
      2019   Phase 3   EUCTR2019-000660-25-PL   Poland;
   Celltrion, Inc
      2019   Phase 3   EUCTR2018-001690-25-LT   Bulgaria;Hungary;Lithuania;Peru;Poland;Ukraine;
      2018   Phase 3   EUCTR2018-001690-25-PL   Bosnia and Herzegovina;Bulgaria;Hungary;Korea, Republic of;Lithuania;Peru;Poland;Russian Federation;Ukraine;
      2018   Phase 3   EUCTR2018-001690-25-HU   Bosnia and Herzegovina;Bulgaria;Hungary;Lithuania;Peru;Poland;Russian Federation;Ukraine;
      2018   Phase 3   EUCTR2018-001690-25-BG   Bulgaria;Hungary;Korea, Republic of;Lithuania;Peru;Poland;Ukraine;
CT-P17 SC   
   Celltrion
      2018   Phase 3   NCT03789292   Bulgaria;
CT-P17 SC AI (adalimumab)   
   Celltrion
      2019   Phase 3   NCT04171414   Poland;
CTLA4Ig   
   BRISTOL-M.SQUIBB
      2005   -   EUCTR2004-002620-18-IT   Belgium;Germany;Italy;Spain;United Kingdom;
   Bristol Myers Squibb International Corporation
      2011   Phase 3   EUCTR2008-001523-57-NO   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2010   Phase 3   EUCTR2010-018674-20-FR   Belgium;Denmark;Finland;France;Germany;Italy;Sweden;
      2010   Phase 3   EUCTR2010-018674-20-BE   Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-SE   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;Sweden;United States;
      2010   -   EUCTR2010-018674-20-FI   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-DK   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2010-018674-20-DE   Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
      2010   -   EUCTR2008-001523-57-HU   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2010   -   EUCTR2008-001523-57-DE   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-001523-57-GB   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-001523-57-ES   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2009   -   EUCTR2008-001523-57-DK   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2008   Phase 3   EUCTR2008-001523-57-FR   Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-005434-37-FR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-NL   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-IE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-HU   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-GR   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-DE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-BE   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-005434-37-AT   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2006   -   EUCTR2005-000784-26-AT   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-GB   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-ES   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-000784-26-DE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-IE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-BE   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-000922-59-DK   Czech Republic;Denmark;Spain;Sweden;
      2005   -   EUCTR2004-000922-59-CZ   Czech Republic;Denmark;Spain;Sweden;
      2004   Phase 3   EUCTR2004-000922-59-ES   Czech Republic;Denmark;Spain;Sweden;
      2004   -   EUCTR2004-000922-59-SE   Czech Republic;Denmark;Spain;Sweden;
   Bristol-Myers Squibb International Corporation
      2008   Phase 3   EUCTR2007-005434-37-GB   Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
      2007   Phase 3   EUCTR2006-003768-67-GB   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-003768-67-ES   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-SE   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-NL   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-DE   Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-003768-67-BE   Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2004-005102-68-CZ   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-005102-68-GB   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2004-005102-68-ES   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-002620-18-GB   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-002620-18-ES   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-000784-26-CZ   Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-IE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-DE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-005102-68-BE   Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002620-18-DE   Belgium;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002620-18-BE   Belgium;Germany;Italy;Spain;United Kingdom;
CZP   
   Astellas Pharma Inc
      2011   Phase 3   NCT01451203   Japan;
Caffeine   
   Bristol-Myers Squibb
      2017   Phase 1   NCT03131973   United States;
   Janssen Research & Development, LLC
      2012   Phase 1   NCT01636557   Germany;Korea, Republic of;Moldova, Republic of;South Africa;
   R-Pharm International, LLC
      2021   Phase 1   NCT04246762   Bulgaria;Moldova, Republic of;
Calcitriol   
   Atlanta VA Medical Center
      2007   -   NCT00427804   United States;
   Guangdong Provincial Hospital of Chinese Medicine
      2016   -   ChiCTR-IPR-16009029   China;
   The Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100042329   China;
Calcium   
   Centre Hospitalier Universitaire de Nimes
      2016   -   NCT02636829   France;
   University of Aarhus
      2015   Phase 2   NCT02944799   Denmark;
Calcium and cholecalciferol   
   University of Missouri-Columbia
      1995   Phase 3   NCT00570934   United States;
Calcium carbonate   
   Children's Hospital Medical Center, Cincinnati
      1996   Phase 2   NCT00000429   United States;
Calcium citrate   
   Brigham and Women's Hospital
      2011   Phase 4   NCT01400516   United States;
Canakinumab   
   NOVARTIS FARMA
      2007   -   EUCTR2007-001665-15-IT   Germany;Italy;Netherlands;Spain;
   Novartis
      2006   Phase 2   NCT00424346   Austria;Belgium;Canada;Finland;Germany;Spain;United States;
   Novartis Farmacéutica S.A.
      2009   Phase 2   EUCTR2008-005320-81-ES   Austria;Belgium;Germany;Spain;
   Novartis Pharma Services AG
      2009   -   EUCTR2008-005320-81-DE   Austria;Germany;Spain;
      2009   -   EUCTR2008-005320-81-BE   Austria;Belgium;Germany;Spain;
      2008   -   EUCTR2008-005320-81-AT   Austria;Germany;Spain;
Canakinumab (investigational)   
   Novartis
      2007   Phase 2   NCT00487825   Belgium;Germany;Italy;Netherlands;Spain;United States;
Canakinumab (proposed)   
   Novartis Farmaceutica S.A.
      2007   -   EUCTR2007-001665-15-ES   Belgium;Germany;Italy;Netherlands;Spain;
   Novartis Farmacéutica S.A
      2007   -   EUCTR2006-004669-32-ES   Spain;
   Novartis Farmacéutica, S.A.
      2007   -   EUCTR2007-000491-16-ES   Austria;Belgium;Germany;Spain;
   Novartis Pharma Services AG
      2007   -   EUCTR2007-001665-15-NL   Germany;Italy;Netherlands;Spain;
      2007   -   EUCTR2007-001665-15-DE   Germany;Italy;Netherlands;Spain;
      2007   -   EUCTR2007-001665-15-BE   Belgium;Germany;Italy;Netherlands;Spain;
      2007   -   EUCTR2007-000491-16-DE   Austria;Germany;Spain;
      2007   -   EUCTR2007-000491-16-BE   Austria;Belgium;Germany;Spain;
      2007   -   EUCTR2007-000491-16-AT   Austria;Germany;Spain;
      2007   -   EUCTR2006-004666-14-DE   Germany;
      2007   -   EUCTR2006-004666-14-BE   Belgium;Germany;
Canakinumab Injection   
   Jeffrey Curtis
      2021   Phase 4   NCT05080218   United States;
Cannabidiol by capsules twice daily   
   University of California, Los Angeles
      2021   Phase 1/Phase 2   NCT04911127   United States;
Cannabidiol tablet   
   King Christian 10th Hospital for Rheumatology
      2018   Phase 2   EUCTR2017-004226-15-DK   Denmark;
Cannabis   
   University Hospital, Clermont-Ferrand
      2020   -   NCT04402554   France;
Carbon Modular Radial Head   
   Ascension Orthopedics, Inc.
      2009   -   NCT00825409   United States;
Carbon Modular Radial Head replacement   
   Integra LifeSciences Corporation
      2009   -   NCT02405234   United States;
Celebra   
   Pfizer AB
      2006   -   EUCTR2004-001234-17-SE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Celebra (celecoxib)   
   University of Dundee
      2007   Phase 4   EUCTR2007-000012-90-DK   Denmark;Netherlands;United Kingdom;
Celebrex   
   Daewon Pharmaceutical Co., Ltd.
      2010   Phase 3   NCT01781702   -
   Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP
      2019   Phase 4   EUCTR2018-004539-54-DE   Germany;
   GlaxoSmithKline Research & Development Limited
      2005   -   EUCTR2005-000158-61-IE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
   Laboratórios Pfizer, Lda
      2006   -   EUCTR2004-001234-17-PT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Merck Sharp & Dohme (Sweden) AB
      2004   Phase 2   EUCTR2004-000612-54-SE   Sweden;
   Pfizer AB
      2006   -   EUCTR2004-001234-17-SE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Healthcare Ireland
      2006   -   EUCTR2004-001234-17-IE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2005   -   EUCTR2004-001234-17-LT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Limited
      2006   Phase 4   EUCTR2004-001234-17-GB   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-001234-17-CZ   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer SA/NV
      2006   -   EUCTR2004-001234-17-BE   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer, S.A.
      2005   -   EUCTR2004-001234-17-ES   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   University of Dundee
      2011   -   EUCTR2007-000012-90-NL   Denmark;Netherlands;United Kingdom;
      2008   Phase 4   EUCTR2007-000012-90-GB   Denmark;Netherlands;United Kingdom;
Celebrex 200 mg Hartkapseln   
   Pfizer Pharma GmbH
      2006   -   EUCTR2004-001234-17-DE   Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Celebrex 200 mg capsule, hard   
   GlaxoSmithKline Research & Development Limited
      2005   -   EUCTR2005-000158-61-GB   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
Celecoxib   
   GLAXO SMITHKLINE
      2005   -   EUCTR2005-000158-61-IT   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
   GlaxoSmithKline Research & Development Limited
      2006   -   EUCTR2005-000158-61-LT   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-EE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-DE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-CZ   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-LV   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-IE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-HU   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-GB   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-DK   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-AT   Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
   GlaxoSmithKline s.a.
      2005   Phase 3   EUCTR2005-000158-61-ES   Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
   Guangdong Provincial Hospital of Chinese Medicine
      2016   -   ChiCTR-IPR-16009029   China;
   Hospital of Chengdu Military Area Command PLA
      2008   -   ChiCTR-TCC-12002824   China;
   Laboratórios Pfizer, Lda
      2006   -   EUCTR2004-001234-17-PT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Merck Sharp & Dohme (Sweden) AB
      2004   Phase 2   EUCTR2004-000612-54-SE   Sweden;
   Mito medical center, Mito Kyodo General Hospital, University of Tsukuba
      2014   Phase 4   JPRN-UMIN000014624   Japan;
   National Institute of Mental Health (NIMH)
      2019   Phase 1/Phase 2   NCT03912428   United States;
   Pfizer
      2006   Phase 2   NCT00424294   United States;
   Pfizer AB
      2006   -   EUCTR2004-001234-17-SE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Healthcare Ireland
      2006   -   EUCTR2004-001234-17-IE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2005   -   EUCTR2004-001234-17-LT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Limited
      2006   Phase 4   EUCTR2004-001234-17-GB   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-001234-17-CZ   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Pharma GmbH
      2006   -   EUCTR2004-001234-17-DE   Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer SA/NV
      2006   -   EUCTR2004-001234-17-BE   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2006   Phase 4   NCT00346216   Australia;Brazil;Canada;Colombia;Costa Rica;Hong Kong;Mexico;Panama;Peru;Philippines;Taiwan;Ukraine;United States;
      2005   Phase 4   NCT00141102   Belgium;Brazil;Canada;China;Colombia;Costa Rica;Croatia;Czech Republic;Czechia;Ecuador;Estonia;Former Serbia and Montenegro;France;Germany;Greece;Guatemala;Hong Kong;India;Ireland;Korea, Republic of;Latvia;Lithuania;Netherlands;Panama;Peru;Portugal;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Taiwan;Ukraine;United Kingdom;
   Pfizer, S.A.
      2005   -   EUCTR2004-001234-17-ES   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   University of Dundee
      2007   Phase 4   NCT00447759   Denmark;Netherlands;United Kingdom;
Celecoxib 200mg capsule   
   Inova Health Care Services
      2018   Phase 4   NCT03699293   United States;
Ceramic on Ceramic articulation   
   Zimmer Biomet
      2013   -   NCT02036931   France;Germany;Ireland;Netherlands;Spain;United States;
Ceramic on Polyethylene articulation   
   Zimmer Biomet
      2013   -   NCT02036931   France;Germany;Ireland;Netherlands;Spain;United States;
Certolizumab   
   Brigham and Women's Hospital
      2016   -   NCT02714881   United States;
   Jagiellonian University
      2013   Phase 4   NCT02132234   Poland;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
   University of Rochester
      2010   -   NCT01098201   United States;
Certolizumab Pegol (CZP)   
   Nathan Wei, MD, FACP, FACR:
      2011   Phase 3   NCT01374971   United States;
   UCB Pharma
      2010   Phase 4   NCT01255761   United States;
      2010   Phase 3   NCT01235598   Denmark;Netherlands;Poland;Sweden;
   UCB Pharma SA
      2011   Phase 4   NCT01500278   Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Monaco;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
Certolizumab Pegol + Methotrexate (MTX)   
   UCB Pharma
      2012   Phase 3   NCT01521923   Argentina;Australia;Austria;Belgium;Canada;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Ireland;Italy;Mexico;Monaco;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;United States;
Certolizumab Pegol 200 MG/ML [Cimzia]   
   RenJi Hospital
      2020   -   NCT04569890   China;
Certolizumab pegol   
   Astellas Pharma Inc
      2009   Phase 3   NCT00851318   Japan;
      2009   Phase 3   NCT00850343   Japan;
   Celltech R&D Ltd
      2005   -   EUCTR2004-002993-49-LV   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2005   -   EUCTR2004-002993-49-HU   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2005   -   EUCTR2004-002993-49-GB   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;United Kingdom;
      2005   -   EUCTR2004-002993-49-DE   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2005   -   EUCTR2004-002993-49-BE   Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Sweden;
   Oklahoma Medical Research Foundation
      2010   Phase 3   NCT01213017   United States;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   UCB Biopharma SRL
      2021   Phase 1   NCT04740814   United States;
   UCB Celltech
      2007   -   EUCTR2004-002993-49-EE   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2006   Phase 3   EUCTR2005-002629-30-SK   Czech Republic;Estonia;Latvia;Lithuania;Slovakia;
      2006   -   EUCTR2005-002629-30-LV   Czech Republic;Estonia;Latvia;Lithuania;
      2006   -   EUCTR2005-002326-63-EE   Czech Republic;Estonia;Latvia;Lithuania;
      2005   Phase 3   EUCTR2005-002326-63-SK   Czech Republic;Estonia;Latvia;Lithuania;Slovakia;
      2005   Phase 3   EUCTR2005-001350-24-SK   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;
      2005   Phase 3   EUCTR2004-002993-49-SK   Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;Sweden;
      2005   -   EUCTR2005-002326-63-LV   Czech Republic;Estonia;Latvia;Lithuania;
      2005   -   EUCTR2005-002326-63-LT   Czech Republic;Estonia;Latvia;Lithuania;
      2005   -   EUCTR2004-002993-49-LT   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
      2005   -   EUCTR2004-002993-49-CZ   Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
   UCB Inc
      2006   -   EUCTR2005-002629-30-LT   Czech Republic;Estonia;Latvia;Lithuania;
      2006   -   EUCTR2005-002629-30-EE   Czech Republic;Estonia;Latvia;Lithuania;
      2006   -   EUCTR2005-002629-30-CZ   Czech Republic;Estonia;Latvia;Lithuania;
   UCB Inc.
      2005   -   EUCTR2005-001350-24-LV   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-LT   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-HU   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-FI   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-EE   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
      2005   -   EUCTR2005-001350-24-CZ   Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
   UCB Italy s.p.a.
      2011   Phase 4   NCT01443364   Italy;
   UCB Pharma
      2009   Phase 4   NCT00993668   United States;
      2008   Phase 3   NCT00753454   Canada;United States;
      2008   Phase 3   NCT00674362   Austria;France;Germany;Italy;Poland;
      2007   Phase 4   NCT00580840   Austria;Canada;France;United States;
   UCB Pharma S.A.
      2010   -   EUCTR2007-000830-38-PL   Austria;France;Germany;Italy;Poland;
      2009   -   EUCTR2007-005288-86-FR   France;
      2009   -   EUCTR2007-000828-40-PL   Austria;France;Germany;Italy;Poland;
      2008   Phase 3   EUCTR2007-000828-40-FR   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000830-38-FR   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000830-38-DE   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000830-38-AT   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000828-40-DE   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000828-40-AT   Austria;France;Germany;Italy;Poland;
      2005   -   EUCTR2005-002326-63-CZ   Czech Republic;Estonia;Latvia;Lithuania;
   UCB Pharma SA
      2009   Phase 3   EUCTR2008-005427-28-FR   France;Germany;Italy;Netherlands;Spain;
      2009   -   EUCTR2008-005427-28-NL   France;Germany;Italy;Netherlands;Spain;
      2009   -   EUCTR2008-005427-28-IT   France;Germany;Italy;Netherlands;Spain;
      2009   -   EUCTR2008-005427-28-ES   France;Germany;Italy;Netherlands;Spain;
      2009   -   EUCTR2008-005427-28-DE   France;Germany;Italy;Netherlands;Spain;
   UCB S.A. (Casa Madre)
      2008   -   EUCTR2007-000830-38-IT   Austria;France;Germany;Italy;Poland;
      2008   -   EUCTR2007-000828-40-IT   Austria;France;Germany;Italy;Poland;
Certolizumab pegol (CDP870)   
   UCB Pharma
      2005   Phase 3   NCT00152386   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Czechia;Israel;Latvia;Russian Federation;Ukraine;United States;
Certolizumab pegol (CDP870, tradename Cimzia)   
   University of Illinois at Chicago
      2015   Phase 4   NCT02451748   United States;
Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)   
   University of Illinois at Chicago
      2015   Phase 4   NCT02451748   United States;
Certolizumab pegol (CZP)   
   UCB Pharma
      2008   Phase 3   NCT00717236   Canada;France;Germany;Italy;Netherlands;Spain;United States;
   UCB Pharma S.A.
      2011   -   EUCTR2009-013758-33-NL   Denmark;Netherlands;Sweden;
      2010   -   EUCTR2009-013758-33-SE   Denmark;Netherlands;Sweden;
      2010   -   EUCTR2009-013758-33-DK   Denmark;Netherlands;Sweden;
Cetrorelix   
   Betanien Hospital
      2008   Phase 2   NCT00667758   Norway;
Cevidoplenib   
   Oscotec Inc.
      2019   Phase 2   EUCTR2018-003330-32-PL   Czech Republic;Korea, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
Chicken type II collagen   
   National Eye Institute (NEI)
      1997   Phase 1   NCT00001614   United States;
Chimeric Human-Murine IgG1    
   Centocor BV
      2009   Phase 4   EUCTR2007-003288-36-GB   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2007-003288-36-ES   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 4   EUCTR2007-003288-36-FR   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003288-36-NL   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003288-36-FI   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003288-36-DE   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003288-36-AT   Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
Chimeric human/mouse anti-CD-20 monoclonal antibody   
   Samsung Electronics Co. Ltd.
      2012   -   EUCTR2011-004171-36-PL   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-004171-36-HU   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-004171-36-GB   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-004171-36-ES   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
      2012   -   EUCTR2011-004171-36-CZ   Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
Chloroquine   
   Hoffmann-La Roche
      2013   Phase 3   NCT01941095   Greece;
   Merck Sharp & Dohme Corp.
      2007   Phase 3   NCT00521924   Austria;
   Sanofi
      2018   Phase 4   NCT03449758   France;
   University of Alberta
      2020   -   NCT04347798   Canada;
Cholecalciferol   
   University Hospital, Clermont-Ferrand
      2011   Phase 3   NCT02243800   France;
Chong Kun Dang Tofacitinib Tablet   
   Chong Kun Dang Pharmaceutical
      2019   Phase 1   NCT03868072   Korea, Republic of;
Chromium   
   Akiyama Haruhiko
      2011   Phase 4   JPRN-jRCTs032180273   Japan;
   Kume Shinichiro
      2012   Phase 4   JPRN-jRCTs032180245   Japan;
   Zimmer Biomet
      2009   -   NCT03681639   Germany;
Ciclosporin   
   King's College London
      2007   Phase 4   EUCTR2007-001190-28-GB   United Kingdom;
   PFIZER
      2007   -   EUCTR2007-001984-31-IT   Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;
Cimzia   
   Karolinska Institutet
      2015   Phase 4   NCT02466581   Sweden;
      2015   -   EUCTR2011-004720-35-NO   Denmark;Finland;Norway;Sweden;
      2014   Phase 4   EUCTR2011-004720-35-DK   Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
      2014   -   EUCTR2011-004720-35-FI   Denmark;Finland;Sweden;
      2012   Phase 4   NCT01491815   Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
   Kings College London
      2008   Phase 4   EUCTR2007-005464-26-GB   United Kingdom;
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
   Med Uni Graz, Univ. Klinik Innere Medizin,Abt. Rheumatologie und Immunologie
      2012   Phase 4   EUCTR2011-005204-15-AT   Austria;
   Michael Schiff, MD
      2010   Phase 4   NCT01147341   United States;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   The Karolinska Institute, ClinTRID
      2017   Phase 4   EUCTR2011-004720-35-NL   Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
      2012   -   EUCTR2011-004720-35-SE   Sweden;
   The Karolinska Institutet, ClinTRID
      2014   Phase 4   EUCTR2014-002374-36-SE   Sweden;
   The Karolinska Instutute, ClinTRID
      2013   Phase 4   EUCTR2011-004720-35-IS   Denmark;Finland;Iceland;Norway;Sweden;
   UCB Celltech, UK Registered Branch of UCB Pharma SA
      2015   Phase 2   EUCTR2014-003307-30-HU   Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
      2015   Phase 2   EUCTR2014-003307-30-GB   Czech Republic;Hungary;Russian Federation;Slovakia;United Kingdom;
      2015   Phase 2   EUCTR2014-003307-30-CZ   Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
      2015   -   EUCTR2014-003307-30-SK   Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
   UCB PHARMA SA/NV.
      2012   -   EUCTR2011-002067-20-IT   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-IT   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   UCB Pharma SA
      2015   -   EUCTR2011-002067-20-FR   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2011-002067-20-GR   Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-PT   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-IE   Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-GB   Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-DE   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-CZ   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-002067-20-BG   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001729-25-SE   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001729-25-IE   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-001729-25-GB   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002067-20-HU   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002067-20-ES   Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-002067-20-AT   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-NL   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-HU   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-ES   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-DE   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-CZ   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2011-001729-25-AT   Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
   University of California, San Francisco
      2013   -   NCT01773681   United States;
   Universitätsklinikum Erlangen
      2015   Phase 3   EUCTR2013-000337-13-PT   Germany;Portugal;Serbia;United States;
      2013   Phase 3   EUCTR2013-000337-13-DE   Germany;Portugal;Serbia;
   Universitätsklinkum Erlangen
      2010   Phase 3   EUCTR2009-015740-42-DE   Germany;
Cimzia 200 mg injeksjonsvæske, oppløsning   
   Diakonhjemmet Hospital AS
      2013   Phase 4   EUCTR2012-005275-14-NO   Norway;
Cimzia 200 mg solution for injection   
   Ghent University Hospital
      2012   Phase 3   EUCTR2009-017998-37-BE   Belgium;
Cimzia®   
   UCB Pharma S.A.
      2011   -   EUCTR2009-013758-33-NL   Denmark;Netherlands;Sweden;
      2010   -   EUCTR2009-013758-33-SE   Denmark;Netherlands;Sweden;
      2010   -   EUCTR2009-013758-33-DK   Denmark;Netherlands;Sweden;
      2010   -   EUCTR2007-000830-38-PL   Austria;France;Germany;Italy;Poland;
Citalopram   
   Vrije Universiteit Brussel
      2010   -   NCT01154647   Belgium;
Classic DMARDs treatment group   
   Zhang, Xiao, M.D.
      2013   -   NCT01915537   China;
Clazakizumab   
   Bristol-Myers K.K.
      2014   Phase 2   JPRN-JapicCTI-142497   -
      2011   Phase 2   JPRN-JapicCTI-111628   -
   CSL Behring
      2012   Phase 2   NCT02015520   Argentina;Australia;Canada;France;Hungary;Italy;Japan;Mexico;South Africa;United States;
Clindamycin   
   Hammersmith Hospitals NHS trust
      2005   Phase 3   EUCTR2004-004893-96-GB   United Kingdom;
Clofarabine   
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States;
Co-medication: Synthetic DMARDs   
   Diakonhjemmet Hospital
      2013   Phase 4   NCT01881308   Norway;
Cobalt   
   Akiyama Haruhiko
      2011   Phase 4   JPRN-jRCTs032180273   Japan;
   Kume Shinichiro
      2012   Phase 4   JPRN-jRCTs032180245   Japan;
   Zimmer Biomet
      2009   -   NCT03681639   Germany;
Cobalt™ Bone Cement   
   Zimmer Biomet
      2006   -   NCT00589485   United States;
Cobiprostone   
   Sucampo Pharma Americas, LLC
      2007   Phase 2   NCT00597818   United States;
Cod liver oil   
   National Institute of Nutrition and Seafood Research, Norway
      2008   -   NCT00805116   Norway;
Coenzyme Q10   
   the Second Hospital of Shanxi Medical University
      2017   -   ChiCTR-IPR-17010325   China;
Colchicine   
   Hospital Central Dr. Ignacio Morones Prieto
      2018   Phase 2   NCT04056039   Mexico;
Colecalciferol   
   AZIENDA OSPEDALIERA ORDINE MAURIZIANO
      2010   Phase 3   EUCTR2009-015835-34-IT   Italy;
Collect of 10 ml of peripheric blood for DNA extraction   
   Centre Hospitalier Universitaire de Fort-de-France
      2010   -   NCT01111357   Martinique;
Combination Product: Exercise, and methotrexate   
   Cairo University
      2020   -   NCT04758689   Egypt;
Combination Product: Laser, exercise, and methotrexate   
   Cairo University
      2020   -   NCT04758689   Egypt;
Combination Product: Methotrexate   
   Jiangsu Alphamab Biopharmaceuticals Co., Ltd
      2019   Phase 2   NCT04038970   China;
Combination Steroid   
   All India Institute of Medical Sciences, New Delhi
      2009   Phase 3   NCT01870128   India;
Combination fish oil and borage seed oil   
   National Center for Complementary and Integrative Health (NCCIH)
      2006   Phase 3   NCT00072982   United States;
Combination of Minocycline and MTX or MTX alone   
   University of Nebraska
      2001   Phase 3   NCT00579644   -
Comirnaty   
   Sint Maartenskliniek
      2021   Phase 4   EUCTR2021-000710-42-NL   Netherlands;
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
Commercial Formulation Etanercept   
   Amgen
      2016   Phase 3   NCT02986139   Puerto Rico;United States;
Comparator: Diclofenac sodium   
   Organon and Co
      2003   Phase 3   NCT00250445   -
      2003   Phase 3   NCT00092742   United States;
Comparator: diclofenac   
   Organon and Co
      2006   Phase 2   NCT00264147   Canada;Colombia;Puerto Rico;Switzerland;United States;
Comparator: naproxen tablet   
   Merck Sharp & Dohme Corp.
      2004   Phase 4   NCT00157872   China;
Computed Tomography   
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States;
Control   
   Chengdu PLA General Hospital
      2013   Phase 2   NCT02254655   China;
   Laval University
      2022   -   NCT04688398   -
Control group   
   University of Erlangen-Nürnberg Medical School
      2009   Phase 3   NCT02779114   Germany;
Control intervention (no dexamethasone)   
   University of Calgary
      2016   -   NCT02666443   Canada;
Conventional DMARD combination   
   Karolinska Institutet
      2002   Phase 4   NCT00764725   -
Conventional DMARDs   
   Ain Shams University
      2019   Phase 2   NCT03863405   Egypt;
Conventional Synthetic DMARD   
   SetPoint Medical Corporation
      2021   Phase 3   NCT04539964   United States;
Conventional syringe - BD Ref 309604   
   University of New Mexico
      2004   -   NCT00651625   United States;
Corn oil capsules   
   Zhejiang University
      2014   -   NCT02173587   China;
Corticosteroid and non-biological agents.   
   University of Athens
      2017   -   NCT03288584   Greece;
Corticosteroid or NSAID   
   Hoffmann-La Roche
      2007   Phase 4   NCT00462345   Korea, Republic of;
Corticosteroids   
   Genentech, Inc.
      2003   Phase 2   NCT00074438   United States;
Corticotrophin 80 units   
   Gaylis, Norman B., M.D.
      2013   Phase 4   NCT01948388   United States;
Creatine   
   Bangor University
      2013   -   NCT01767844   United Kingdom;
Creatinine   
   Affiliated Hospital of North Sichuan Medical College
      2018   -   ChiCTR1800018637   China;
CsDMARD(s)   
   GlaxoSmithKline
      2020   Phase 3   NCT04333147   Argentina;Australia;Belgium;Bulgaria;Canada;Colombia;Czechia;Estonia;Germany;Hungary;India;Japan;Korea, Republic of;Latvia;Lithuania;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
CsDMARDs   
   Gilead Sciences
      2016   Phase 3   NCT02873936   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
   GlaxoSmithKline
      2019   Phase 3   NCT04134728   Argentina;Belgium;Canada;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   NCT03970837   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
   Hoffmann-La Roche
      2014   Phase 3   NCT02001987   France;
Cura-100   
   Cura Biotech LLC
      2007   Phase 1/Phase 2   NCT00455208   United States;
Curcumin (Longvida™)   
   University of California, Los Angeles
      2010   Phase 0   NCT00752154   United States;
Cyclophosphamide   
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
   Hoffmann-La Roche
      2001   Phase 2   NCT02693210   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
Cyclosporin A   
   Merck Sharp & Dohme Corp.
      2007   Phase 3   NCT00521924   Austria;
Cyclosporine   
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Cyklokapron®   
   University Hospital of North Tees and Hartlepool
      2009   -   EUCTR2009-012141-34-GB   United Kingdom;
D2E7   
   Reade
      2019   Phase 4   EUCTR2019-001793-28-NL   Netherlands;
      2019   Phase 1;Phase 4   EUCTR2019-001554-25-NL   Netherlands;
D569 Tab.   
   Chong Kun Dang Pharmaceutical
      2019   Phase 1   NCT03858725   Korea, Republic of;
DECORTIN (PREDNISONA) 5 MG COMPRIMIDOS   
   Pfizer S.A.
      2009   Phase 2   EUCTR2009-013223-37-ES   Czech Republic;Hungary;Spain;
DELTACORTENE FORTE*10CPR   
   OSPEDALE POLICLINICO S. MATTEO
      2006   -   EUCTR2006-003843-22-IT   Italy;
DEPALGOS*20+325MG 28CPR RP   
   A.U.S.L. RIMINI
      2006   -   EUCTR2006-004062-13-IT   Italy;
DEXA scan   
   University of Texas Southwestern Medical Center
      2006   -   NCT00286689   United States;
DIBASE*IM OS 2F 1ML 300000UI/M   
   AZIENDA OSPEDALIERA ORDINE MAURIZIANO
      2010   Phase 3   EUCTR2009-015835-34-IT   Italy;
DMARD   
   Amgen
      2001   -   NCT00116714   United States;
   Hoffmann-La Roche
      2013   Phase 3   NCT01995201   Ireland;Portugal;Spain;
      2011   Phase 4   NCT01251120   Finland;
DMARD Therapy   
   Amgen
      2011   Phase 4   NCT01313208   Canada;United States;
   Zalicus
      2004   Phase 2   NCT00747214   -
DMARD cessation   
   Newcastle-upon-Tyne Hospitals NHS Trust
      2014   -   NCT02219347   United Kingdom;
DMARD maintenance   
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 4   NCT00780793   France;
DMARDS   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2008   Phase 4   NCT00783536   Mexico;
DMARDs   
   Columbia University
      2011   Phase 4   NCT01548768   United States;
   Hoffmann-La Roche
      2014   Phase 3   NCT02046603   United Kingdom;
      2013   Phase 4   NCT01715831   Brazil;
      2013   Phase 3   NCT01941940   Italy;
      2009   Phase 3   NCT00996606   Italy;
   JW Pharmaceutical
      2010   Phase 3   NCT01256736   Korea, Republic of;
      2009   Phase 3   NCT01211834   Korea, Republic of;
   Mycenax Biotech Inc.
      2013   Phase 3   NCT01787149   Taiwan;
   Sun Yat-sen University
      2018   Phase 4   NCT04066803   China;
DMARDs (disease-modifying antirheumatic drugs)   
   Hoffmann-La Roche
      2009   Phase 4   NCT00996203   Russian Federation;
DMARDs (methotrexate   
   Merck Sharp & Dohme Corp.
      2007   Phase 3   NCT00521924   Austria;
DMARDs or Biologics   
   Pfizer
      2009   -   NCT00929357   Denmark;
DRL_RI   
   Dr. Reddy's Laboratories Limited
      2014   Phase 1/Phase 2   NCT02296775   India;Ukraine;
DW1809-1   
   Daewon Pharmaceutical Co., Ltd.
      2020   Phase 1   NCT05214690   Korea, Republic of;
      2020   Phase 1   NCT05214677   Korea, Republic of;
DW1809-T2   
   Daewon Pharmaceutical Co., Ltd.
      2020   Phase 1   NCT05214690   Korea, Republic of;
DWP422   
   Daewoong Pharmaceutical Co. LTD.
      2012   Phase 1   NCT01635686   Korea, Republic of;
Dacortin ®   
   Zalicus, Inc.
      2012   -   EUCTR2011-002392-41-HU   Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
      2012   -   EUCTR2011-002392-41-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
      2011   -   EUCTR2011-000436-28-PL   Argentina;Brazil;Bulgaria;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
      2011   -   EUCTR2011-000436-28-HU   Argentina;Brazil;Bulgaria;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
      2011   -   EUCTR2011-000436-28-BG   Argentina;Brazil;Bulgaria;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
Daily supplementation   
   Adeline BLOT
      2018   -   NCT04696718   France;
Dalacin C phosphate   
   Hammersmith Hospitals NHS trust
      2005   Phase 3   EUCTR2004-004893-96-GB   United Kingdom;
Decortin   
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2011   -   EUCTR2010-023782-22-CZ   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
      2011   -   EUCTR2010-023782-22-DE   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
   Pfizer Inc.235 East 42nd Street, New York, NY 10017
      2012   -   EUCTR2010-023782-22-SK   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
      2011   -   EUCTR2010-023782-22-HU   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
      2011   -   EUCTR2010-023782-22-BG   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
   Pfizer, S.L.U.
      2011   -   EUCTR2010-023782-22-ES   Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
Decortin 5mg tablets   
   Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc.
      2009   -   EUCTR2007-006150-25-DE   Austria;Belgium;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;
      2008   -   EUCTR2007-006150-25-HU   Austria;Belgium;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc.
      2008   Phase 2   EUCTR2007-006150-25-FR   Austria;Belgium;France;Germany;Hungary;Netherlands;
      2008   Phase 2   EUCTR2007-006150-25-BE   Austria;Belgium;France;Germany;Hungary;Netherlands;
      2008   -   EUCTR2007-006150-25-NL   Austria;Belgium;France;Germany;Hungary;Netherlands;
      2008   -   EUCTR2007-006150-25-AT   Austria;Belgium;France;Germany;Hungary;Netherlands;
Decortin®   
   Pfizer Inc.
      2009   Phase 2   EUCTR2009-013223-37-CZ   Czech Republic;Hungary;Spain;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2009   -   EUCTR2009-013223-37-HU   Hungary;Spain;
   Pfizer S.A.
      2009   Phase 2   EUCTR2009-013223-37-ES   Czech Republic;Hungary;Spain;
Decrease Tocilizumab, Abatacept   
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 4   NCT01557374   France;
Defanyl 50 and   
   CombinatoRx, Inc
      2006   -   EUCTR2004-001490-26-EE   Estonia;United Kingdom;
Dekavil   
   Philogen S.p.A.
      2015   Phase 2   EUCTR2013-005418-37-DE   Germany;Italy;Switzerland;
      2014   -   EUCTR2013-005418-37-IT   Germany;Italy;
Deltacortril Enteric   
   GlaxoSmithKline Research & Development Limited
      2005   Phase 2   EUCTR2005-001977-82-GB   United Kingdom;
Denosumab   
   Amgen
      2011   Phase 1   NCT01294397   United States;
      2004   Phase 2   NCT00095498   United States;
   Chinese University of Hong Kong
      2017   Phase 2   NCT03239080   China;
      2012   Phase 4   NCT01770106   Hong Kong;
   DAIICHISANKYO Co.,Ltd.
      2013   Phase 3   JPRN-JapicCTI-132277   -
      2010   Phase 2   JPRN-JapicCTI-101263   -
   Daiichi Sankyo Company, Limited
      2018   -   JPRN-UMIN000030575   Japan;
   Daiichi Sankyo, Inc.
      2013   -   NCT01973569   Japan;
   Hokkaido Medical Center for Rheumatic Diseases
      2017   -   JPRN-UMIN000028376   Japan;
   Indiana University
      2019   Phase 1/Phase 2   NCT02418273   United States;
   Kawakami Atsushi
      2018   Phase 4   JPRN-jRCTs071180018   Japan;
   Osaka City University Graduate School of Medicine
      2018   -   JPRN-UMIN000030828   Japan;
   Yokohama City University Medical Center
      2014   -   JPRN-UMIN000014737   Japan;
Depemedrone   
   University Hospital Birmingham
      2007   Phase 4   NCT00523692   United Kingdom;
Depo Medrol   
   Sun Pharma Global FZE
      2016   Phase 3   EUCTR2015-002924-17-BE   Belgium;Netherlands;
      2015   Phase 3   EUCTR2015-002924-17-NL   Belgium;Netherlands;
Depo medrol   
   Attune Health Research, Inc.
      2018   Phase 3   NCT03511625   United States;
Depo-Medrone   
   University Hospitals Birmingham NHS Foundation Trust
      2006   Phase 4   EUCTR2006-001428-38-GB   United Kingdom;
Dexamethason   
   UMC Utrecht
      2010   -   EUCTR2009-017051-10-NL   Netherlands;
Dexmedetomidine   
   West China Hospital, Sichuan University
      2021   Phase 0   ChiCTR2000036316   China;
      2021   Phase 0   ChiCTR2000036164   china;
Dextromethorphan hydrobromide   
   Taichung Veterans General Hospital
      2010   -   NCT02368093   -
Diacerein   
   TRB Chemedica
      2010   Phase 2   NCT01264211   Thailand;
Diazepam, melatonin   
   Kobe University
      2006   -   NCT00287794   Japan;
Diclofenac   
   Mallinckrodt
      2012   -   NCT01579890   -
   Northumbria Healthcare NHS Foundation Trust
      2010   Phase 4   NCT01067430   United Kingdom;
   University of Dundee
      2007   Phase 4   NCT00447759   Denmark;Netherlands;United Kingdom;
Diclofenac + Omeprazole   
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2005   Phase 4   NCT00141102   Belgium;Brazil;Canada;China;Colombia;Costa Rica;Croatia;Czech Republic;Czechia;Ecuador;Estonia;Former Serbia and Montenegro;France;Germany;Greece;Guatemala;Hong Kong;India;Ireland;Korea, Republic of;Latvia;Lithuania;Netherlands;Panama;Peru;Portugal;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Taiwan;Ukraine;United Kingdom;
Diclofenac sodium   
   Laboratórios Pfizer, Lda
      2006   -   EUCTR2004-001234-17-PT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer AB
      2006   -   EUCTR2004-001234-17-SE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Healthcare Ireland
      2006   -   EUCTR2004-001234-17-IE   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2005   -   EUCTR2004-001234-17-LT   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Limited
      2006   Phase 4   EUCTR2004-001234-17-GB   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-001234-17-CZ   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer Pharma GmbH
      2006   -   EUCTR2004-001234-17-DE   Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer SA/NV
      2006   -   EUCTR2004-001234-17-BE   Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
   Pfizer, S.A.
      2005   -   EUCTR2004-001234-17-ES   Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Dietary Fiber Supplementation   
   University Hospital, Montpellier
      2020   -   NCT04421313   France;
Dietary supplement omega3 fatty acids aand vitamins   
   Physicians Committee for Responsible Medicine
      2011   -   NCT01544101   United States;
Digoxin   
   AstraZeneca
      2011   Phase 1   NCT01355354   United Kingdom;
   Bristol-Myers Squibb
      2017   Phase 1   NCT03131973   United States;
   Tanta University
      2021   Phase 2   NCT04834557   -
Dihuang   
   Shanghai Traditional Chinese Medicine Hospital
      2020   Phase 0   ChiCTR2000037675   China;
Dimeythl Fumarate   
   Biogen Idec Limited
      2009   Phase 2   EUCTR2008-004754-33-SK   Czech Republic;Poland;Slovakia;
      2009   -   EUCTR2008-004754-33-PL   Czech Republic;Poland;
      2009   -   EUCTR2008-004754-33-CZ   Czech Republic;Poland;
Dipotassium Salt   
   Chelsea Therapeutics, Inc
      2010   -   EUCTR2010-019134-27-CZ   Bulgaria;Czech Republic;
      2010   -   EUCTR2010-019134-27-BG   Argentina;Bulgaria;Czech Republic;Mexico;Poland;United States;
Diprofos Depot   
   Knowledge Centre for Rheumatology and Back Diseases
      2013   -   EUCTR2013-003486-34-DK   Denmark;
   Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet
      2017   Phase 4   EUCTR2017-003425-15-DK   Denmark;
Dipyridamole   
   CombinatoRx, Incorporated
      2008   -   EUCTR2007-004399-38-LT   Estonia;Lithuania;United Kingdom;
      2008   -   EUCTR2007-004399-38-GB   Estonia;Lithuania;United Kingdom;
      2008   -   EUCTR2007-004399-38-EE   Estonia;Lithuania;United Kingdom;
      2008   -   EUCTR2007-003069-42-LT   Estonia;Hungary;Lithuania;United Kingdom;
      2008   -   EUCTR2007-003069-42-HU   Estonia;Hungary;Lithuania;United Kingdom;
      2008   -   EUCTR2007-003069-42-GB   Estonia;Hungary;Lithuania;United Kingdom;
      2007   -   EUCTR2007-003069-42-EE   Estonia;Hungary;Lithuania;United Kingdom;
   Zalicus
      2011   Phase 2   NCT01369745   United States;
      2007   Phase 2   NCT00551707   Argentina;Canada;Estonia;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa;United States;
   Zalicus, Inc.
      2012   -   EUCTR2011-002392-41-HU   Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
      2012   -   EUCTR2011-002392-41-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
Dipyridamole and Amoxapine   
   CombinatoRx, Inc
      2006   -   EUCTR2004-001490-26-EE   Estonia;United Kingdom;
Disease modified antirheumatic drugs or biological agents   
   Nanfang Hospital of Southern Medical University
      2018   -   NCT03508713   -
Disease-modifying anti-rheumatic drugs   
   Hoffmann-La Roche
      2005   Phase 3   NCT00720798   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Puerto Rico;Russian Federation;Serbia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
Disease-modifying antirheumatic drug   
   Pfizer
      2010   Phase 3   NCT01039688   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Czechia;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
Disease-modifying antirheumatic drugs (DMARDs)   
   Astellas Pharma China, Inc.
      2018   Phase 3   NCT03660059   China;Korea, Republic of;Taiwan;
   Hoffmann-La Roche
      2010   Phase 3   NCT01194414   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
DnaJ peptide   
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      1999   Phase 2   NCT00000435   United States;
Dolquine   
   Fundació Clínic per a la Recerca Biomèdica
      2019   Phase 4   EUCTR2017-004543-20-ES   Spain;
Donepezil   
   RenJi Hospital
      2018   Phase 3   NCT02927522   China;
Doppler ultrasound.   
   Assistance Publique Hopitaux De Marseille
      2011   Phase 3   NCT01954381   France;
Dose level 1   
   Pfizer
      2009   Phase 1   NCT00838565   Korea, Republic of;Spain;United States;
Dose level 2   
   Pfizer
      2009   Phase 1   NCT00838565   Korea, Republic of;Spain;United States;
Dose level 3   
   Pfizer
      2009   Phase 1   NCT00838565   Korea, Republic of;Spain;United States;
Dose level 4   
   Pfizer
      2009   Phase 1   NCT00838565   Korea, Republic of;Spain;United States;
Double-blind Abatacept   
   Bristol-Myers Squibb
      2002   Phase 3   NCT00048932   United States;
Double-blind adalimumab   
   Abbott
      2009   Phase 3   NCT00870467   Japan;
Doxycycline   
   Hong Kong Baptist University
      2015   -   ChiCTR-OPB-15007284   China;
   New York University School of Medicine
      2010   -   NCT01198509   United States;
Doxycycline Tablets   
   Assiut University
      2019   -   NCT03194204   Egypt;
Dr. Reddy’s Rituximab (DRL_RI)   
   Dr. Reddy’s Laboratories S.A.
      2020   Phase 3   EUCTR2019-002810-37-PL   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
      2020   Phase 3   EUCTR2019-002810-37-LT   Bulgaria;Czechia;Germany;Hungary;Lithuania;Poland;United States;
      2020   Phase 3   EUCTR2019-002810-37-HU   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
      2020   Phase 3   EUCTR2019-002810-37-DE   Bulgaria;Czech Republic;Germany;Hungary;Lithuania;Poland;United States;
      2020   Phase 3   EUCTR2019-002810-37-BG   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
Dronabinol capsule   
   King Christian 10th Hospital for Rheumatology
      2018   Phase 2   EUCTR2017-004226-15-DK   Denmark;
Drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom   
   Groupe Hospitalier Pitie-Salpetriere
      2018   -   NCT03480529   France;
Drug protocol   
   Federal University of São Paulo
      2014   -   NCT04752748   -
Drug treatment   
   Xijing Hospital
      2019   -   NCT04037111   China;
Dummy Qing Re Huo Xue (QRHX)   
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2019   Phase 2/Phase 3   NCT04170504   -
E-Device   
   UCB Biopharma S.P.R.L.
      2017   Phase 3   NCT03357471   United States;
E1-Hip Bearing   
   Zimmer Biomet
      2013   -   NCT02087449   Korea, Republic of;
E6011   
   Eisai Co., Ltd.
      2016   Phase 2   NCT02960490   Japan;
      2016   Phase 2   NCT02960438   Japan;
      2014   Phase 1/Phase 2   NCT02196558   Japan;
EC 3.1.3.1   
   Alloksys Life Sciences B.V.
      2011   -   EUCTR2008-007346-63-GB   United Kingdom;
EMEA/H/C/004214   
   Erasmus Medical Center
      2022   Phase 4   EUCTR2021-004131-84-NL   Netherlands;
EMEA/H/C000262   
   University Hospitals Leuven
      2013   -   EUCTR2012-004631-22-BE   Belgium;
ENBREL (Etanercept)   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 4   EUCTR2016-003129-40-IT   Italy;
ENBREL - 50 MG POLV SOLUZ INIET SOTTOC. POLV. FLAC VETRO SOLV. SIRI. VET. SOLV 1 ML (50 MG/ML) 12 FLAC+12 SIRI. PRE+12 AGHI+12 ADAT PER FLAC+24 TAMP. PRE INIEZ   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 4   EUCTR2016-003129-40-IT   Italy;
   SOCIETA' ITALIANA DI REUMATOLOGIA - SIR
      2017   Phase 4   EUCTR2016-001987-12-IT   Italy;
ENBREL - 50 MG SOLUZIONE INIETTABILE IN SIRINGA (VETRO DA 1 ML) PRERIEMPITA - USO SOTTOCUTANEO 12 SIRINGHE PRERIEMPITE + 24 TAMPONI IMBEVUTI DI ALCOL   
   AMGEN INC.
      2016   Phase 3   EUCTR2014-004868-38-IT   Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
ENBREL 25 mg injeksjonsvæske, oppløsning i ferdigfylt sprøyte.   
   Diakonhjemmet Hospital AS
      2013   Phase 4   EUCTR2012-005275-14-NO   Norway;
ENBREL 25MG PFS INJ.   
   Daewoong Pharmaceutical Co. LTD.
      2012   Phase 1   NCT01635686   Korea, Republic of;
ENBREL*SC 4FL 25MG+4SIR 1ML   
   WYETH LEDERLE
      2004   -   EUCTR2004-000563-96-IT   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
   Wyeth Pharmaceuticals France, Wyeth Research Division
      2008   -   EUCTR2007-000896-41-IT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
ENBREL*SC 4FL 50MG+4SIR+4AGHI+   
   Wyeth Pharmaceuticals France, Wyeth Research Division
      2008   -   EUCTR2007-000896-41-IT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
ENBREL*SC 4SIR 25MG 0,5ML+8TAM   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   -   EUCTR2008-002623-85-IT   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
ENBREL*SC 4SIR 50MG 1ML+8TAMP   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   -   EUCTR2008-002623-85-IT   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
ENBREL®   
   Amgen
      2002   -   NCT00116727   United States;
ENIA11   
   Mycenax Biotech Inc.
      2012   Phase 3   NCT01709760   Taiwan;
EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)   
   Rabin Medical Center
      2011   -   NCT01274910   Israel;
ERB-041   
   WYETH LEDERLE
      2005   -   EUCTR2005-001319-23-IT   Hungary;Italy;Spain;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development
      2005   Phase 2   EUCTR2005-001319-23-ES   Hungary;Italy;Spain;
      2005   -   EUCTR2005-001319-23-HU   Hungary;Italy;Spain;
ERMM-1   
   CIS bio international
      2007   Phase 4   EUCTR2006-006380-22-DE   Germany;
ESAOTE MyLab60   
   University Hospital, Rouen
      2011   Phase 4   NCT01765374   France;
ETN   
    Research Center, the University of Tokyo
   22nd Century Medical &
   TAP Corporation
      2009   -   JPRN-UMIN000002687   Japan,Asia(except Japan);
ETN Alone   
   Japan Biological Agent Study Integrated Consortium
      2005   Phase 4   NCT00688103   Japan;
ETN+MTX   
   Japan Biological Agent Study Integrated Consortium
      2005   Phase 4   NCT00688103   Japan;
EU-Humira   
   Fresenius Kabi SwissBioSim GmbH
      2017   Phase 3   NCT03052322   Bulgaria;Czech Republic;Czechia;Germany;Hungary;Poland;United Kingdom;
EU-approved RoActemra   
   Fresenius Kabi SwissBioSim GmbH
      2020   Phase 3   NCT04512001   Bulgaria;Czechia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;
EU/1/99/126/017   
   University of Leeds
      2011   Phase 4   EUCTR2010-023910-30-GB   United Kingdom;
EU/1/99/126/020   
   University of Leeds
      2011   Phase 4   EUCTR2010-023910-30-GB   United Kingdom;
Ebetrexat   
   Ludwig Boltzmann Cluster für Rheumatologie, Balneologie und Rehabilitation
      2008   -   EUCTR2007-006288-56-AT   Austria;
Edoxaban   
   Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
      2016   -   JPRN-UMIN000026819   Japan;
   Yokohama City University School of Medicine
      2012   -   JPRN-UMIN000018101   Japan;
Efalizumab   
   XOMA (US) LLC
      2002   Phase 2   NCT00034203   United States;
Efexor XL 75 mg (venlafaxine)   
   Newcastle upon Tyne Hospitals NHS Trust
      2005   -   EUCTR2004-002482-20-GB   United Kingdom;
Eldecalcitol   
   Department of Orthopaedic Surgery Shinshu University School of Medicine
      2016   -   JPRN-UMIN000022364   Japan;
Enalapril Maleate   
   University of Guadalajara
      2017   Phase 2   NCT03667131   Mexico;
Enbrel   
   AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA
      2018   Phase 3   EUCTR2017-004079-30-IT   Belgium;Italy;Portugal;Spain;
   Amgen
      2000   Phase 4   NCT00132418   United States;
   Amgen Inc.
      2017   Phase 3   EUCTR2014-004868-38-DE   Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2014-004868-38-PT   Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2014-004868-38-HU   Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2014-004868-38-GR   Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2014-004868-38-FR   Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2014-004868-38-ES   Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2014-004868-38-BG   Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
      2015   Phase 3   EUCTR2014-004868-38-CZ   Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
   AstraZeneca AB
      2008   Phase 2   EUCTR2007-007539-14-SK   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;Slovakia;
      2008   -   EUCTR2007-007539-14-PL   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-MT   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-LV   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-HU   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-CZ   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-BG   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-001420-12-CZ   Czech Republic;France;Poland;Sweden;
      2007   Phase 2   EUCTR2007-001420-12-SK   Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
      2007   Phase 2   EUCTR2007-001420-12-FR   Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
      2007   -   EUCTR2007-001420-12-SE   Czech Republic;France;Poland;Sweden;
      2007   -   EUCTR2007-001420-12-PL   Czech Republic;France;Poland;Sweden;
      2007   -   EUCTR2007-001420-12-BE   Belgium;Czech Republic;France;Poland;Sweden;
   Biogen
      2017   -   NCT03100734   Germany;
   CHU Saint-Etienne
      2008   -   EUCTR2008-006256-22-FR   France;
   Coherus BioSciences, Inc
      2014   Phase 3   EUCTR2014-000443-33-PL   Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000443-33-GB   Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   Coherus Biosciences, Inc
      2014   Phase 3   EUCTR2014-000443-33-IT   Argentina;Belarus;Brazil;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000443-33-HU   Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000443-33-ES   Argentina;Belarus;Brazil;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000443-33-DE   Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   DAIICHISANKYO Co.,Ltd.
      2014   Phase 3   JPRN-JapicCTI-142621   -
   Department of Clinical Biochemestry, Aarhus University Hospital
      2015   Phase 4   EUCTR2015-004173-32-DK   Denmark;
   Derby Hospitals NHS Foundation Trust
      2008   Phase 4   EUCTR2006-006562-42-GB   United Kingdom;
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 4   EUCTR2018-003351-37-IT   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
   Eli Lilly and Company
      2020   Phase 3;Phase 4   EUCTR2018-003351-37-FR   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-PL   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-NL   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-LT   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-HU   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-GR   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-GB   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-DK   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-DE   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-AT   Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2008   Phase 4   EUCTR2007-000593-24-GB   Sweden;United Kingdom;
   F.Hoffmann-La Roche Ltd
      2008   -   EUCTR2007-000593-24-SE   Sweden;United Kingdom;
   Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP
      2019   Phase 4   EUCTR2018-004539-54-DE   Germany;
   Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
      2020   Phase 4   EUCTR2018-004558-30-PT   Portugal;Spain;
      2020   Phase 4   EUCTR2018-004558-30-DK   Denmark;Portugal;Spain;
      2019   Phase 4   EUCTR2018-004558-30-ES   Spain;
   Greater Glasgow Health Board
      2006   Phase 4   EUCTR2006-000363-28-GB   United Kingdom;
   Imperial College London South Kensington London
      2009   Phase 4   EUCTR2009-012424-87-GB   United Kingdom;
   Joint Research & Development Office (QMUL)
      2018   Phase 3   EUCTR2017-004079-30-PT   Belgium;Italy;Portugal;Spain;
      2018   Phase 3   EUCTR2017-004079-30-ES   Belgium;Italy;Portugal;Spain;
      2018   Phase 3   EUCTR2017-004079-30-BE   Belgium;Italy;Portugal;Spain;
      2014   Phase 3   EUCTR2014-003529-16-GB   United Kingdom;
   Joint Stock Company Farmak
      2018   Phase 3   NCT04079374   Ukraine;
   Kings College London
      2008   Phase 4   EUCTR2007-005464-26-GB   United Kingdom;
   LG Life Sciences
      2015   Phase 3   NCT02357069   Japan;Korea, Republic of;
   Lilly S.A
      2019   Phase 3;Phase 4   EUCTR2018-003351-37-ES   Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark;
   Med Uni Graz, Univ. Klinik Innere Medizin,Abt. Rheumatologie und Immunologie
      2012   Phase 4   EUCTR2011-005204-15-AT   Austria;
   NHS Greater Glasgow and Clyde
      2009   -   EUCTR2009-011268-13-GB   United Kingdom;
   National Eye Institute (NEI)
      1999   Phase 2   NCT00001862   United States;
   Pfizer
      2020   -   NCT04428424   Iraq;
      2011   -   NCT01411215   China;
   Pfizer Inc.
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 4   EUCTR2012-003644-71-BE   Australia;Belgium;Chile;Colombia;France;Hong Kong;Israel;Netherlands;New Zealand;Poland;Russian Federation;Spain;
      2013   -   EUCTR2012-003644-71-ES   Australia;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Israel;Netherlands;Russian Federation;Spain;
   Pfizer Inc. 235 East 42nd Street, New York, 10017
      2015   Phase 3;Phase 4   EUCTR2013-003177-99-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-SE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003177-99-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc., 235 EAst 42nd Street, New York, NY 10017, United States
      2013   -   EUCTR2012-003644-71-NL   Australia;Belgium;Chile;Colombia;France;Hong Kong;Israel;Netherlands;Russian Federation;Spain;
   Pfizer Inc., 235 East 42nd Street, New York, 10017
      2015   Phase 3;Phase 4   EUCTR2013-003177-99-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
      2015   Phase 1   NCT02481180   China;
   Sorrento Therapeutics, Inc.
      2021   Phase 1   NCT04559412   United States;
   University Hospital Birmingham NHS Foundation Trust
      2007   Phase 4   EUCTR2006-006275-21-GB   United Kingdom;
   University Hospitals Birmingham NHS Foundation Trust
      2006   Phase 4   EUCTR2006-001428-38-GB   United Kingdom;
   University Hospitals Leuven
      2013   -   EUCTR2012-004631-22-BE   Belgium;
   University of Leeds
      2011   Phase 4   EUCTR2010-023880-17-GB   United Kingdom;
   Universitätsklinkum Erlangen
      2010   Phase 3   EUCTR2009-015740-42-DE   Germany;
   Wyeth Pharmaceuticals France
      2008   Phase 4   EUCTR2007-001625-10-ES   Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
      2008   Phase 4   EUCTR2007-000896-41-FR   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-001625-10-PL   Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
      2008   -   EUCTR2007-001625-10-DE   Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
      2008   -   EUCTR2007-001625-10-AT   Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
      2008   -   EUCTR2007-000896-41-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000896-41-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-000896-41-NL   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-005137-38-DE   Denmark;Finland;France;Germany;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA
      2008   -   EUCTR2007-000896-41-SE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
      2010   -   EUCTR2007-000896-41-AT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 4   EUCTR2007-000896-41-GB   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   Phase 4   EUCTR2007-000896-41-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000896-41-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmceuticals Inc. A Pfizer Company, Philadelphia, PA-19101, USA
      2008   -   EUCTR2007-000896-41-DE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2003   -   NCT00245934   -
   YL Biologics Ltd
      2016   Phase 3   EUCTR2015-002809-12-BG   Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Romania;Spain;Ukraine;
      2015   Phase 3   EUCTR2015-002809-12-LV   Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Poland;Romania;Russian Federation;Spain;Ukraine;
      2015   Phase 3   EUCTR2015-002809-12-HU   Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Romania;Spain;Ukraine;
      2015   Phase 3   EUCTR2015-002809-12-ES   Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Poland;Romania;Russian Federation;Spain;Ukraine;
      2015   Phase 3   EUCTR2015-002809-12-CZ   Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Poland;Romania;Russian Federation;Spain;Ukraine;
Enbrel (Etanercept)   
   Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320
      -   -   EUCTR2012-001171-37-Outside-EU/EEA   Canada;United States;
      -   -   EUCTR2012-001145-40-Outside-EU/EEA   Canada;United States;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   -   EUCTR2008-002623-85-NL   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2004   -   NCT00484809   -
Enbrel (etanercept)   
   EMS
      2013   Phase 3   NCT01394913   Brazil;
   Pfizer
      2007   -   NCT00503139   Japan;
   Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases
      2009   -   EUCTR2008-005450-20-BE   Belgium;
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   NCT01895309   Poland;United Kingdom;
   Wyeth Pharmaceuticals
      2005   -   EUCTR2004-000563-96-FI   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2005   -   EUCTR2004-000563-96-AT   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-SE   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-IE   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-HU   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-ES   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      2004   -   EUCTR2004-000563-96-DK   Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
      -   Phase 4   EUCTR2004-000563-96-NO   Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2005   -   NCT00503503   -
Enbrel 25 mg powder and solvent for solution for injection   
   Pfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom
      2010   -   EUCTR2007-006657-63-IS   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
      2009   -   EUCTR2007-006657-63-SE   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
      2009   -   EUCTR2007-006657-63-FI   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
      2009   -   EUCTR2007-006657-63-DK   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
   Wyeth Pharmaceuticals France
      2010   Phase 4   EUCTR2007-006657-63-HU   Denmark;Finland;Hungary;Iceland;Sweden;
Enbrel 25mg PFS   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   -   EUCTR2008-002623-85-NL   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Enbrel 50 mg powder and solvent for solution for injection   
   Pfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom
      2010   -   EUCTR2007-006657-63-IS   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
      2009   -   EUCTR2007-006657-63-SE   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
      2009   -   EUCTR2007-006657-63-FI   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
      2009   -   EUCTR2007-006657-63-DK   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
   Wyeth Pharmaceuticals France
      2010   Phase 4   EUCTR2007-006657-63-HU   Denmark;Finland;Hungary;Iceland;Sweden;
Enbrel 50 mg solution for injection in pre-filled syringe   
   Hexal AG
      2016   Phase 3   EUCTR2012-002009-23-HU   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2012-002009-23-DE   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-SK   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-PL   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-LV   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-LT   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-GB   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-ES   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-EE   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-CZ   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-BG   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2015   Phase 3   EUCTR2013-004569-16-DE   Bulgaria;Colombia;Croatia;Germany;Greece;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;South Africa;
   sanofi-aventis Recherche & Développement
      2013   Phase 3   EUCTR2012-001984-66-NO   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001984-66-GB   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-LV   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-LT   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-IT   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-HU   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-GR   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-FI   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-ES   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-DE   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-001984-66-CZ   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Enbrel 50mg PFS   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   -   EUCTR2008-002623-85-NL   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Enbrel 50mg pre-filled pen   
   University of Leeds
      2011   Phase 4   EUCTR2010-023910-30-GB   United Kingdom;
Enbrel 50mg pre-filled syringe   
   University of Leeds
      2011   Phase 4   EUCTR2010-023910-30-GB   United Kingdom;
Enbrel Auto Injector   
   Wyeth Pharmaceuticals France
      2008   -   EUCTR2006-006591-37-GR   Austria;Greece;
      2008   -   EUCTR2006-006591-37-AT   Austria;Greece;
      2007   Phase 3   EUCTR2006-005137-38-GB   Denmark;Finland;France;Germany;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-005137-38-FR   Denmark;Finland;France;Germany;Sweden;United Kingdom;
      2007   -   EUCTR2006-006591-37-BE   Austria;Belgium;Greece;
      2007   -   EUCTR2006-005137-38-SE   Denmark;Finland;France;Germany;Sweden;United Kingdom;
      2007   -   EUCTR2006-005137-38-FI   Denmark;Finland;France;Germany;Sweden;United Kingdom;
      2007   -   EUCTR2006-005137-38-DK   Denmark;Finland;France;Germany;Sweden;United Kingdom;
Enbrel Pre-filled syringe   
   Wyeth Pharmaceuticals France
      2007   Phase 3   EUCTR2006-005137-38-FR   Denmark;Finland;France;Germany;Sweden;United Kingdom;
Enbrel liquid   
   Amgen
      2005   Phase 3   NCT00249041   Canada;United States;
Enbrel pre-filled pen   
   King's College London
      2010   Phase 4   EUCTR2010-020738-24-GB   United Kingdom;
Enbrel pre-filled syringe   
   King's College London
      2010   Phase 4   EUCTR2010-020738-24-GB   United Kingdom;
Enbrel, Benepali, Erelzi   
   Reade
      2019   Phase 4   EUCTR2019-001754-25-NL   Netherlands;
Enbrel®   
   Amgen
      2002   -   NCT00121056   -
      2000   -   NCT00078793   Canada;United States;
   F. Hoffmann-La Roche Ltd.
      2011   Phase 4   EUCTR2010-020065-24-NL   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-LV   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-HU   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-GR   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-GB   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-ES   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-DE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-CZ   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   Phase 4   EUCTR2010-020065-24-AT   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-020065-24-LT   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-020065-24-BE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
   ROCHE
      2011   Phase 4   EUCTR2010-020065-24-IT   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Czech Republic;Ecuador;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-LT   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
   Wyeth Pharmaceuticals Inc. Philadelphia (A Pfizer Company)
      2009   Phase 4   EUCTR2008-002623-85-GB   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
      2009   -   EUCTR2008-002623-85-IE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2009   -   EUCTR2008-002623-85-DE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Enbrel® 50 mg Solution for Injection in Pre-filled Syringe   
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2012   -   EUCTR2011-005448-87-HU   Argentina;Brazil;China;Colombia;Czech Republic;Egypt;Hungary;India;Malaysia;Mexico;Philippines;Poland;Romania;Russian Federation;Saudi Arabia;Slovakia;South Africa;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;
      2012   -   EUCTR2011-005448-87-CZ   Argentina;Brazil;China;Colombia;Czech Republic;Egypt;Hungary;India;Malaysia;Mexico;Philippines;Poland;Romania;Russian Federation;Saudi Arabia;Slovakia;South Africa;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;
Engineered humanized monoclonal anti-human CD19 antibody.   
   Xencor Inc.
      2012   Phase 2   EUCTR2012-003057-29-HU   Czech Republic;Hungary;Slovakia;
      2012   -   EUCTR2012-003057-29-SK   Czech Republic;Hungary;Slovakia;
Engineered humanized monoclonal anti-human CD19 antibody. Lot Numbers: 1-FIN-1588 (9.6mg/ml)   
   Xencor Inc.
      2013   -   EUCTR2012-003057-29-CZ   Czech Republic;Hungary;Slovakia;
Enoxaparin   
   Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
      2016   -   JPRN-UMIN000026819   Japan;
Entanercept   
   Peking University First Hospital
      2015   -   NCT02320630   China;
Entecavir   
   Department of general internal medicine, Kyushu-University hospital
      2012   -   JPRN-UMIN000018017   Japan;
   Seoul National University Hospital
      2012   Phase 3   NCT01694264   Korea, Republic of;
   Taipei Veterans General Hospital, Taiwan
      2013   Phase 4   NCT01907230   Taiwan;
Epaxal   
   HY, HUS
      2011   -   EUCTR2009-016055-22-SE   Finland;Sweden;
      2009   -   EUCTR2009-016055-22-FI   Finland;Sweden;
Epinephrine   
   Nekoyama Miyao Hospital
      2017   -   JPRN-UMIN000029759   Japan;
      2017   -   JPRN-UMIN000029003   Japan;
Epoetin alfa   
   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
      2004   Phase 2   NCT00236678   -
   Ortho Biotech Products, L.P.
      2005   Phase 2   NCT00123149   -
Erbium citrate   
   CIS bio international
      2007   Phase 4   EUCTR2006-006380-22-DE   Germany;
Ergocalciferol   
   Johns Hopkins University
      2009   -   NCT01426347   United States;
Ergocalciferol 1.25 mg tablet   
   Tanta University
      2019   Phase 4   NCT04472481   Egypt;
Esbriet   
   University Hospitals of Leicester NHS Trust
      2017   Phase 2   EUCTR2017-000149-30-GB   Australia;Canada;United Kingdom;United States;
Esomeprazole   
   AstraZeneca
      2007   Phase 3   NCT00595517   Japan;
      2007   Phase 3   NCT00542789   Japan;
      -   Phase 3   JPRN-JapicCTI-080565   -
      -   Phase 3   JPRN-JapicCTI-080531   -
   Hospital of Chengdu Military Area Command PLA
      2008   -   ChiCTR-TCC-12002824   China;
Eszopiclone   
   Sunovion
      2004   Phase 3   NCT00367965   United States;
Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab   
   Reade
      2019   Phase 4   EUCTR2019-001754-25-NL   Netherlands;
Etanercept   
   Amgen
      2013   Phase 4   NCT01927757   Canada;Puerto Rico;United States;
      2011   Phase 4   NCT01313208   Canada;United States;
      2011   Phase 1   NCT01294397   United States;
      2008   Phase 4   NCT00654368   Canada;
      2006   Phase 4   NCT00346294   United States;
      2006   Phase 3   NCT00413452   Canada;United States;
      2006   Phase 1   NCT00361634   United Kingdom;United States;
      2005   Phase 4   NCT00115219   United States;
      2005   Phase 3   NCT00249041   Canada;United States;
      2004   Phase 4   NCT00099554   Canada;United States;
      2004   Phase 4   NCT00094341   United States;
      2001   Phase 3   NCT00078806   Canada;United States;
      2000   Phase 3   NCT03781375   -
      1998   Phase 3   NCT00356590   Canada;United States;
      1997   Phase 3   NCT00357903   Canada;United States;
      1997   Phase 2/Phase 3   NCT03780959   -
   AryoGen Pharmed Co.
      2014   -   NCT04582084   Iran, Islamic Republic of;
   Astellas Pharma Inc
      2014   Phase 3   NCT02308163   Japan;Korea, Republic of;Taiwan;
   AstraZeneca
      2008   Phase 2   NCT00713544   Argentina;Bulgaria;Colombia;Czech Republic;Hungary;Italy;Latvia;Malta;Netherlands;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Ukraine;
      2007   Phase 2   NCT00520572   Argentina;Australia;Belgium;Canada;Czech Republic;France;Hungary;Mexico;Poland;Romania;Russian Federation;Slovakia;Sweden;United States;
   AstraZeneca AB
      2008   Phase 2   EUCTR2007-007539-14-SK   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;Slovakia;
      2008   -   EUCTR2007-007539-14-PL   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-MT   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-LV   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-HU   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-CZ   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-007539-14-BG   Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
      2008   -   EUCTR2007-001420-12-CZ   Czech Republic;France;Poland;Sweden;
      2007   Phase 2   EUCTR2007-001420-12-SK   Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
      2007   Phase 2   EUCTR2007-001420-12-FR   Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
      2007   -   EUCTR2007-001420-12-SE   Czech Republic;France;Poland;Sweden;
      2007   -   EUCTR2007-001420-12-PL   Czech Republic;France;Poland;Sweden;
      2007   -   EUCTR2007-001420-12-BE   Belgium;Czech Republic;France;Poland;Sweden;
   Biogen
      2006   Phase 2   NCT00298272   United States;
   CHU Saint-Etienne
      2008   -   EUCTR2008-006256-22-FR   France;
   Coherus BioSciences, Inc.
      2015   Phase 3   EUCTR2015-000665-30-GB   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
      2015   Phase 3   EUCTR2015-000665-30-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
      2015   Phase 3   EUCTR2015-000665-30-DE   Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
   Coherus Biosciences, Inc.
      2014   Phase 3   NCT02115750   Belarus;France;Germany;Hungary;Israel;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
   DAIICHISANKYO Co.,Ltd.
      2014   Phase 3   JPRN-JapicCTI-142621   -
   Department of Rheumatology and infectious disease, Kitasato university school of medicine
      2012   -   JPRN-UMIN000008572   Japan;
   Department of Rheumatosurgery, Osaka City University Medical School
      2009   Phase 4   JPRN-UMIN000002340   Japan;
   Dept. of orthopedic surgery, Osaka Medical College
      2012   -   JPRN-UMIN000012613   Japan;
   Derby Hospitals NHS Foundation Trust
      2008   Phase 4   EUCTR2006-006562-42-GB   United Kingdom;
   Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences
      2011   -   JPRN-UMIN000013750   Japan;
   Dr. Frank Behrens
      2019   Phase 4   NCT04485325   Germany;
   F. Hoffmann-La Roche Ltd
      2008   Phase 4   EUCTR2007-000593-24-GB   Sweden;United Kingdom;
   F.Hoffmann-La Roche Ltd
      2008   -   EUCTR2007-000593-24-SE   Sweden;United Kingdom;
   Faiq Gorial
      2017   Phase 1/Phase 2   NCT03160001   Iraq;
   Fen Li
      2016   Phase 4   NCT02878161   -
   Gema Biotech S.A.
      2016   Phase 3   NCT03403140   Argentina;
      2016   Phase 3   NCT03332719   Argentina;
   Georgetown University
      2013   Phase 4   NCT01793519   United States;
   Greater Glasgow Health Board
      2006   Phase 4   EUCTR2006-000363-28-GB   United Kingdom;
   Hanwha Chemical
      2010   Phase 3   NCT01270997   Korea, Republic of;
   Hoffmann-La Roche
      2011   Phase 4   NCT01331837   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Czechia;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2011   -   NCT01592292   Korea, Republic of;
   Imperial College London South Kensington London
      2009   Phase 4   EUCTR2009-012424-87-GB   United Kingdom;
   Innovaderm Research Inc.
      2014   Phase 4   NCT02109289   Canada;
   Jagiellonian University
      2013   Phase 4   NCT02132234   Poland;
   Johoku Biological Summit
      2006   Phase 4   JPRN-C000000452   Japan;
   Joint Stock Company Farmak
      2018   Phase 3   NCT04079374   Ukraine;
   Julia Brown
      2011   Phase 4   NCT01295151   United Kingdom;
   Kawakami Atsushi
      2020   Phase 4   JPRN-jRCTs071200054   Japan;
      2020   Phase 4   JPRN-jRCTs071190046   Japan;
   King's College London
      2010   Phase 4   EUCTR2010-020738-24-GB   United Kingdom;
   Lawson Health Research Institute
      2020   Phase 4   NCT03976245   Canada;
   Mario Negri Institute for Pharmacological Research
      2018   Phase 4   NCT03100253   Italy;
   Merck Sharp & Dohme Corp.
      2008   -   NCT00724672   -
   NHS Greater Glasgow and Clyde
      2009   -   EUCTR2009-011268-13-GB   United Kingdom;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2009   Phase 4   NCT00837434   United States;
      2008   Phase 4   NCT00796705   United States;
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 2   NCT00034060   United States;
   Osaka City University Medical School
      2011   Phase 4   JPRN-UMIN000008164   Japan;
   Pfizer
      2018   -   NCT04267614   Iraq;
      2015   Phase 3   NCT02378506   Bulgaria;Croatia;Germany;Greece;Hungary;Poland;Russian Federation;Serbia;Slovakia;South Africa;
      2015   -   NCT02486302   Germany;
      2014   Phase 4   NCT02092467   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czech Republic;Czechia;Finland;Hong Kong;Israel;Jordan;Lebanon;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   -   NCT02202837   Belgium;
      2013   Phase 4   NCT01783015   Australia;Belgium;France;Hong Kong;Israel;Netherlands;Russian Federation;Spain;
      2013   -   NCT01558089   Greece;
      2012   Phase 4   NCT01578850   Brazil;China;Colombia;Czech Republic;Egypt;Hungary;Jordan;Lebanon;Malaysia;Mexico;Philippines;Qatar;Romania;Russian Federation;Saudi Arabia;South Africa;Taiwan;Thailand;Ukraine;United Arab Emirates;
      2012   -   NCT01646385   -
      2012   -   NCT01623752   -
      2011   -   NCT01557322   -
      2009   Phase 4   NCT00913458   France;Germany;Ireland;Italy;Monaco;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Switzerland;United Kingdom;
      2009   Phase 4   NCT00858780   Denmark;Finland;Hungary;Iceland;Norway;Sweden;
      2008   Phase 4   NCT00565409   Australia;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;Former Serbia and Montenegro;France;Germany;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;United Kingdom;
      2006   Phase 3   NCT00445770   Japan;
      2006   -   NCT00488475   Germany;
      2004   -   NCT00195403   Korea, Republic of;
      2004   -   NCT00195338   Luxembourg;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   Samsung Bioepis Co., Ltd.
      2017   Phase 2   NCT03193957   Poland;
   Sanofi
      2013   Phase 3   NCT01764997   Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Czechia;Ecuador;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
   Takarazuka city hospital
      2014   -   JPRN-UMIN000013362   Japan;
   Team RA, Rheumatosurgery, Osaka City University Medical School
      2008   -   JPRN-UMIN000001798   Japan;
   University of Alabama at Birmingham
      2004   Phase 4   NCT00259610   United States;
   University of California, Davis
      2017   -   NCT03178955   United States;
   University of Leeds
      2011   Phase 4   NCT02433184   United Kingdom;
      2011   Phase 4   EUCTR2010-023880-17-GB   United Kingdom;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
   University of Pittsburgh
      2009   Phase 4   NCT01009879   United States;
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy;
   VA Office of Research and Development
      2007   -   NCT00405275   Canada;United States;
   Wyeth Pharmaceuticals France
      2008   -   EUCTR2007-000896-41-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Pharmaceuticals Inc. Philadelphia (A Pfizer Company)
      2009   Phase 4   EUCTR2008-002623-85-GB   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA
      2010   Phase 4   EUCTR2008-002623-85-SE   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
      2009   -   EUCTR2008-002623-85-IE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2009   -   EUCTR2008-002623-85-DE   France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2009   Phase 4   EUCTR2008-002623-85-FR   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 4   EUCTR2008-002623-85-ES   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002623-85-IT   France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2008   Phase 4   NCT00768053   France;Monaco;
      2007   Phase 3   NCT00484237   Japan;
      2007   Phase 3   NCT00418717   Japan;
      2006   Phase 3   NCT00443950   China;
      2004   Phase 4   NCT00252668   -
      2004   Phase 4   NCT00195494   United States;
      2003   Phase 4   NCT00546533   -
      2003   -   NCT00195377   Spain;
      2003   -   NCT00195364   Spain;
      2000   Phase 3   NCT00393471   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Italy;Netherlands;Norway;Poland;Portugal;Romania;Spain;Sweden;United Kingdom;
Etanercept (ETN)   
   University of Leeds
      2006   Phase 4   NCT01303874   United Kingdom;
Etanercept (Enbrel)   
   University of Leeds
      2011   Phase 4   EUCTR2010-023910-30-GB   United Kingdom;
Etanercept (EnbrelTM)   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2008   Phase 4   NCT00706797   Austria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Turkey;United Kingdom;United States;
Etanercept + Methotrexate   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2008   Phase 4   NCT00783536   Mexico;
Etanercept , Methotrexate   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2007   Phase 4   NCT00422227   Hong Kong;India;Korea, Republic of;Malaysia;Philippines;Singapore;Taiwan;Thailand;
Etanercept / Autoinjector A   
   Amgen
      2013   Phase 3   NCT01901185   United States;
Etanercept 50 MG/ML   
   P. Verschueren
      2018   Phase 4   NCT03649061   Belgium;
Etanercept Auto-Injector   
   Wyeth Pharmaceuticals France
      2007   -   EUCTR2006-005137-38-DE   Denmark;Finland;France;Germany;Sweden;United Kingdom;
Etanercept Liquid   
   Amgen
      2004   Phase 3   NCT00110903   -
Etanercept Optimal dosing   
   Duke University
      2023   Phase 1   NCT04585711   United States;
Etanercept Pre-filled syringe   
   Wyeth Pharmaceuticals France
      2007   -   EUCTR2006-005137-38-DE   Denmark;Finland;France;Germany;Sweden;United Kingdom;
Etanercept Treatment   
   Assistance Publique Hopitaux De Marseille
      2011   Phase 3   NCT02164214   France;
Etanercept biosimilar   
   TcLand Expression S.A.
      2016   -   NCT03016260   Czech Republic;Czechia;France;Israel;Netherlands;Turkey;
Etanercept or adalimumab   
   University of Glasgow
      2010   Phase 4   NCT01021735   United Kingdom;
Etanercept pre-filled syringe sq injection   
   Amgen
      2015   Phase 3   NCT02373813   Argentina;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Mexico;Poland;Portugal;South Africa;Spain;United States;
Etanercept via Autoinjector A   
   Amgen
      2013   Phase 4   NCT01875991   Canada;United States;
Etanercept via Autoinjector B   
   Amgen
      2013   Phase 4   NCT01875991   Canada;United States;
Etanercept, methotrexate and depomedrone   
   University Hospital Birmingham
      2007   Phase 4   NCT00523692   United Kingdom;
Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc   
   Pfizer
      2013   -   NCT01932372   Japan;
Etoricoxib   
   Chung Shan Medical University
      2007   Phase 4   NCT04144101   -
   Northumbria Healthcare NHS Foundation Trust
      2010   Phase 4   NCT01067430   United Kingdom;
   Organon and Co
      2010   Phase 3   NCT01208181   Argentina;Austria;Canada;Colombia;Czech Republic;Finland;Germany;Guatemala;India;Lithuania;Mexico;Panama;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
      2006   Phase 2   NCT00264147   Canada;Colombia;Puerto Rico;Switzerland;United States;
      2006   -   NCT01685424   United States;
Eupatilin   
   Seoul National University Boramae Hospital
      2021   Phase 4   NCT04885751   -
Evobrutinib   
   Merck KGaA
      2017   Phase 2   EUCTR2017-000384-32-CZ   Argentina;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Germany;Japan;Mexico;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
      2017   Phase 2   EUCTR2017-000384-32-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Germany;Japan;Mexico;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
Exhaled nitric oxide assessment   
   GlaxoSmithKline
      2004   -   NCT00242853   United Kingdom;
Experimental: Arm A: DRL_RI   
   Dr. Reddy's Laboratories Limited
      2020   Phase 3   NCT04268771   United States;
Extracorporeal Photopheresis   
   Mallinckrodt
      2003   Phase 2   NCT00221000   Australia;Austria;Belgium;Canada;France;Germany;Italy;Mexico;Slovakia;South Africa;United States;
F8IL10   
   Philogen S.p.A.
      2015   Phase 2   EUCTR2013-005418-37-DE   Germany;Italy;Switzerland;
      2014   Phase 2   NCT02270632   Germany;Italy;Switzerland;
      2014   -   EUCTR2013-005418-37-IT   Germany;Italy;
      2011   Phase 1   NCT02076659   Italy;
FANG(30)   
   Juan C. Bertoglio, MD
      2006   Phase 2   NCT00749645   Chile;
FB704A   
   Fountain Biopharma Inc.
      2019   Phase 1   NCT03890302   United States;
FBL-MTX   
   SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd
      2021   Phase 1   NCT05117593   Portugal;
FKB327   
   Fujifilm Kyowa Kirin Biologics Co., Ltd.
      2015   Phase 3   NCT02405780   Bulgaria;Canada;Chile;Czech Republic;Czechia;Germany;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2015   Phase 3   EUCTR2014-000110-61-ES   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2015   Phase 3   EUCTR2014-000109-11-DE   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2015   Phase 3   EUCTR2014-000109-11-BG   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   Phase 3   NCT02260791   Bulgaria;Canada;Chile;Czech Republic;Czechia;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2014-000109-11-ES   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   Phase 3   EUCTR2014-000109-11-CZ   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
FKB327 AI   
   Fujifilm Kyowa Kirin Biologics Co., Ltd.
      2015   Phase 3   EUCTR2014-000110-61-DE   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2015   Phase 3   EUCTR2014-000110-61-CZ   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
FKB327 PFS   
   Fujifilm Kyowa Kirin Biologics Co., Ltd.
      2015   Phase 3   EUCTR2014-000110-61-DE   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2015   Phase 3   EUCTR2014-000110-61-CZ   Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
FMT+MTX   
   Peking Union Medical College Hospital
      2019   Phase 2   NCT03944096   China;
FPA008   
   Five Prime Therapeutics, Inc.
      2013   Phase 1   NCT01962337   Hungary;Netherlands;Poland;
FR104   
   OSE Immunotherapeutics
      2015   Phase 1   NCT02800811   Belgium;
FURESTEM-RA Inj   
   Kang Stem Biotech Co., Ltd.
      2018   Phase 1/Phase 2   NCT03618784   Korea, Republic of;
FURESTEM-RA Inj.   
   Kang Stem Biotech Co., Ltd.
      2016   -   NCT03106259   Korea, Republic of;
      2014   Phase 1   NCT02221258   Korea, Republic of;
FX125L   
   Funxional Therapeutics Ltd
      2011   -   EUCTR2011-005036-26-GB   United Kingdom;
Faecal microbiota transplantation   
   Torkell Ellingsen
      2022   Phase 2   NCT04924270   -
Faecal sampling   
   Assistance Publique - Hôpitaux de Paris
      2020   -   NCT04292067   France;
Famotidine   
   Hoshigaoka Koseinenkin Hospital
      2009   -   JPRN-UMIN000004271   Japan;
Fang yi qing feng shi granule   
   Maoxiang Group Jilin Pharmaceutical Co., Ltd.
      2014   Phase 2   NCT02029599   China;
Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).   
   FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
      2018   Phase 4   EUCTR2018-002368-18-ES   Spain;
Fentanyl   
   Yamaguchi University
      2018   -   JPRN-UMIN000031692   Japan;
Fentanyl transdermal patch   
   Janssen Pharmaceutica N.V., Belgium
      2001   Phase 4   NCT00524160   -
Ferrograd Folic Tablets   
   University of Leeds
      2006   Phase 4   EUCTR2005-005013-37-GB   United Kingdom;
Fexofenadine   
   October 6 University
      2022   Phase 1/Phase 2   NCT05264025   -
Filgotinib   
   DeparShinshu University School of Medicine
      2021   -   JPRN-UMIN000043547   Japan;
   GILEAD SCIENCES INCORPORATED
      2017   Phase 3   EUCTR2016-000568-41-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
   Galapagos NV
      2021   -   NCT04871919   Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
      2019   Phase 2   NCT03926195   Belgium;Bosnia and Herzegovina;Bulgaria;Czechia;Estonia;Georgia;Latvia;Poland;Spain;Ukraine;
      2017   Phase 3   NCT03025308   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   NCT02065700   Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
   Gilead Sciences
      2020   Phase 1   NCT04608344   United States;
      2018   Phase 1   NCT03417778   Germany;New Zealand;United States;
      2016   Phase 3   NCT02889796   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   NCT02886728   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Czechia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   NCT02873936   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2016   Phase 2   NCT02885181   Bulgaria;Czech Republic;Czechia;Georgia;Hungary;Moldova, Republic of;Poland;Ukraine;United States;
   Kawakami Atsushi
      2021   -   JPRN-jRCTs071200107   Japan;
   R.Bos
      2021   Phase 4   NCT04985435   Netherlands;
Filgotinib 200mg/day   
   Atsushi Kawakami
      2021   Phase 3   NCT05090410   Japan;
Filgrastim   
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Fish oil supplement   
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2004   Phase 2   NCT00094562   United States;
Fish oil, gamma-linolenic acid   
   Charite University, Berlin, Germany
      2008   Phase 2   NCT01179971   -
Fludarabine   
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      1998   Phase 2   NCT00001677   United States;
Fluorescence Imaging   
   University Medical Center Groningen
      2022   Phase 1   NCT03938701   Netherlands;
Flurbiprofen   
   Bristol-Myers Squibb
      2017   Phase 1   NCT03131973   United States;
Focetria   
   Div KIR AMC
      2010   -   EUCTR2009-016789-10-NL   Netherlands;
Focetria (Monovalent MF59-Adjuvanted vaccine)   
   Tel-Aviv Sourasky Medical Center
      2009   Phase 2   NCT01006681   -
Folate   
   Biogen
      2006   Phase 2   NCT00298272   United States;
   Genentech, Inc.
      2006   Phase 3   NCT00299104   United States;
      2006   Phase 3   NCT00266227   United States;
      2005   Phase 3   NCT00299130   United States;
      2005   Phase 2   NCT00243412   United States;
   Hoffmann-La Roche
      2011   Phase 4   NCT01283971   Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Puerto Rico;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2007   Phase 4   NCT00462345   Korea, Republic of;
FolateScan (Technetium Tc 99mEC20)   
   Mayo Clinic
      2006   Phase 2   NCT00588393   United States;
Folic (or folinic) acid   
   GlaxoSmithKline
      2019   Phase 3   NCT03980483   Argentina;Canada;China;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 2   NCT02799472   Germany;Poland;United States;
Folic acid   
   Biocad
      2016   Phase 3   NCT02762838   Belarus;India;Russian Federation;
   GlaxoSmithKline
      2017   Phase 1/Phase 2   NCT03028467   Japan;
      2015   Phase 2   NCT02504671   Bulgaria;Canada;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
   Hoffmann-La Roche
      2009   Phase 1   NCT00965653   Canada;New Zealand;Spain;United Kingdom;
   Kaneko Yuko
      2018   Phase 4   JPRN-jRCT1031180088   Japan;South Korea;Taiwan;
   Kojima Toshihisa
      2020   -   JPRN-jRCTs041200048   Japan;
   Sanofi
      2014   Phase 3   NCT02293902   Japan;
      2013   Phase 1   NCT01850680   Japan;
   Takahashi Nobunori
      2020   -   JPRN-jRCT1041190125   Japan;
   The Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100042659   China;
      2021   Phase 0   ChiCTR2100042329   China;
   The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100041819   China;
   University of Alabama at Birmingham
      1996   Phase 2   NCT00000395   United States;
   University of Dundee
      2005   Phase 4   EUCTR2005-000551-15-GB   United Kingdom;
   University of Leeds
      2006   Phase 4   NCT01308255   United Kingdom;
   Yunnan Hospital of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100041894   China;
   Yunnan Hospital of Traditional Chinese Medicine (The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine)
      2021   Phase 0   ChiCTR2100042328   China;
   Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100042440   China;
   Yunnan Provincial Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100041821   China;
Folic acid or folate   
   Hoffmann-La Roche
      2007   Phase 3   NCT00578305   Argentina;Brazil;Canada;Czech Republic;Denmark;Estonia;Former Serbia and Montenegro;France;Germany;Greece;Latvia;Lithuania;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;United Kingdom;
Folic/folinic acid   
   Sanofi
      2010   Phase 2   NCT01217814   Brazil;Canada;Colombia;Czech Republic;Czechia;Germany;Hungary;Italy;Mexico;Norway;Spain;United States;
   Takeda
      2014   Phase 2   NCT02379091   Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Germany;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United Kingdom;
Folimet   
   Chelsea Therapeutics, Inc
      2010   -   EUCTR2010-019134-27-BG   Argentina;Bulgaria;Czech Republic;Mexico;Poland;United States;
Folinic acid   
   University of Alabama at Birmingham
      1996   Phase 2   NCT00000395   United States;
Fontolizumab   
   PDL BioPharma, Inc.
      2005   Phase 2   NCT00281294   United States;
FosD   
   ASTRAZENECA
      2011   -   EUCTR2010-020892-22-IT   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-020745-27-IT   Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-020744-35-IT   Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
   Astra Zeneca AB
      2010   -   EUCTR2010-020743-12-EE   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
   AstraZeneca AB
      2013   -   EUCTR2010-020892-22-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020892-22-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020892-22-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020745-27-HU   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-020745-27-DE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-020744-35-DE   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020743-12-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020743-12-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020892-22-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020892-22-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020745-27-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020745-27-FR   Belgium;Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2010   Phase 3   EUCTR2010-020745-27-BE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020743-12-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020743-12-GB   Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
      2010   Phase 3   EUCTR2010-020743-12-FR   Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
      2010   Phase 3   EUCTR2010-020743-12-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020743-12-BE   Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
      2010   -   EUCTR2010-020892-22-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020892-22-PT   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020892-22-LV   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020892-22-LT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020892-22-HU   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020892-22-ES   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020892-22-EE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020892-22-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020745-27-PT   Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020745-27-ES   Belgium;Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020745-27-CZ   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2010   -   EUCTR2010-020744-35-PT   Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020744-35-LV   Canada;Czech Republic;Germany;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020744-35-LT   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020744-35-GB   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020744-35-ES   Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020744-35-CZ   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020743-12-HU   Bulgaria;Estonia;France;Germany;Hungary;Poland;United Kingdom;
Fosfamatinib Disodium   
   RIGEL PHARMACEUTICALS INC
      2009   -   EUCTR2008-000744-13-IT   Bulgaria;France;Germany;Italy;
Fostamatinib   
   AstraZeneca
      2012   Phase 2   NCT01640054   Hong Kong;Japan;Korea, Republic of;Taiwan;Thailand;Vietnam;
      2012   Phase 2   NCT01569074   Hong Kong;Japan;Korea, Republic of;Taiwan;Thailand;Vietnam;
      2012   Phase 2   NCT01563978   Argentina;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2012   Phase 1   NCT01725230   United States;
      2011   Phase 3   NCT01242514   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 2   NCT02092961   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;South Africa;United Kingdom;United States;
      2011   Phase 2   NCT01264770   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   Phase 1   NCT01355354   United Kingdom;
      2011   Phase 1   NCT01336218   United States;
      2011   Phase 1   NCT01311622   United Kingdom;
      2011   Phase 1   NCT01309854   United States;
      2011   Phase 1   NCT01276262   United Kingdom;
      2010   Phase 3   NCT01197755   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2010   Phase 3   NCT01197534   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   Phase 3   NCT01197521   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2010   Phase 1   NCT01245790   United States;
      -   Phase 2   JPRN-JapicCTI-121990   -
      -   Phase 2   JPRN-JapicCTI-121843   -
Fostamatinib 50 mg blue film-coated tablet   
   AstraZeneca AB
      2012   -   EUCTR2011-006070-73-DE   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2012   -   EUCTR2011-006070-73-CZ   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2012   -   EUCTR2011-006070-73-BG   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
Fostamatinib Disodium   
   AstraZeneca AB
      2009   -   EUCTR2008-000744-13-BG   Belgium;Bulgaria;Colombia;France;Germany;Italy;Mexico;Peru;Poland;Romania;United States;
      2008   Phase 2   EUCTR2008-000744-13-BE   Belgium;Bulgaria;France;Germany;Italy;
      -   -   EUCTR2008-000744-13-DE   Belgium;Bulgaria;France;Germany;Italy;
   Rigel Pharmaceuticals, Inc
      2009   -   EUCTR2008-000744-13-FR   Bulgaria;France;Germany;Italy;
   Rigel Pharmaceuticals, Inc.
      2008   -   EUCTR2008-000743-34-FR   France;Germany;Italy;
      2008   -   EUCTR2008-000743-34-DE   France;Germany;Italy;
      2008   -   EUCTR2008-000743-34-BE   Belgium;France;Germany;Italy;
      2008   -   EUCTR2008-000742-30-PL   Bulgaria;Hungary;Poland;
      2008   -   EUCTR2008-000742-30-HU   Bulgaria;Hungary;Poland;
      2008   -   EUCTR2008-000742-30-BG   Bulgaria;Hungary;Poland;
Fostamatinib Disodium (R935788)   
   AstraZeneca
      2008   Phase 2   NCT00805467   Belgium;Bulgaria;Colombia;France;Germany;Italy;Mexico;Peru;Poland;Romania;United States;
Fostamatinib disodium   
   ASTRAZENECA
      2011   -   EUCTR2010-020892-22-IT   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-020745-27-IT   Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-020744-35-IT   Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
   Astra Zeneca AB
      2010   -   EUCTR2010-020743-12-EE   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
   AstraZeneca AB
      2013   -   EUCTR2010-020892-22-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-006070-73-DE   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2012   -   EUCTR2011-006070-73-CZ   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2012   -   EUCTR2011-006070-73-BG   Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
      2011   Phase 2   EUCTR2010-023692-26-SK   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   Phase 2   EUCTR2010-023692-26-GB   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-023692-26-HU   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-023692-26-CZ   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-023692-26-BG   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020892-22-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020892-22-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020745-27-HU   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-020745-27-DE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-020744-35-DE   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020743-12-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020743-12-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020892-22-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020892-22-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020745-27-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020745-27-FR   Belgium;Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2010   Phase 3   EUCTR2010-020745-27-BE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020743-12-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020743-12-GB   Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
      2010   Phase 3   EUCTR2010-020743-12-FR   Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
      2010   Phase 3   EUCTR2010-020743-12-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020743-12-BE   Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
      2010   -   EUCTR2010-020892-22-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020892-22-PT   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020892-22-LV   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020892-22-LT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020892-22-HU   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020892-22-ES   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020892-22-EE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020892-22-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020745-27-PT   Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020745-27-ES   Belgium;Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020745-27-CZ   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
      2010   -   EUCTR2010-020744-35-PT   Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020744-35-LV   Canada;Czech Republic;Germany;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020744-35-LT   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020744-35-GB   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020744-35-ES   Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020744-35-CZ   Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020743-12-HU   Bulgaria;Estonia;France;Germany;Hungary;Poland;United Kingdom;
      -   -   EUCTR2010-023692-26-DE   Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
Fostamatinib disodium (R935788)   
   Rigel Pharmaceuticals
      2008   Phase 2   NCT00665925   Bulgaria;Colombia;Israel;Mexico;Poland;Romania;United States;
      2008   Phase 2   NCT00665626   Belgium;Brazil;Colombia;France;Germany;Italy;Peru;United States;
Fresenius-Kabi)   
   Humanis Klinikum Niederosterreich
      2004   Phase 3   NCT00412256   Austria;
G1567970   
   Galapagos NV
      2020   Phase 2   EUCTR2020-000658-83-BG   Bulgaria;Georgia;Poland;Ukraine;
GB224   
   Genor Biopharma Co., Ltd.
      2019   Phase 1   NCT04179513   China;
      2017   Phase 1   NCT04178070   China;
GB242   
   Genor Biopharma Co., Ltd.
      2017   Phase 3   NCT04178850   China;
GCK   
   Zhejiang Hisun Pharmaceutical Co. Ltd.
      2017   Phase 1   NCT03755258   China;
GDC-0853   
   Genentech, Inc.
      2016   Phase 2   NCT02983227   Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
      2016   Phase 2   NCT02833350   Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
      2016   Phase 2   EUCTR2016-000335-40-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
GDC-0853 RO7010939   
   Genentech, Inc.
      2016   Phase 2   EUCTR2016-000498-19-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
GFI 38518168-AEK-B-007   
   Janssen-Cilag International NV
      2009   -   EUCTR2009-012118-27-NL   Czech Republic;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2009-012118-27-GB   Czech Republic;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2009-012118-27-ES   Czech Republic;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2009-012118-27-CZ   Czech Republic;Netherlands;Spain;United Kingdom;
GLPG0259   
   Galápagos NV
      2010   -   EUCTR2009-015898-12-NL   Belgium;Netherlands;
      2010   -   EUCTR2009-015898-12-BE   Belgium;Netherlands;
GLPG0259 (Part B)   
   Galapagos NV
      2010   Phase 2   NCT01211249   Belgium;Netherlands;Poland;Russian Federation;Ukraine;
GLPG0259 oral capsule   
   Galapagos NV
      2010   Phase 2   NCT01211249   Belgium;Netherlands;Poland;Russian Federation;Ukraine;
GLPG0634   
   Galapagos NV
      2019   Phase 2   EUCTR2018-003933-14-LV   Belgium;Bulgaria;Czech Republic;Estonia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
      2019   Phase 2   EUCTR2018-003933-14-ES   Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
      2019   Phase 2   EUCTR2018-003933-14-EE   Bulgaria;Czech Republic;Estonia;Latvia;Poland;Spain;Ukraine;
      2019   Phase 2   EUCTR2018-003933-14-CZ   Belgium;Bulgaria;Czech Republic;Estonia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
      2019   Phase 2   EUCTR2018-003933-14-BG   Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Czechia;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
      2019   Phase 2   EUCTR2018-003933-14-BE   Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
      2017   Phase 2   EUCTR2012-003655-11-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2014   -   EUCTR2012-003654-86-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   -   EUCTR2012-003654-86-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   -   EUCTR2012-003654-86-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2014   -   EUCTR2012-003635-31-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   Phase 2   NCT01894516   Argentina;Australia;Austria;Bulgaria;Chile;Colombia;Germany;Guatemala;Hungary;Latvia;Mexico;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2013   Phase 2   NCT01888874   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003654-86-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003654-86-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003654-86-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2013   -   EUCTR2012-003635-31-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
      2012   Phase 2   NCT01668641   Hungary;Moldova, Republic of;Russian Federation;Ukraine;
      2011   Phase 2   NCT01384422   Moldova, Republic of;
   Galapagos SASU
      2012   -   EUCTR2011-005008-14-HU   European Union;Hungary;Moldova, Republic of;Russian Federation;Ukraine;
   Gilead Sciences Inc.
      2014   Phase 2   EUCTR2012-003655-11-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
GLPG3970   
   Galapagos NV
      2020   Phase 2   NCT04577781   Bulgaria;Georgia;Poland;Ukraine;
      2020   Phase 2   EUCTR2020-000658-83-BG   Bulgaria;Georgia;Poland;Ukraine;
GOL   
   University Medical Center Utrecht (UMCU)
      2016   Phase 4   EUCTR2015-004858-17-NL   Netherlands;
GP2013   
   Hexal AG
      2015   Phase 1;Phase 2   EUCTR2010-021184-32-PL   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2015   Phase 1;Phase 2   EUCTR2010-021184-32-HU   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2015   Phase 1;Phase 2   EUCTR2010-021184-32-GB   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2015   Phase 1;Phase 2   EUCTR2010-021184-32-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2012   Phase 2   EUCTR2010-021184-32-EE   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
      2011   Phase 2   EUCTR2010-021184-32-IT   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
      2011   Phase 2   EUCTR2010-021184-32-BE   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
      2010   Phase 2   EUCTR2010-021184-32-FR   Austria;Belgium;Bulgaria;Estonia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;
      2010   Phase 2   EUCTR2010-021184-32-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
      2010   Phase 2   EUCTR2010-021184-32-AT   Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
   Hexal AG (a Sandoz company)
      2015   Phase 3   EUCTR2012-003876-38-PL   Germany;Hungary;Poland;United States;
      2015   Phase 3   EUCTR2012-003876-38-HU   Germany;Hungary;Poland;United States;
      2015   Phase 3   EUCTR2012-003876-38-DE   Germany;Hungary;Poland;United States;
   Sandoz
      2011   Phase 1/Phase 2   NCT01274182   Argentina;Austria;Belgium;Brazil;Estonia;France;Germany;Hungary;India;Italy;Romania;Spain;Turkey;United States;
GP2013 - A Proposed biosimilar rituximab   
   Sandoz
      2015   Phase 3   NCT02514772   Germany;Hungary;Poland;United States;
GP2015   
   Hexal AG
      2016   Phase 3   EUCTR2012-002009-23-HU   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2012-002009-23-DE   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-SK   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-PL   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-LV   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-LT   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-GB   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-ES   Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-EE   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-CZ   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-002009-23-BG   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
   Sandoz
      2015   Phase 3   NCT02638259   Bulgaria;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
GP2017   
   HEXAL AG
      2016   Phase 3   EUCTR2015-003433-10-IT   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
   Hexal, AG
      2016   Phase 3   EUCTR2015-003433-10-HU   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003433-10-GB   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003433-10-ES   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003433-10-DE   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-003433-10-CZ   Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
GRC 4039   
   Glenmark Pharmaceuticals SA
      2011   -   EUCTR2011-000107-40-GB   India;Philippines;Poland;Sri Lanka;United Kingdom;
GS-5745   
   Gilead Sciences
      2014   Phase 1   NCT02176876   Czech Republic;Hungary;
   Gilead Sciences, Inc.
      2017   Phase 2   EUCTR2016-000897-39-HU   Australia;Belgium;Germany;Hungary;Mexico;Taiwan;United States;
      2017   Phase 2   EUCTR2016-000897-39-DE   Australia;Belgium;Germany;Hungary;Mexico;Taiwan;United States;
      2017   Phase 2   EUCTR2016-000897-39-BE   Australia;Belgium;Germany;Hungary;Mexico;Taiwan;United States;
GS-6034   
   GILEAD SCIENCES INCORPORATED
      2017   Phase 3   EUCTR2016-000568-41-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
   Galapagos NV
      2017   Phase 3   EUCTR2016-003630-25-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003630-25-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003630-25-BE   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2012-003655-11-HU   Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2014   Phase 2   EUCTR2012-003655-11-BG   Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2014   Phase 2   EUCTR2012-003655-11-BE   Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      2013   Phase 2   EUCTR2012-003655-11-LV   Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
      -   Phase 3   EUCTR2016-003630-25-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      -   Phase 2   EUCTR2012-003655-11-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
   Gilead Sciences Inc.
      2014   Phase 2   EUCTR2012-003655-11-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
   Gilead Sciences, Inc.
      2018   Phase 3   EUCTR2016-003630-25-NL   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003630-25-PL   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003630-25-HU   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003630-25-GB   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003630-25-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000570-37-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000569-21-PL   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000569-21-NL   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000569-21-FR   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000569-21-ES   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000569-21-DE   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000569-21-BE   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000568-41-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000570-37-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000570-37-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000570-37-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000569-21-HU   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000569-21-GB   Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000568-41-SK   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000568-41-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000568-41-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-001496-75-PL   Bulgaria;Czech Republic;Hungary;Poland;Serbia;Ukraine;United States;
      2016   Phase 2   EUCTR2016-001496-75-CZ   Bulgaria;Czech Republic;Hungary;Poland;Serbia;Ukraine;United States;
GS-9876   
   Gilead Sciences
      2016   Phase 2   NCT02885181   Bulgaria;Czech Republic;Czechia;Georgia;Hungary;Moldova, Republic of;Poland;Ukraine;United States;
   Gilead Sciences, Inc.
      2016   Phase 2   EUCTR2016-001496-75-PL   Bulgaria;Czech Republic;Hungary;Poland;Serbia;Ukraine;United States;
      2016   Phase 2   EUCTR2016-001496-75-CZ   Bulgaria;Czech Republic;Hungary;Poland;Serbia;Ukraine;United States;
GSK 3196165   
   GlaxoSmithKline Research & Development Limited
      2021   Phase 3   EUCTR2019-000878-30-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-LV   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-LT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000878-30-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2019-000878-30-EE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
GSK1827771   
   GlaxoSmithKline
      2007   Phase 1   NCT00539760   United States;
GSK1841157   
   GlaxoSmithKline Research & Development Ltd
      2008   Phase 1;Phase 2   EUCTR2008-002046-27-FR   Belgium;France;Germany;Spain;
      2008   -   EUCTR2008-002046-27-DE   Belgium;France;Germany;Spain;
      2008   -   EUCTR2008-002046-27-BE   Belgium;France;Germany;Spain;
   GlaxoSmithKline S.A.
      2008   -   EUCTR2008-002046-27-ES   Belgium;France;Germany;Spain;
GSK2982772   
   GlaxoSmithKline
      2016   Phase 2   NCT02858492   Germany;Italy;Poland;Russian Federation;Spain;United Kingdom;
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2016-000912-13-PL   Germany;Italy;Poland;Romania;Spain;United Kingdom;
      2016   Phase 2   EUCTR2016-000912-13-GB   Germany;Italy;Poland;Romania;Spain;United Kingdom;
      2016   Phase 2   EUCTR2016-000912-13-DE   Germany;Italy;Poland;Romania;Spain;United Kingdom;
GSK2982772A, where A denotes the free base   
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2016-000912-13-PL   Germany;Italy;Poland;Romania;Spain;United Kingdom;
      2016   Phase 2   EUCTR2016-000912-13-GB   Germany;Italy;Poland;Romania;Spain;United Kingdom;
      2016   Phase 2   EUCTR2016-000912-13-DE   Germany;Italy;Poland;Romania;Spain;United Kingdom;
GSK3117391   
   GlaxoSmithKline
      2016   Phase 2   NCT02965599   Mexico;Poland;Romania;
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2015-005800-27-PL   Poland;Romania;Russian Federation;
GSK3152314A   
   GlaxoSmithKline
      2008   Phase 2   NCT00674635   Australia;Former Serbia and Montenegro;New Zealand;Russian Federation;Serbia;Ukraine;United Kingdom;
GSK315234   
   GlaxoSmithKline Research & Development Ltd
      2008   -   EUCTR2006-000923-32-GB   United Kingdom;
GSK315234 Injection 100mg/mL   
   GlaxoSmithKline Research & Development Limited
      2010   Phase 2   EUCTR2009-012055-19-FR   Belgium;France;Ireland;United Kingdom;
      2010   -   EUCTR2009-012055-19-IE   Belgium;France;Ireland;United Kingdom;
      2010   -   EUCTR2009-012055-19-GB   Belgium;France;Ireland;United Kingdom;
      2010   -   EUCTR2009-012055-19-BE   Belgium;France;Ireland;United Kingdom;
GSK3196165   
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2019   Phase 3   EUCTR2019-000868-18-IT   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-IT   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003453-34-IT   Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
   GlaxoSmithKline
      2016   Phase 2   NCT02799472   Germany;Poland;United States;
      2015   Phase 2   NCT02504671   Bulgaria;Canada;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
   GlaxoSmithKline Research & Development Limited
      2020   Phase 3   EUCTR2019-000868-18-DE   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000867-26-DE   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-PL   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-LT   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-HU   Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-GB   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-ES   Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000868-18-CZ   Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-PL   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-HU   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-GB   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-ES   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-EE   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000867-26-BG   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-PL   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-LV   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-LT   Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-HU   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-GB   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-ES   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000797-39-CZ   Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2015-004386-91-PL   Germany;Poland;United States;
      2016   Phase 2   EUCTR2015-004386-91-DE   Germany;Poland;United States;
      2015   Phase 2   EUCTR2014-003453-34-PL   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-HU   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-GB   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-ES   Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-EE   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-DE   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
      2015   Phase 2   EUCTR2014-003453-34-CZ   Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
GSK3196165 (Otilimab)   
   GlaxoSmithKline
      2019   Phase 3   NCT04134728   Argentina;Belgium;Canada;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   NCT03980483   Argentina;Canada;China;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   NCT03970837   Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
GSK3196165 Dose 1   
   GlaxoSmithKline
      2017   Phase 1/Phase 2   NCT03028467   Japan;
GSK3196165 Dose 2   
   GlaxoSmithKline
      2017   Phase 1/Phase 2   NCT03028467   Japan;
GSK3196165 Dose 3   
   GlaxoSmithKline
      2017   Phase 1/Phase 2   NCT03028467   Japan;
GSK706769   
   GlaxoSmithKline
      2010   Phase 2   NCT00979771   Netherlands;
   GlaxoSmithKline Research & Development Limited
      2009   -   EUCTR2009-012204-42-IE   Belgium;Ireland;
      2009   -   EUCTR2009-012204-42-BE   Belgium;Ireland;
GW274150   
   GlaxoSmithKline
      2006   Phase 2   NCT00379990   Serbia;United Kingdom;
      2005   Phase 2   NCT00370435   United Kingdom;
GW274150 Tablets   
   GlaxoSmithKline Research & Development Limited
      2005   Phase 2   EUCTR2005-001977-82-GB   United Kingdom;
GW406381   
   GLAXO SMITHKLINE
      2005   -   EUCTR2005-000158-61-IT   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
   GlaxoSmithKline
      2005   Phase 3   NCT00113308   Argentina;Austria;Belgium;Bulgaria;Canada;Chile;Costa Rica;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
   GlaxoSmithKline Research & Development Limited
      2006   -   EUCTR2005-000158-61-LT   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-EE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-DE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-CZ   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-LV   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-IE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-HU   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-GB   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-DK   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-AT   Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
   GlaxoSmithKline Research & Development Ltd
      2004   -   EUCTR2004-000106-41-SE   Sweden;
   GlaxoSmithKline s.a.
      2005   Phase 3   EUCTR2005-000158-61-ES   Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GW406381X   
   GlaxoSmithKline Research & Development Limited
      2006   -   EUCTR2005-000158-61-LT   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-EE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-DE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2005-000158-61-CZ   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-LV   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-IE   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-HU   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-GB   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-DK   Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2005   -   EUCTR2005-000158-61-AT   Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
   GlaxoSmithKline s.a.
      2005   Phase 3   EUCTR2005-000158-61-ES   Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GW856553   
   GlaxoSmithKline
      2007   Phase 1   NCT00517543   United States;
      2006   Phase 2   NCT00393146   Romania;Russian Federation;Spain;
      2005   Phase 2   NCT00256919   Bulgaria;Germany;Spain;Sweden;Ukraine;
   GlaxoSmithKline Research & Development Ltd
      2005   -   EUCTR2005-002969-37-SE   Germany;Spain;Sweden;
      -   -   EUCTR2005-002969-37-DE   Germany;Spain;Sweden;
   GlaxoSmithKline S.A.
      2005   Phase 2   EUCTR2005-002969-37-ES   Germany;Spain;Sweden;
Gadobutrol   
   GlaxoSmithKline
      2015   Phase 1   NCT02350426   United Kingdom;
Gadolinium   
   Tokyo Medical and Dental University
      2013   -   JPRN-UMIN000012399   Japan;
Gamma-Linolenic acid   
   FDA Office of Orphan Products Development
      1994   -   NCT00004420   -
Geleli   
   Peking University People's Hospital
      2022   -   NCT05240859   China;
General anesthesia with tourniquet   
   Riku Antero Palanne
      2016   -   NCT03364088   Finland;
General anesthesia without tourniquet   
   Riku Antero Palanne
      2016   -   NCT03364088   Finland;
Gerilimzumab   
   Bird Rock Bio, Inc.
      2018   Phase 2   NCT02795299   -
Ginger   
   Hospital of Chengdu Military Area Command PLA
      2008   -   ChiCTR-TCC-12002824   China;
Ginseng   
   Zhejiang Provincal Hospital of TCM
      2019   Phase 2   ChiCTR1900026257   China;
Ginsenoside   
   Institute of Clinical Pharmacology, Central South University
      2015   Phase 1 study   ChiCTR-IPR-15006107   China;
      2015   Phase 1 study   ChiCTR-IPR-15005787   China;
      2014   Phase 1 study   ChiCTR-TRC-14004824   China;
GlucoCorticoid   
   University Hospital, Toulouse
      2017   Phase 4   NCT02997605   France;
Glucocorticoid Agent   
   Hoffmann-La Roche
      2017   -   NCT03291457   Belgium;
Glucocorticoids (permitted,not necessary)   
   Fen Li
      2016   Phase 4   NCT02878161   -
Glucophage (metformin)   
   Queen Mary University of London
      2010   Phase 2   EUCTR2008-005708-18-GB   United Kingdom;
Gold   
   Affiliated Hospital of North Sichuan Medical College
      2018   -   ChiCTR1800018637   China;
   Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
      2011   -   ChiCTR-DDT-12002268   China;
   Peking University People's Hospital
      2012   -   ChiCTR-DDT-12002658   China;
Golimumab   
   CENTOCOR
      2010   -   EUCTR2009-010582-23-IT   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2004-003295-10-IT   Austria;Hungary;Italy;Spain;United Kingdom;
   Centocor B.V.
      2006   -   EUCTR2005-003232-21-MT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LV   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-DE   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-001742-16-NL   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-ES   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2004-003296-36-HU   Germany;Hungary;
   Centocor BV
      2006   -   EUCTR2004-003295-10-HU   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-ES   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-AT   Austria;Hungary;Italy;Spain;United Kingdom;
   Centocor, Inc.
      2010   Phase 3   NCT01248780   China;
      2009   Phase 3   NCT00973479   Argentina;Australia;Colombia;Hungary;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Ukraine;United States;
      2007   Phase 1   NCT01362153   United States;
      2006   Phase 3   NCT00361335   Argentina;Australia;Belgium;Colombia;Germany;Hungary;Latvia;Lithuania;Malaysia;Malta;Mexico;New Zealand;Peru;Poland;Russian Federation;Ukraine;United States;
      2006   Phase 3   NCT00299546   Australia;Austria;Canada;Finland;France;Germany;Netherlands;New Zealand;Spain;Switzerland;United Kingdom;United States;
      2005   Phase 3   NCT00264550   Argentina;Australia;Brazil;Canada;Chile;Germany;Hungary;India;Korea, Republic of;Mexico;New Zealand;Poland;Taiwan;Turkey;United States;
      2003   Phase 2   NCT00207714   -
   Janssen Biotech, Inc.
      2009   -   NCT01081717   United States;
   Janssen Inc.
      2019   -   NCT03729349   Canada;
   Janssen-Cilag, S.A.
      2015   -   NCT02414984   Colombia;
   Julia Brown
      2011   Phase 4   NCT01295151   United Kingdom;
   Mario Negri Institute for Pharmacological Research
      2018   Phase 4   NCT03100253   Italy;
   MedImmune LLC
      2013   Phase 2   NCT01715896   Argentina;Colombia;Czech Republic;France;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Serbia;Slovakia;Spain;Turkey;United Kingdom;
   MedImmune Ltd
      2013   -   EUCTR2011-005649-10-PT   Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2010   -   EUCTR2009-011137-26-PT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
   Osaka City University Medical School
      2012   Phase 4   JPRN-UMIN000009425   Japan;
   Osaka Medical College
      2015   -   JPRN-UMIN000016950   Japan;
   Peking Union Medical College Hospital
      2019   -   NCT04188249   China;
   READE
      2015   -   EUCTR2015-002284-42-FI   Finland;
   Rheumatology, Internal MedicineJuntendo University School of Medicine, Juntendo Koshigaya Hospital
      2013   -   JPRN-UMIN000014485   Japan;
   Sanofi
      2010   Phase 2   NCT01217814   Brazil;Canada;Colombia;Czech Republic;Czechia;Germany;Hungary;Italy;Mexico;Norway;Spain;United States;
   Schering-Plough Research Institute, A Division of Schering Corporation
      2010   Phase 3   EUCTR2009-011137-26-BE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2009-011137-26-PL   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2009-011137-26-GR   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2009-011137-26-CZ   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2009-011137-26-AT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011137-26-SK   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011137-26-GB   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011137-26-FR   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011137-26-ES   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-NL   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-IE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-HU   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-FI   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-DK   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-011137-26-DE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
   Shering Plough Research Institute, A division of Schering Plough Corporation
      2010   -   EUCTR2009-011137-26-IT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
   St.Marianna University School of Medicine
      2013   -   JPRN-UMIN000011891   Japan;
   Takarazuka city hospital
      2014   -   JPRN-UMIN000016844   Japan;
   TcLand Expression S.A.
      2016   -   NCT03016260   Czech Republic;Czechia;France;Israel;Netherlands;Turkey;
   University of Nebraska
      2007   Phase 3   NCT03414502   United States;
Golimumab 100 mg injections   
   Centocor, Inc.
      2005   Phase 3   NCT00264537   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Golimumab 2 mg/kg IV   
   Janssen Biotech, Inc.
      2013   Phase 3   NCT01962974   Argentina;Brazil;Canada;Colombia;Mexico;United States;
      2009   Phase 3   NCT01004432   Austria;Belgium;Canada;France;Germany;Greece;Spain;Sweden;United Kingdom;United States;
Golimumab 50 mg SC   
   Janssen Biotech, Inc.
      2009   Phase 3   NCT01004432   Austria;Belgium;Canada;France;Germany;Greece;Spain;Sweden;United Kingdom;United States;
Golimumab 50 mg injections   
   Centocor, Inc.
      2005   Phase 3   NCT00264537   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Golimumab Final Vialed Product (FVP)   
   Centocor B.V.
      2010   -   EUCTR2008-006064-11-HU   Hungary;Lithuania;
   Centocor BV
      2010   -   EUCTR2009-010582-23-GR   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
   Janssen Biologics B.V.
      2010   Phase 3   EUCTR2009-010582-23-BE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2010   -   EUCTR2009-010582-23-DE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-010582-23-GB   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   -   EUCTR2009-010582-23-SE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   -   EUCTR2009-010582-23-AT   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   -   EUCTR2008-006064-11-LT   Argentina;Australia;Colombia;Hungary;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Ukraine;United States;
Golimumab Intravenous   
   Janssen Inc.
      2015   -   NCT02390700   Canada;
Golimumab Intravenous (IV)   
   Janssen Scientific Affairs, LLC
      2016   -   NCT02728934   United States;
Golimumab Liquid in Vial   
   Centocor B.V.
      2006   Phase 3   EUCTR2005-001742-16-GB   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-003232-21-LT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-HU   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2004-003296-36-DE   Germany;Hungary;
   Centocor BV
      2006   Phase 3   EUCTR2004-003295-10-GB   Austria;Hungary;Italy;Spain;United Kingdom;
   Janssen Biologics B.V.
      2006   -   EUCTR2005-001742-16-FI   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-DE   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-AT   Austria;Germany;Netherlands;Spain;United Kingdom;
Golimumab Liquid in prefilled syringe   
   Janssen Biologics B.V.
      2011   Phase 3   EUCTR2009-015019-42-BE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2011   -   EUCTR2009-015019-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
      2010   -   EUCTR2009-015019-42-LT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2010   -   EUCTR2009-015019-42-FI   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2010   -   EUCTR2009-015019-42-AT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      -   -   EUCTR2009-015019-42-Outside-EU/EEA   Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
Golimumab Pre-Filled Syringe   
   Centocor B.V.
      2006   Phase 3   EUCTR2005-001742-16-GB   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-003232-21-HU   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2004-003296-36-DE   Germany;Hungary;
   Centocor BV
      2006   Phase 3   EUCTR2004-003295-10-GB   Austria;Hungary;Italy;Spain;United Kingdom;
   Janssen Biologics B.V.
      2006   -   EUCTR2005-001742-16-FI   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-DE   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-AT   Austria;Germany;Netherlands;Spain;United Kingdom;
Golimumab liquid in prefilled pen   
   Janssen Biologics B.V.
      2010   -   EUCTR2009-010582-23-DE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   -   EUCTR2009-010582-23-SE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Golimumab liquid in prefilled pen or Prefilled Syringe   
   Janssen Biologics B.V.
      2009   -   EUCTR2009-010582-23-AT   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Golimumab liquid in prefilled pen or prefilled syringe   
   Janssen Biologics B.V.
      2010   Phase 3   EUCTR2009-010582-23-BE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Golimumab pre-filled syringe   
   Centocor B.V.
      2006   -   EUCTR2005-003232-21-LT   Germany;Hungary;Latvia;Lithuania;Malta;
Golimumab prefilled pen   
   Centocor BV
      2010   -   EUCTR2009-010582-23-GR   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Golimumab prefilled pen or prefilled syringe   
   Janssen Biologics B.V.
      2009   Phase 3   EUCTR2009-010582-23-GB   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Grapefruit   
   Department of Rheumatology and Clinical Immunology, Kyoto University Hospital
      2014   -   JPRN-UMIN000013546   Japan;
Green tea group   
   King Saud University
      2015   -   NCT03719469   -
Group 1 or Orencia treated group   
   University of California, Los Angeles
      2012   Phase 4   NCT01717846   United States;
Guna-Anti Interleukin 1   
   GUNA SPA
      2011   -   EUCTR2011-003016-23-IT   Italy;
Guna-Antiinterleukin 1 alfa   
   GUNA SPA
      2011   -   EUCTR2011-003016-23-IT   Italy;
Guna-Antiinterleukin 1 beta   
   GUNA SPA
      2011   -   EUCTR2011-003016-23-IT   Italy;
Guna-Interleukin 10   
   GUNA SPA
      2011   -   EUCTR2011-003016-23-IT   Italy;
Guna-Interleukin 4   
   GUNA SPA
      2011   -   EUCTR2011-003016-23-IT   Italy;
H.P. Acthar Gel   
   Ronald J. Rapoport, MD
      2014   -   NCT02434757   United States;
H.P. Acthar gel   
   Iraj Sabahi Research Inc.
      2017   Phase 4   NCT03082573   United States;
H02AB04   
   Leiden University medical Centre
      2015   Phase 2   EUCTR2014-004472-35-NL   Netherlands;
H02AB07   
   CHU de Bordeaux
      2019   Phase 2   EUCTR2018-004287-56-FR   France;
HA20 (IMMU-106)   
   Nycomed GmbH
      2011   -   EUCTR2010-022378-15-GB   Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022378-15-CZ   Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
HA20 (Immu-106)   
   Nycomed GmbH
      2011   -   EUCTR2010-022378-15-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom;
      2011   -   EUCTR2010-022378-15-ES   Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022378-15-DE   Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
HB-adMSCs   
   Hope Biosciences
      2018   Phase 1/Phase 2   NCT03691909   United States;
HBVAXPRO 5 micrograms/0.5 ml Suspension for injection Hepatitis B vaccine (rDNA)   
   FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
      2018   Phase 4   EUCTR2018-002368-18-ES   Spain;
HBVAXPRO® 40 micrograms   
   FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
      2018   Phase 4   EUCTR2018-002368-18-ES   Spain;
HCQ   
   Leiden University Medical Center, department of rheumatology
      2007   -   EUCTR2006-006186-16-NL   Netherlands;
   Peking University First Hospital
      2015   -   NCT02320630   China;
   Qilu Hospital of Shandong University
      2017   Phase 4   NCT03855007   China;
HD-TIV   
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2016   Phase 4   NCT02936180   Canada;
HE3286   
   Harbor Therapeutics
      2008   Phase 1/Phase 2   NCT00712114   United States;
HEPATITIS B VACCINE (RDNA)   
   FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
      2018   Phase 4   EUCTR2018-002368-18-ES   Spain;
HEPATITIS B VIRUS SURFACE ANTIGEN RECOMBINANT (S PROTEIN)   
   FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
      2018   Phase 4   EUCTR2018-002368-18-ES   Spain;
HL237   
   Hanlim Pharm. Co., Ltd.
      2018   Phase 1   NCT03896594   Korea, Republic of;
      2017   Phase 1   NCT03278470   Korea, Republic of;
HL237 tablet   
   Hanlim Pharm. Co., Ltd.
      2020   Phase 2   NCT04638426   Korea, Republic of;
HLX01   
   Shanghai Henlius Biotech
      2018   Phase 3   NCT03522415   China;
      2016   Phase 1/Phase 2   NCT03355872   -
HM71224 Multiple ascending dose   
   Hanmi Pharmaceutical Company Limited
      2013   Phase 1   NCT01765478   Netherlands;
HM71224 food effect   
   Hanmi Pharmaceutical Company Limited
      2013   Phase 1   NCT01765478   Netherlands;
HM71224 single ascending dose   
   Hanmi Pharmaceutical Company Limited
      2013   Phase 1   NCT01765478   Netherlands;
HMPL-523   
   Hutchison Medipharma Limited
      2014   Phase 1   NCT02105129   Australia;
HUC-MSC + DMARDs   
   Shenzhen Hornetcorn Bio-technology Company, LTD
      2016   Phase 1   NCT02643823   China;
HUC-MSC infusion (BC-U001)   
   Beijing Baylx Biotech Co., Ltd.
      2021   Phase 1/Phase 2   NCT04971980   China;
HUC-MSC suspension   
   Baylx Inc.
      2020   Phase 1   NCT03828344   -
HUMIRA   
   CHRU de TOURS
      2010   -   EUCTR2010-021449-28-FR   France;
   FRANCISCO J. BLANCO GARCÍA
      2013   -   EUCTR2012-004482-40-ES   Spain;
   Helsingin reumakeskus
      2010   -   EUCTR2009-017325-19-FI   Finland;
   MERCK SERONO INTERNATIONAL SA
      2008   -   EUCTR2007-002536-29-IT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
   Pfizer Inc.
      2015   Phase 3   EUCTR2014-000352-29-HR   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-FR   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-EE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-000352-29-BG   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000352-29-LT   Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000352-29-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-GB   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-ES   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
      2014   Phase 3   EUCTR2014-000352-29-CZ   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
HUMIRA (ADALIMUMAB)   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 4   EUCTR2016-003129-40-IT   Italy;
HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER   
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 4   EUCTR2016-003129-40-IT   Italy;
HUMIRA - 40MG/0.8ML SOLUZ. INIETTABILE- USO SOTTOCUTANEO-FLACONCINO(VETRO) 0.8ML 2 ASTUCCI:1 FLACONCINO+1SIRINGA+1AGO+1ADATT.STERILE-2TAMPONI IMBEVUTI ALCOOL   
   SOCIETA' ITALIANA DI REUMATOLOGIA - SIR
      2017   Phase 4   EUCTR2016-001987-12-IT   Italy;
HUMIRA 40 mg solución inyectable en jeringa precargada   
   Abbott GmbH & Co. KG
      2011   -   EUCTR2010-019514-24-ES   Austria;Czech Republic;Germany;Spain;
   F. Hoffmann-La Roche Ltd.
      2011   Phase 4   EUCTR2010-023587-40-ES   Denmark;Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
      2010   Phase 4   EUCTR2009-015845-21-ES   Australia;Belgium;Brazil;Czech Republic;Finland;Germany;Greece;Mexico;Portugal;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   GENENTECH, Inc
      2011   -   EUCTR2010-021577-37-ES   Bulgaria;Germany;Hungary;Spain;
   Pfizer, S.A
      2009   Phase 3   EUCTR2008-008338-35-ES   Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
HUMIRA*SC 2SIR+F 40MG 0,8ML+2T   
   OSPEDALE POLICLINICO S. MATTEO
      2006   -   EUCTR2006-003843-22-IT   Italy;
HYDROXYCHLOROQUINE SULFATE   
   Karolinska Institutet
      2015   -   EUCTR2011-004720-35-NO   Denmark;Finland;Norway;Sweden;
      2014   -   EUCTR2011-004720-35-FI   Denmark;Finland;Sweden;
   Leiden University Medical Center, department of rheumatology
      2007   -   EUCTR2006-006186-16-NL   Netherlands;
   Universitätsklinkum Erlangen
      2010   Phase 3   EUCTR2009-015740-42-DE   Germany;
HZT-501   
   Horizon Pharma Ireland, Ltd., Dublin Ireland
      2009   Phase 3   NCT00984815   United States;
      2007   Phase 3   NCT00613106   United States;
Havrix   
   HY, HUS
      2011   -   EUCTR2009-016055-22-SE   Finland;Sweden;
Hematopoietic Stem Cell Transplantation   
   Northwestern University
      2002   Phase 1   NCT00282412   United States;
Hemay007 1200 mg QD group   
   Tianjin Hemay Pharmaceutical Co.,Ltd
      2021   Phase 2   NCT05247216   China;
Hemay007 600 mg QD group   
   Tianjin Hemay Pharmaceutical Co.,Ltd
      2021   Phase 2   NCT05247216   China;
Hemay007 800 mg QD group   
   Tianjin Hemay Pharmaceutical Co.,Ltd
      2021   Phase 2   NCT05247216   China;
Hepatitis A vaccine ( HAVRIX or EPAXAL)   
   Lars Rombo
      2009   Phase 2   NCT01360970   Finland;Sweden;
Hepatitis A vaccine and tetanus vaccine   
   University of Zurich
      2013   -   NCT01947465   Switzerland;
Herpes Zoster Vaccine   
   University of Alabama at Birmingham
      2016   Phase 2   NCT02538341   United States;
      2014   Phase 2   NCT01967316   United States;
      2013   Phase 2   NCT02538757   United States;
High dose ORTD-1   
   Oryn Therapeutics, LLC
      2021   Phase 1   NCT04286789   United States;
High dose of BIIL 284 BS tablets   
   Boehringer Ingelheim
      2000   Phase 1   NCT02247375   -
High dose vehicle control   
   Oryn Therapeutics, LLC
      2021   Phase 1   NCT04286789   United States;
High frequency ultrasonography   
   GlaxoSmithKline
      2004   -   NCT00242853   United Kingdom;
High-resolution peripheral quantitative computed tomography (HR-pQCT)   
   University of California, San Francisco
      2013   -   NCT01773681   United States;
HrIL-2 active   
   Peking University People's Hospital
      2015   Phase 2   NCT02467504   China;
HuMax-CD20   
   GENMAB A/S
      2007   -   EUCTR2007-002945-18-IT   Czech Republic;Italy;
   Genmab A/S
      2008   Phase 3   EUCTR2007-002951-18-FR   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002951-18-SE   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002951-18-DK   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002950-42-BE   Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
      2007   Phase 3   EUCTR2007-002951-18-IT   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2007-002951-18-ES   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-002951-18-NL   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-002950-42-LT   Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
      2007   -   EUCTR2007-002950-42-HU   Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
      2007   -   EUCTR2007-002950-42-ES   Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
      2007   -   EUCTR2007-002945-18-CZ   Czech Republic;
      2006   -   EUCTR2004-003771-37-HU   Hungary;
   GlaxoSmithKline Research & Development
      2008   Phase 3   EUCTR2007-002951-18-GB   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002951-18-DE   Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002950-42-GB   Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
   GlaxoSmithKline Research & Development Ltd
      2008   Phase 1;Phase 2   EUCTR2008-002046-27-FR   Belgium;France;Germany;Spain;
      2008   -   EUCTR2008-002046-27-DE   Belgium;France;Germany;Spain;
      2008   -   EUCTR2008-002046-27-BE   Belgium;France;Germany;Spain;
      2007   Phase 2   EUCTR2007-004878-31-GB   Denmark;Hungary;United Kingdom;
      2007   -   EUCTR2007-004878-31-DK   Denmark;Hungary;United Kingdom;
   GlaxoSmithKline Research & Development Ltd.
      2008   -   EUCTR2007-004878-31-HU   Denmark;Hungary;United Kingdom;
   GlaxoSmithKline Research and Development
      2008   -   EUCTR2007-002950-42-PL   Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
      2007   -   EUCTR2007-002950-42-CZ   Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
   GlaxoSmithKline S.A.
      2008   -   EUCTR2008-002046-27-ES   Belgium;France;Germany;Spain;
HuMax-CD4   
   Emergent Product Development Seattle LLC
      2002   Phase 2/Phase 3   NCT00042406   Canada;United States;
Huang qi gui zhi wu wu granule   
   Cui xuejun
      2018   Phase 2/Phase 3   NCT03593837   -
Human Anti-TNF IgG1 Monoclonal Antibody   
   Centocor B.V.
      2006   Phase 3   EUCTR2005-001742-16-GB   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-003232-21-MT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LV   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-HU   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-DE   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-001742-16-NL   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-ES   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2004-003296-36-HU   Germany;Hungary;
      2006   -   EUCTR2004-003296-36-DE   Germany;Hungary;
   Centocor BV
      2006   Phase 3   EUCTR2004-003295-10-GB   Austria;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-HU   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-ES   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-AT   Austria;Hungary;Italy;Spain;United Kingdom;
   Janssen Biologics B.V.
      2006   -   EUCTR2005-001742-16-FI   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-DE   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-AT   Austria;Germany;Netherlands;Spain;United Kingdom;
Human Anti-TNFalfa   
   Centocor B.V.
      2006   Phase 3   EUCTR2005-001742-16-GB   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-003232-21-MT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LV   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-LT   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-HU   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-003232-21-DE   Germany;Hungary;Latvia;Lithuania;Malta;
      2006   -   EUCTR2005-001742-16-NL   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-ES   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2004-003296-36-HU   Germany;Hungary;
      2006   -   EUCTR2004-003296-36-DE   Germany;Hungary;
   Centocor BV
      2006   Phase 3   EUCTR2004-003295-10-GB   Austria;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-HU   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-ES   Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2004-003295-10-AT   Austria;Hungary;Italy;Spain;United Kingdom;
   Janssen Biologics B.V.
      2006   -   EUCTR2005-001742-16-FI   Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-DE   Austria;Germany;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2005-001742-16-AT   Austria;Germany;Netherlands;Spain;United Kingdom;
Human Recombinant IgG1, lambda   
   MorphoSys AG
      2010   -   EUCTR2007-006129-29-PL   Belarus;Bulgaria;Germany;Netherlands;Poland;Ukraine;
      2010   -   EUCTR2007-006129-29-NL   Belarus;Bulgaria;Germany;Netherlands;Poland;Ukraine;
      2010   -   EUCTR2007-006129-29-BG   Belarus;Bulgaria;Germany;Netherlands;Poland;Ukraine;
      2009   -   EUCTR2007-006129-29-DE   Bulgaria;Germany;Netherlands;Poland;Ukraine;
Human anti TNF-alpha monoclonal   
   Centocor BV
      2010   -   EUCTR2009-010582-23-GR   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Human anti TNF-alpha monoclonal antibody   
   Janssen Biologics B.V.
      2010   Phase 3   EUCTR2009-010582-23-BE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2010   -   EUCTR2009-010582-23-DE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-010582-23-GB   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
      2009   -   EUCTR2009-010582-23-SE   Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Human anti-IL6 monoclonal antibody   
   JANSSEN-CILAG INTERNATIONAL N.V.
      2012   -   EUCTR2010-022243-38-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Germany;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Portugal;Spain;Taiwan;United Kingdom;United States;
   Janssen-Cilag International N.V.
      2015   Phase 3   EUCTR2012-001176-10-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-PL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-HR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-001176-10-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001176-10-LT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001176-10-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2010-022242-24-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;United States;
      2013   -   EUCTR2010-022243-38-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Ne